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Resumo 
A variação de número de cópias (CNV em inglês) é uma modificação de uma 
sequência de DNA que apresenta uma inserção ou deleção em comparação com um 
genoma de referência com um número de cópias de N = 2. Com um comprimento variável, 
desde 50 pares de bases até várias megabases, as CNVs identificadas têm um tamanho 
médio de ~ 3 Kb e representam cerca de 4% do genoma humano. As CNVs, como outras 
variações genéticas, podem afetar directamente os níveis de expressão dos genes 
afectados. Os efeitos indirectos na expressão genética podem ser causados por alterações 
da posição, interrompendo o quadro de leitura do gene ou posteriormente, perturbando as 
redes de regulação genética. Foi demonstrado que as CNVs são em grande parte 
responsáveis pela evolução humana e diversidade genética entre os indivíduos. A relevância 
das CNVs no genoma humano foi salientada por vários estudos de associação que 
mostraram o efeito das CNVs na susceptibilidade a doenças neurodegenerativas, doenças 
de características complexas, e por serem a principal causa do aparecimento de doenças 
mendelianas ou por conferirem um fenótipo benigno. 
A doença de Huntington (DH) é uma doença degenerativa e progressiva do cérebro 
que é fatal. Clínicamente é caracterizada por disfunção motora, distúrbios emocionais / 
psiquiátricos graves, declínio cognitivo e demência. A DH é monogénica e autossómica 
dominante, sendo causada por uma expansão anormal do trinucleótido citosina-adenina-
guanina (CAG) no terminal 5' do gene da Huntingtina (HTT), localizado no cromossoma 4. 
Normalmente, a manifestação dos sintomas da doença dá-se por volta dos 40 anos, mas 
formas mais precoces (início <20 anos) e mais tardias (> 70 anos) também existem. O 
comprimento da expansão aberrante da repetição CAG no gene HTT está inversamente 
correlacionado com a idade de ocorrência (IO) da doença. O comprimento desta repetição 
explica ~ 50-70% na variação da IO sendo o restante da variação explicado por outros 
fatores genéticos e ambientais. Vários estudos têm como objectivo identificar 
modificadores genéticos da IO em DH, ou seja, nomeadamente um gene que quando 
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mutado  tem a sua função alterada e determina o aparecimento do fenótipo associado com 
a mutação CAG. Há poucos modificadores genéticos identificados através de abordagens 
multi-translacionais de grandes estudos de coorte da doença para validação em vários 
modelos experimentais, representando, no entanto uma abordagem válida para identificar 
novos alvos terapêuticos para a DH. 
O nosso objetivo neste estudo foi identificar genes candidatos com variação de 
número de cópias com potencial para modificar a IO na DH. Após a triagem de uma 
biblioteca de CNVs a partir de análise de dados matriz-CGH (disponível em linha através do 
navegador genoma UCSC), foram seleccionados vários candidatos: a região da β-defensine 
(DEFB4) e o transportador de glicose neuronal 3 (SLC2A3). Colocámos a hipótese de que a 
CNV na região de β-defensine (que varia de 2 a 8 cópias) poderia afectar o início da DH 
através de uma expressão variável do gene DEFB4 (presente nesta região) que codifica para 
um péptido antimicrobiano importante. Um aumento do número de cópias, codificantes 
para um nível mais elevado de proteína, podem contribuir a inflamação neuronal presente 
na DH e consequentemente piorando a evolução da doença. Assim, investigámos o papel 
potencial da CNV do gene SLC2A3 (que variam de 1 a 3 cópias), assumindo que o maior 
número de cópias pode ser protector na DH, codificando para um nível mais elevado do 
transportador de glicólise (GLUT3).  
Analisámos a distribuição das CNVs dos nossos genes candidatos em indivíduos do 
estudo REGISTRY realizado pela Grupo Europeu da Doença de Huntington (EHDN), utilizando 
o Teste da Razão de Parálogos (PRT). PRT é uma tipagem de elevada capacidade de variação 
do número de cópias que se baseia em PCR quantitativo e relativo.  
Determinámos o número de cópias da β-defensine em 490 indivíduos da nossa 
coorte de DH. A distribuição de CNVs de β-defensine nesta coorte não é significativamente 
diferente da população europeia sem DH (valor de p= 0,91) e também não está associada a 
uma alteração significativa da IO (valor de p = 0,41). Assim, podemos concluir que a CNV de 
β-defensine não é relevante na patologia da DH durante a fase inicial da progressão da 
doença. No entanto, com o nosso estudo, não podemos descartar qualquer papel potencial 
do gene DEFB4 numa outra fase da doença. 
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Determinámos depois a distribuição de CNVs no gene SLC2A3 em 988 indivíduos 
com a DH e não foi significativamente diferente da população britânica (valor de p =0.38). 
Curiosamente, verificou-se uma associação significativa entre a CNV de SLC2A3 e uma 
variação de IO na nossa coorte de DH (valor de p = 0,028). Indivíduos com três cópias de 
SLC2A3 mostraram um atraso do IO em comparação com o resto do grupo de até cerca de 6 
anos. De modo a investigar a base molecular deste efeito protector da GLUT3 analisámos os 
níveis de expressão da proteína em linhas linfocíticas imortalizadas obtidas a partir de 
pacientes da nossa coorte, portadores de 1, 2 e 3 cópias de SLC2A3 (5 por cada genótipo). 
Pela análise immunoblot detectou-se que um maior número de cópias no gene SLC2A3 está 
associado a um maior nível de expressão da proteína (valor de p = 0,02). Assim, o efeito 
protector do aumento do número de cópias de SLC2A3 é devido a uma maior expressão do 
transportador de glicose. 
Para investigar a base funcional deste efeito protector, foi utilizado um modelo de 
Drosophila de DH para estudar o efeito de sobre-ou sub-expressão do funcional homólogo 
de SLC2A3 em Drosophila, Glut1. Analisámos vários indicadores relevantes da doença, 
incluindo a neurodegeneração dos fotorreceptores, longevidade e taxa de eclosão. 
Descobrimos que em moscas com DH a sobreexpressão de Glut1 pode reduzir 
significativamente a perda de rhabdomeres e portanto a neurodegeneração (valor de p 
<0,001). Pelo contrário, a redução ou a alteração génica deste transportador estão 
associados com um pior cenário que se manifesta por uma perda maior de rhabdomeres 
(valor de p = 0,00012 *), uma redução da longevidade média (valor de p = 0,034) e uma 
redução da taxa de eclosão (valor de p = 0,015). Alterações do principal transportador de 
glicose num modelo de Drosophila da DH agrava a progressão da doença numa fase inicial, e 
sobrerexpressão deste transportador protege da neurodegeneração na mosca adulta, 
confirmando os resultados na coorte de DH. 
Do que sabemos, este é o primeiro estudo que investigou a função potencial das 
CNVs em DH. Conclui-se que a CNV no gene SLC2A3 é um novo modificador genético do IO 
em grandes coortes de DH (988 amostras), em que un aumento de cópias do gene está 
associado a um efeito protector na DH. Testámos o efeito molecular da ocorrência desta 
CNV em linhas celulares obtidas directamente dos pacientes e descobrimos que o evento de 
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CNV do gene é responsável por um aumento da expressão de GLUT3 na DH, o que poderá 
repor a deficiência energética nos neurônios de pacientes com a DH e atrasar a 
neurodegeneração. Além disso, usámos um modelo de Drosophila de DH para testar a 
função funcional da homólogo de SLC2A3 em moscas (Glut1), confirmando que uma sobre-
expressão deste transportador pode diminuir a progressão da doença na mosca adulta,  e a 
alteração do gene piora a progressão da doença num estadio inicial. É necessária futura 
investigação para reproduzir esta observação e confirmar o SLC2A3 como um alvo de 
potencial terapeutico para o tratamento da DH. 
 
* os dados referem-se a moscas no dia 1 pós eclosão. 
 
Palavras-chave: variação do número de cópia (CNV), doença de Huntington (DH), 
modificadores genéticos, DEFB4, SLC2A3, Drosophila. 
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Abstract 
Huntington’s disease (HD) is a fatal neurodegenerative disorder caused by the 
expansion of an unstable triplet repeat within the huntingtin gene. The length of this repeat 
is inversely correlated with the age of onset (AO) of the disease, which ranges from 1 to 80 
years of age. The length of this repeat explains 50-70% of the variance of AO with the 
remaining variation attributable to environmental and other genetic factors.  
Copy number variation (CNV) is a structural variation of the human genome wherein 
a genomic sequence is duplicated or deleted compared to a reference genome. As CNVs 
have the potential to affect gene expression either directly by dosage effects or indirectly by 
affecting gene product interactions and pleiotropic effects, they are found to be associated 
with phenotypic variance, disease susceptibility and Mendelian disorders.  
The aim of the study was to investigate CNVs as candidate genetic modifiers of the 
AO in HD. Specifically we investigated CNV of the human β-defensin region (including 
DEFB4) and CNV involving SLC2A3, with potential impacts, respectively, in the 
neuroinflammatory response and in neuronal glucose uptake. CNVs were analysed within a 
large HD sample cohort (provided by EHDN) using the paralogue ratio test (PRT) to test their 
potential impact on a variance of the AO in HD.  
In 490 HD individuals analysed the frequency distribution of β-defensin copy number 
was shown to be equivalent to the general European population. Furthermore, no 
significant association was shown between β-defensin CNV and a variance of the AO in HD.  
987 HD patients were genotyped for SLC2A3 CNV and a modest but significant 
association with a variance of AO in HD was found (p value = 0.028). Individuals with three 
copies showed a delay in the AO of up to nearly 6 years compared to individuals with one or 
two copies. In order to test if SLC2A3 CNV affects gene expression 15 cell lines from patients 
with different SLC2A3 copy number were immunoblotted for GLUT3 (encoded by SLC2A3) 
and it was found that the protein level was significantly correlated with the genomic copy 
number (p value = 0.020). Therefore, we concluded that SLC2A3 CNV is a genetic modifier of 
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the AO in HD, associated to a variance of the disease onset and affecting the gene 
expression.  
To investigate the functional basis of this effect, we analysed lines showing over- or 
under-expression of the functional homolog of SLC2A3 (Glut1) in a Drosophila model of HD. 
After analysing several disease-relevant metrics, including neurodegeneration of the 
photoreceptors, eclosion rate and longevity, we found that gain and loss of Glut1 expression 
can delay and worsen, respectively, neurodegeneration in HD flies.  
In conclusion, β-defensin genomic copy number is not associated with modulation of 
HD AO. On the other hand, SLC2A3 CNV is a genetic modifier of the AO in HD, and likely has 
functional consequences, based on our findings in patient cells and in a Drosophila HD 
model. 
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Network 
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Angelica Vittori, Carlo Breda, Mariaelena Repici, Michael Orth, Raymund A.C. Roos, 
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INTRODUCTION 
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1.1 Copy Number Variation 
Variation in the human genome encompasses single-nucleotide polymorphisms (SNPs), 
small insertion-deletion (indel) polymorphisms, variable numbers of repetitive sequences, 
and genomic structural variations (Iafrate et al. 2004). Structural variation (SV) is a broad 
term that refers to genetic variants bigger than ~1 kilo base (kb), able to modify the 
chromosomal architecture (Feuk, Carson, Scherer 2006); it includes balanced changes, as 
inversions and reciprocal translocations, and alteration of DNA copy number, namely copy 
number variation (CNV) (Hurles, Dermitzakis, Tyler-Smith 2008). In the last six decades, 
some SV of phenotypic relevance have been catalogued through the use of molecular 
genetics and cytogenetic tools. Only with the advent of the array-based comparative 
genomic hybridization (array-CGH) technology coupled with the publication of the draft 
human sequence in 2001 was it possible to analyse SV in large scale data sets, of 
phenotypically normal and diseased populations. Through use of array-CGH technology, 
several studies identified the presence of a number of CNVs, highlighting their role as the 
largest component of the SV within the human genome (Conrad et al. 2010; Iafrate et al. 
2004; Kidd et al. 2008; Redon et al. 2006; Sebat et al. 2004; Tuzun et al. 2005).  
CNV is an alteration of a DNA sequence showing an insertion or deletion compared to a 
reference genome with a copy number of N = 2 (Feuk, Carson, Scherer 2006). The extent of 
detected CNVs ranges from 50 base pairs (bp), as an operational demarcation from indels, 
up to megabases (Mb), with a median size of ~ 3 kb (Alkan, Coe, Eichler 2011; Conrad et al. 
2010). CNV can arise in a diallelic or multiallelic configuration (Wain, Armour, Tobin 2009): 
diallelic variation takes place with homozygous or heterozygous deletion or duplication of a 
DNA fragment; a multiallelic CNV consists of homozygous or heterozygous deletion or 
duplication as equal or/and unequal change in each chromosome (Figure 1). Moreover, CNV 
can manifest as a complex rearrangement of a DNA region, where different regions, present 
in a variable number of copies, are involved in the same event (Figure 1).  
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Figure 1. Diallelic and multiallelic configurations of CNV. 
The copy number variable site (grey), flanked by invariant regions (blue and green), is involved in a 
diallelic (A) deletion and (B) duplication, each showing the site with (i) normal diploid set, (ii) 
heterozygous modification, and (iii) homozygous modification. (C) Multiallelic locus showing (i) 
normal copy number, (ii) multiple rounds of duplication on one chromosome and a deletion on the 
homologous chromosome, (iii) duplication on one chromosome and no deletion on the homologous 
chromosome, (iv) multiple rounds of duplication on one chromosome and no deletion on the 
homologous chromosome, (v) one round of duplication on each chromosome, (vi) one round of 
duplication on one chromosome and multiple rounds of duplication on the homologous chromosome. 
(D) Multiallelic locus showing (i) normal copy number and (ii) a complex rearrangement of the two 
different alleles A and B. [Adapted from Wain, Armour, Tobin 2009]. 
 
Despite the increasing number of studies investigating CNV, it is not possible to 
determine an exact coverage of CNV in the human genome. Due to limitations in the 
resolution of CNV detection tools, many observed CNVs are described with an approximate 
size and the location of the variant boundaries is overestimated (Hurles, Dermitzakis, Tyler-
Smith 2008). Furthermore, with the absence of standardised controls, the variability 
between array-based platforms and the different calling algorithms used for the discovery 
of CNVs in several independent studies (Pinto et al. 2011) there has certainly been a large 
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number of redundant entries of these variants (> 610,834), as the Database of Genomic 
Variants reports (http://dgvbeta.tcag.ca/dgv/app/home?ref=NCBI36/hg18).   
A recent study performed by the Genome Structural Variation consortium (Conrad et 
al., 2010), based on tiling oligo array-CGH platform, analysed CNV events of 450 individuals 
from the HapMap project (International HapMap Consortium 2005) and 45 individuals from 
China; the identified CNVs (8,599) extend for 3.7% of the human genome, coverage that 
realistically fits previous analyses, where the total amount of duplicated sequence in the 
human genome is nearly 5% of the entire genome (Bailey et al. 2002; Cheung et al. 2003; 
Cheung et al. 2001; She et al. 2004). In particular, ~ 18% of the validated CNVs overlap with 
coding regions of the human genome and an average of 45 OMIM (Online Mendelian 
Inheritance in Man, http://www.omim.org/) genes per analysed sample were showed to be 
affected by 48 CNVs, highlighting the role of these variants as a relevant factor in human 
diversity, evolution and disease susceptibility (Conrad et al. 2010). 
 1.1.1 Mechanisms of CNV formation 
CNV occurs as de-novo mutation in germline and in somatic cells at a significant rate, 
and can become heritable polymorphisms. The CNV mutation rate has been estimated to 
range from 1.7 × 10−6 to 1.0 ×10−4 per locus per generation and can vary broadly at different 
loci and between different tissue, showing somatic mosaicism (Breckpot et al. 2011; Bruder 
et al. 2008; Lupski 2007; Notini, Craig, White 2008; Piotrowski et al. 2008; van Ommen 
2005).  
CNV formation is the result of changes in the chromosomal structure, changes which 
themselves arise when two formerly separated DNA fragments become juxtaposed 
(Hastings et al. 2009). CNV is more likely to occur in the proximity of centromeres and 
telomeres (Guryev et al. 2008; Nguyen, Webber, Ponting 2006) and in regions containing 
highly homologous duplicated sequence and more specifically segmental duplication (also 
called “low-copy repeats” (LCR)) (Sharp et al. 2005), which themselves are blocks that 
exhibit a high degree of nucleotide sequence identity (commonly > 95%) and enclose large 
genomic distances (1-100kb) (Eichler 2001). Segmental duplications are normally located in 
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pericentromeric and subtelomeric regions (Eichler 2001), usually associated with 
chromosomal instability or evolutionary rearrangement (Sharp et al. 2005), suggesting the 
implication of segmental duplications with genomic disorders (Sharp et al. 2006; Stankiewicz 
and Lupski 2002). Through ectopic homologous recombination (HR), specifically non allelic 
homologous recombination (NAHR), LCRs participate in the formation of recurrent CNV. 
 
 
Figure 2. NAHR mechanisms. 
(A,B) Deletion or duplication can occur by NAHR in two ways, interchromosomal crossover and 
interchromatidal crossover. (C) Deletion can also arise by intrachromatidal crossover. (D) NAHR 
between inverted LCRs on sister chromatids can also result in isochromosome formation (normally 
observed in somatic cells within a tumour). [Adapeted from Liu at al. 2012]. 
 
NAHR is a mechanism that leads to de novo mutation events in germline and somatic 
cells, and is a major cause of copy number change occurring when control of allelic 
recombination fails (Liu et al. 2012). The likelihood of NAHR event occurring is proportional 
to the LCR or paralogous repeat sequence length and is inversely correlated to the distance 
between the loci involved in the potential recombination event (Liu et al. 2011). Ectopic 
recombination produces change in copy number, which results in a deletion and reciprocal 
duplication. NAHR events can follow different model or genomic rearrangements involving 
paralogous LCRs on both single chromosome and homologous chromosomes, or inverted 
LCRs on sister chromatids (Figure 2) (Lange et al. 2009; Liu et al. 2012). Furthermore, NAHR 
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can occur between LCRs in non-homologous chromosome, recurrent translocations may 
ensue (Ou et al. 2011). 
Less frequent CNV can originate from mechanisms of DNA repair that, with lower 
stringency, use very limited homology (2-15 bp) or no homology. The breakpoint regions of 
these CNVs are characterized by blunt ends, microhomologies, and small insertions, 
suggesting the involvement of a nonhomologous repair mechanism in their formation (Lee, 
Carvalho, Lupski 2007; Luo et al. 2011b; Shaw and Lupski 2005).  
Non homologous end joining (NHEJ) is with HR one of the main pathways for DNA 
double-strand break repair in eukaryotic cells; it is a stable but imprecise mechanism and 
compared to HR it does not require substrates with extended homology (Lieber et al. 2003; 
Lieber 2008). Through rearrangements within scattered breakpoints, NHEJ can lead to 
translocations and telomere fusion (Espejel et al. 2002) as a consequence of erroneous loss 
or addition of several nucleotides at the end joining point (Lieber 2008). Several studies 
showed the role of NHEJ in the formation of deletion CNVs (Luo et al. 2011a; Shaw and 
Lupski 2005; Toffolatti et al. 2002) and, combined with HR, of duplication CNVs (Inoue et al. 
2002; Lee, Carvalho, Lupski 2007).  
An alternative repair mechanism to NHEJ is microhomology mediated end joining 
(MMEJ) which requires different intermediary factors compared to NHEJ and results in a 
deletion with microhomology at the repair junction. MMEJ is involved in genomic 
rearrangements in spontaneous and therapy related cancer (Bennardo et al. 2008). 
Non-recurrent CNVs showing highly complex structure, that cannot be readily explained 
by NHEJ, are attributable to fork stalling and a template switching (FoSTeS) mechanism (Lee, 
Carvalho, Lupski 2007). FoSTeS is a replication based model able to generate large genomic 
duplications of several mega base, which may lead to gene duplications/ triplication or exon 
shuffling (Bi et al. 2009; Zhang et al. 2009). During DNA replication, the active replication 
fork can stall and switch between complementary templates, sharing microhomology and 
apart in the genome, to anneal and prime DNA replication (Kitamura, Blow, Tanaka 2006; 
Lee, Carvalho, Lupski 2007; Zhang et al. 2009). FoSTes as a replicative method occurs in 
mitosis (Lee, Carvalho, Lupski 2007) or can be induced in stressed cells (Arlt et al. 2009; 
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Slack et al. 2006). In case of break-induced replication, CNV may also occur by way of a 
repair model, suggested by Hastings et al. called microhomology-mediated break-induced 
replication, which enables formation of complex structure by several round of template 
switching (Hastings, Ira, Lupski 2009). 
1.1.2 Methods of CNV identification and genotyping 
Historically, only large chromosomic rearrangements were detected in the context of 
severe developmental disorders (such as Down syndromes) by cytogenetic analysis (Jacobs 
et al. 1959) and were not referred to in any systematic fashion. Only the advance of 
genomic investigative tools, such a microarray and sequencing technologies, applied to 
genome-wide studies of apparently healthy individuals made possible the discovery and 
genotyping of a broad range of CNVs. Several techniques are currently available for the 
detection and genotyping of CNVs (Table 1). 
1.1.2.1 Microarray-based techniques  
Microarrays, the experimental workhorse of CNV discovery and genotyping (Alkan, 
Coe, Eichler 2011), are represented primarily in the context of CNV studies by array CGH 
(Pinkel et al. 1998) and SNP microarrays (Huang et al. 2004) and both platforms infer the 
copy number by comparison with a reference genome, which could be a single sample or 
population data set (Figure 3).  
The array CGH technology (Kallioniemi et al. 1992) is based on the hybridization of 
two different labelled samples, a test and a reference, to a set of specific targets, typically 
oligonucleotides (Conrad et al. 2010; Kidd et al. 2008) or, historically, bacterial artificial 
chromosome clones (Redon et al. 2006). The signal ratio between test and reference is 
normalized and converted to a log2 ratio: an increase of the log2 ratio indicates a gain of 
copy number of the test region compared to the reference; conversely, a diminution 
represents a decrease in copy number (Figure 3) (Oostlander, Meijer, Ylstra 2004; Pinkel et 
al. 1998). It is of crucial importance that an appropriate reference genome(s) is chosen to 
minimise the risk of incorrect CNV calling. For example, if a non-detected deletion is present 
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Table 1. Comparative table between CNV detection and genotyping techniques. 
 array-CGH SNP Array Fiber FISH PFGE NGS MAPH MLPA PRT 
Detection 
Relative Copy 
Number 
Relative Copy 
Number 
Absolute Copy 
Number 
Inferred Absolute Copy 
Number 
Absolute Copy 
Number 
Relative Copy 
Number 
Relative Copy 
Number 
Relative Copy 
Number 
Sample 2-5 µg DNA 2-5 µg DNA Cells 2-5 µg DNA 2-5 µg DNA 0.5-1 µg DNA 100-200 ng DNA 5 - 10 ng DNA 
Loci ≥ 2 Million ≥ 2 Million Single Single Genome-Wide Up To 40 Up To 50 Single 
Throughput High High Low Low High/moderate High High High 
Minimum 
Resolution 
5 – 10 kb 5 – 10 kb ≥ 1 kb 0.5 - 1 kb ≥ 1 kb 100 bp 100 bp 100 bp 
Cost Per Sample Moderate Moderate Low Low High Low Low Low 
Time ≥ 24 h ≥ 24 h ≥ 24 h 2- 3 days 2 -3 days ≥ 24 h ≥ 24 h 4 h 
Labor 
Requirement 
Moderate Moderate High High High Low Low Low 
[Adapted from Cantsilieris, Baird, White 2012].
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in the reference genome then a duplication event would be called in all the analysed 
samples. 
SNP arrays generate a similar output by comparing the signal intensity for a sample 
compared to a collection of the normalized total intensity of reference hybridizations (Log R 
Ratio). Furthermore, the B allele frequency (BAF), namely the normalized measure of the 
allelic intensity ratio of two alleles of each SNP studied, is analysed. The combination of the 
Log R Ratio and BAF ratio can be used to infer copy number changes in the genome 
especially for multi-allelic copy number (Figure 3) (Wang and Bucan 2008). The BAF metric is 
not informative in the case of homozygous or balanced structural variants.   
 
Figure 3. Analysis of intensity signal from array CGH and SNP array. 
Array CGH (a) is informative on CNV with reduced signal noise compared to SNP array (b), that 
through BAF is informative in case of multi-allelic-copy number: in the case of AA, AB and BB 
genotype the BAF ratio should be 0, 0.5 and 1.0 respectively; for higher copy number the BAF 
resulting ratios are indicative of the allelic asset, e.g. in case of ABB genotype the ratio would be 
0.33/ 0.67. [Adapted from Alkan, Coe, Eichler 2011]. 
 
Microarray technology proffers a tangible advantage in terms of throughput and cost 
allowing one to assay CNV architecture for large data sets, an essential requisite in the 
identification of rare-disease variants. Disadvantages of the microarray technology are the 
detection of copy number differences of sequences that are not present in the reference 
genome used for the probe design (Kidd et al. 2010) and in the localization of breakpoints at 
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a single-base pair level. Microarray technology is not yet suitable for the analysis of repeat-
rich and duplicated regions where the probe coverage would not be accurate and the CNV 
call is not sensitive enough. Furthermore, the algorithm applied for the CNV call accounts 
for another important limitation: the analysis of the same raw data with different 
algorithms leads to a higher variability in the CNV calling than when the same algorithm is 
used on raw data from identical samples, samples analysed by different laboratories (Pinto 
et al. 2011).  
1.1.2.2 Hybridization-based techniques 
Southern blotting is a hybridization technique used for typing structural 
rearrangements. Southern blotting procedure consists of fragmentation of DNA with a 
cutting restriction enzyme, separation of the products in electrophoretic run and transfer to 
a nylon membrane (blotting), which will be treated with a labelled DNA probe for the 
identification of the target band (Southern 1975). Through analyses of band intensities and 
normalization on a copy stable locus band, Southern blotting can be used for typing CNV 
genes (Aitman et al. 2006). However, several disadvantages of this method such as the 
intense work flow, the high DNA amount required and the scarce accuracy for the 
distinction of consequential copy number make the Southern blotting alone not suitable for 
CNV studies.    
Pulsed field gel electrophoresis (PFGE) is an umbrella term referring to technique 
based on the digestion of DNA with a rare-cutter restriction enzyme, followed by separation 
on a pulse field electrophoresis gel and Southern-blot analysis (Schwartz and Cantor 1984). 
PFGE can accurately resolve CNV thanks to the separation of restriction fragments, which 
size is specific for each copy number, on a periodic alternate electric filed gel. PFGE is used 
to type complex CNVs and to infer absolute copy number (Aldred, Hollox, Armour 2005; 
Yang et al. 2007).  
Fiber FISH (fluorescent in situ hybridization) is an accurate technique based on the 
hybridization of a fluorescent labeled probe to microscope slide within DNA in metaphase or 
interphase and allows the identification of complex chromosomal rearrangements (Price 
1993). Compared to others techniques, fiber FISH allows to identify high copy number (> 10) 
and is the only one that specifically consents to call CNV per allele, which is important for 
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studies of inheritance and disease (Perry et al. 2007; Pinkel et al. 1998; Sebat et al. 2004; 
Trask et al. 1998). 
Due to their limited throughput and high laboriousness, PFGE and fiber FISH have a 
restricted application. They are commonly used as experimental validation methods and 
FISH is specifically applied to clinical test for chromosomal abnormalities screening. 
1.1.2.3 Next generation sequencing techniques  
Next generation sequencing (NGS) is a term that refers to a wide range of non-
Sanger sequencing techniques based on a computational high throughput approach (Korbel 
et al. 2007; Tuzun et al. 2005; Volik et al. 2003). In NGS, the sequence of interest is 
processed as a single molecule template or PCR-clonal colonies, both are tethered to a solid 
surface or support and sequenced and analysed in parallel with the application of specific 
algorithms, reducing costs and time of the procedure (Medvedev, Stanciu, Brudno 2009; 
Metzker 2009). Compared to hybridization techniques, NGS technology is theoretically 
suitable for discovering all genomic variants with a much higher precision. CNV can be 
detected and genotyped using different NGS strategies, which differ for sensitivity and 
specificity depending on the dimension and type of CNV: read-depth, read-pair, split-read 
and de novo assembly methods (Alkan, Coe, Eichler 2011). 
The read pair strategy can be used for detecting any sort of structural variations, 
using paired-end reads which are assessed for span and orientation compared to a 
reference genome. For example, a deletion or duplication are detected when an alteration 
of the distance between the read pairs occurs in the reference genome and a new insertion 
when one of the read does not map the reference genome (Kidd et al. 2008; Korbel et al. 
2009; Tuzun et al. 2005).  
The high coverage of NGS makes it possible to infer absolute copy number of known 
targets based on read-depth strategy. The read-depth approach infers CNV of a genomic 
locus detecting lower or higher than expected sequencing coverage of that region, assuming 
that the coverage of any region follows a Poisson distribution (or modified Poisson model). 
The read depth approach can also be used to discriminate among paralogs within a highly 
duplicated gene family (Alkan et al. 2009; Sudmant et al. 2010). 
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Figure 4.  Read pair signatures. 
The read pair is represented by the two arrows, sampled from the donor and mapped on the 
reference genome. (a, b) Insertion and duplication are detected respectively by a reduction or 
increased of the mapped distance between the two reads. (c) Inversion can be detected as a well 
from a variation of the order of the mapped reads. (d) New insertion can be detected when only one 
of the reads is mapped in the reference genome. [Adapted from Medvedev, Stanciu, Brudno 2009]. 
 
A split read approach can be used to define the breakpoint of a structural variant 
detecting deletions and small insertions with a single-base-pair resolution, respectively   
analysing reads misalignments in the test or reference genome. Split read methods have a 
limited application in CNV detection due to the use of longer reads than the other NGS 
methods and have less power in highly repeated regions (Abyzov and Gerstein 2011; Ye et 
al. 2009). 
De novo genome assembly using NGS technology is the most accurate strategy for 
the detection of novel CNV and any sort of genomic variation. This approach has been 
applied to a small number of samples highlighting 4.1 terabases of raw sequence not 
present in the reference genome and several novel SVs (Altshuler et al. 2010; Mills et al. 
2011; Wheeler et al. 2008). Optimisation of NGS technologies, reducing the laboriousness 
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and improving the algorithms used is necessary to adapt this method for large scale studies, 
which is a basic requirement for studying phenotypic effect of the detected variants.  
NGS technologies allow the identification of break points, inversions, novel 
insertions, and specifically through the read-depth analysis is possible to distinguish 
between paralogous copies of duplicate genes within a family and to predict the absolute 
copy number call of genomic duplication/deletion intervals (Alkan et al. 2009). The 
combination of two complementary signatures for detection of structural variants by 
integrating read pair and read depth or split read approaches is a more accurate and 
efficient strategy than using a single method (Mills et al. 2011; Rausch et al. 2012). 
Nevertheless, there are several limitations in the NGS technologies: the algorithms used and 
the scarce manageability of large data-sets produced make the analyses time expenditure 
quite high; moreover, technical issues related to the length of the read analysed, which are 
too short for efficient assembly. These drawbacks make these techniques not yet suitable 
for large scale studies, reducing their power. 
1.1.2.4 PCR based methods  
The discovery of new SV by microarray or sequencing techniques requires the 
application of high narrow thresholds to restrain the detection of false positives. Genotyping 
analyses, designed for investigation of a few loci, are powerful tools characterized by less 
stringency, high sensitivity and specificity. CGH array, SNPs array and NGS methods can be 
applied and customized for CNV genotypes, presenting similar advantages and limitations. 
PCR (polymerase chain reaction)-based methods are single base pair sensitive tools that 
allow one to pinpoint breakpoint mutation locus and quantify copy number change; once 
optimised they permit analyses of large data set with low-cost and time saving frame.  
Real-time quantitative PCR 
Real-time quantitative PCR (qPCR) is a PCR-based method that allows absolute or 
relative quantification of mRNA levels and small genetic regions. The copy number is 
inferred as a ratio between the amplification products of a gene of interest versus a 
reference gene, amplicons that are detected at several time points by fluorescent signals of 
the incorporated probes. The kinetics of amplification of the two targets are required to be 
similar and equally efficient in order to make sure that the detected product will be an 
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accurate indication of abundance of the initial DNA product (Gonzalez et al. 2005; Higuchi et 
al. 1993). Although qPCR is characterized by high-throughput and simple work-flow, 
different studies, through comparison of with other PCR-based techniques for CNV calling, 
showed that qPCR is not suitable for complex CNV genotyping as it is inaccurate in the 
distinction of small fold changes, causing extensive overlap between copy number integer 
classes and leading to biased CNV associations (Aldhous et al. 2010; Field et al. 2009; Fode 
et al. 2011). 
Multiplex amplifiable probe methods 
Multiplex amplifiable probe hybridisation (MAPH) and multiplex ligation-dependent 
probe amplification (MLPA) are high-throughput techniques for the relative quantification of 
copy number changes of genomic DNA, using labelled probes for the simultaneous 
detection of several loci ( up to ~ 45 ) (Armour et al. 2000; Schouten et al. 2002). These 
techniques are single base pair specific and allow analysis of large number of samples with 
reduced costs. The copy number of a specific target is inferred by the relative intensity 
between the amplification products, which can be distinguished from other targets thanks 
to a target-specific stuffer bound to one of the oligos, besides the primer used for the PCR 
reaction (Figure 5).  
 
Figure 5. Basic principle of MAPH and MLPA techniques. 
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The amplification products are analysed according to the label used: polyacrylamide 
gel electrophoresis for MAPH (radioactive label), capillary electrophoresis for MLPA 
(fluorescent label). With the detection of events located on a single DNA fragment, this 
technology allows analysis of rare subpopulations or individual CNV events. Disadvantages 
reside in the laborious optimisation of these techniques and in the possibility to detect false 
mosaicism resulting from a lack of alignment of the primers caused by the presence of 
polymorphisms. 
 Paralogue Ratio Test  
 The paralogue ratio test (PRT) is a high-throughput typing of copy number variation 
method based on a relative quantitative PCR (Armour et al. 2007). The method requires 
small amounts of genomic DNA (5-10 ng) and consists of a PCR reaction performed under 
quantitative conditions (30 cycles), followed by capillary electrophoresis. PRT employs a 
single pair of fluorescent labelled primers designed to amplify simultaneously a fragment 
within a variable repeat locus of interest and within a reference locus that is not copy 
number variable (Figure 6). The products are resolved by size difference (optimally designed 
to range between 2 to 50 bp in order to minimize amplification variance) in capillary 
electrophoresis run.  
The copy number is inferred from the ratio between the test and the reference locus 
amplification products. For complex CNV regions multiple PRTs can be performed in a single 
PCR reaction and analysed in parallel; PRT ratios, normalized for control copy number 
samples, are pooled to infer the copy number by likelihood calculations (Hollox, Armour, 
Barber 2003; Hollox, Detering, Dehnugara 2009; Walker, Janyakhantikul, Armour 2009). 
One of the main challenges of this method is the design of the primers, which must 
anneal only the reference locus and copy number variable locus. This can be achieved with 
the help of an algorithm, which can quickly design couple of primers, suitable for PRT 
methods. The algorithm blasts the region of interest with the entire genome sequence, 
masking repeated regions, in order to find specific and unique paralogous regions and in 
combination with primer design software, selects the oligos annealing only for those (Veal 
et al. 2013).  
 
16 
 
 
Figure 6. Capillary electropherogram of a multiplex PRT analysis. 
Each electropherogram shows the amplification product of three different PRT (in duplicated for 
PRT3, using different labelled probes) where the ratio between test and reference peak areas is a 
clear indication of the variable copy number of the test compared to the reference locus. [Adapted 
from Walker, Janyakhantikul, Armour 2009]. 
 
A disadvantage of this test is the low accuracy in calling among odd and even copy 
number, this however can be resolved by combining the PRT to other assay such as a 
restriction enzymatic digest variant (REDVR) or an indel assay (Abu Bakar, Hollox, Armour 
2009; Aldred, Hollox, Armour 2005). These methods reduce disambiguation between CNV 
calls based on the allelic distribution of SNPs or indel polymorphisms between the several 
units of the repeated region (Figure 7). 
A REDVR method consists in the amplification of a SNP (commonly heterozygous in 
normal population) within the copy number variable locus followed by SNP-allele specific-
restriction enzyme digestion. The digestion products are resolved by capillary 
electrophoresis. In the case of heterozygous genotype, the ratio between the digested and 
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undigested fragments area informs the distribution of two alleles that must agree with the 
number of copy of that region: for instance a ratio of 5:3 can only fit a 8 copy number model 
(in case of a homozygous genotype there is a single product which is not informative). 
Redundant ratios from multiple numbers of copies (2:2, 3:3 from 4 and 6 copies number or  
4:2, 6:3 from 6 and 9 copies number) does not allow the use of this method alone, which is, 
in fact, coupled with the PRT approach to distinguish between consequential copy number. 
The indel assay is based on a similar rationale, where an indel within the copy number 
variable region is amplified instead of SNP. The PCR products are directly analysed on 
capillary electrophoresis and, similarly for the REDVR assay, the ratio between the different 
products is informative of the copy number (Figure 7). Data from the REDVR assay and indel 
assays are pooled with PRT data in maximum likelihood calculations to infer copy number 
calls (Abu Bakar, Hollox, Armour 2009; Aldred, Hollox, Armour 2005). 
 
 Figure 7. Indel and PRT amplification products. 
In the electropherogram are represented indel and PRTs amplification products from the β-defensin 
multiplex PRT analysis. The approximate 1:1:2 ratios of alleles for the multi-allelic indel rs5889219 is 
consistent with a total of four copies, estimated by the ratio between the test (DEFB) and the 
reference product of the two PRTs (PRT107A and HSPD21-PRT). [Adapted from Aldhous et al. 2010]. 
 
Compared to other PCR based methods, PRT offers high accuracy in CNV calling, 
comparable to microarray analysis (Aldhous et al. 2010; Fode et al. 2011). PRT is suitable for 
CNV association studies as a rapid and inexpensive CNV genotyping method. 
1.1.2.5 Future directions 
The above techniques are significantly changing our point of view regarding the human 
genome, which cannot be defined by a single reference genome but can only be described 
by a dynamic series of variants, moreover, no single existing methodology can be used to 
analyse absolute copy number for all genomic regions (Cantsilieris, Baird, White 2012). 
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Despite the great advancement and augmentation of analytical tools of investigation, much 
progress is still to be made in the detection of structural variations. Firstly, the use of “gold  
standard” controls for discovery and genotyping CNV methods is necessary to increase the 
reproducibility and verify the reliability of intra- and inter-methodological results (Aldhous 
et al. 2010; Pinto et al. 2011). Accurate analysis of the human genome revealed bias 
towards the identification of deletion CNVs: quantitative differences between deletion copy 
numbers are greater than duplications and multiallelic loci. In fact, distinguishing between 
four and five copy number, with a relative increase of 0.25, is a considerable challenge using 
current standard methodologies and complex CNVs require even more thorough 
investigation due to unclear information from the reference genome and erroneous use of 
the investigative tools (Hollox 2010; Hollox 2012). Therefore, the detection of multiallelic 
CNV has to be improved in order to completely understand the impact of CNV on the human 
genome and disease. Ultimately, the optimization of combined NGS technologies to a 
routinely laboratory approach could significantly increase our knowledge of the human 
genome and its variants, such as CNV. 
1.1.3 Molecular impact of CNV on gene expression 
Associated to phenotypic variants in disease and healthy populations (Lupski and 
Stankiewicz 2006), CNV, as other genetic variation, can directly affect gene expression 
altering gene dosage. Indirect effects can occur through position effects or downstream 
pathways, disrupting the gene reading frame or perturbing gene regulatory networks 
(Dermitzakis and Stranger 2006; Hurles, Dermitzakis, Tyler-Smith 2008; Reymond et al. 
2007).  
Comprehensive transcriptome analyses and gene expression studies investigate the 
effects of CNV either from a population point of view or in a disease context (Aldred, Hollox, 
Armour 2005; Hollox, Armour, Barber 2003; Perry et al. 2007; Pollack et al. 2002; Stranger et 
al. 2007). Analyses of expression levels of 14,925 transcripts with SNPs and CNVs in 
lymphoblastoid cell lines of 210 unrelated HapMap individuals associated change in copy 
number to about one-fifth of the detected genetic variation (Stranger et al. 2007). Studies 
on mice and rat transcriptosomes indentified a less strong but still significant correlation 
between CNVs and gene expression (Guryev et al. 2008; Henrichsen et al. 2009). 
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Several gene expression studies showed that the functional effect of CNV can be 
described with a simple model where a duplication or a deletion of the gene copy are 
respectively correlated with an increase or decrease of its expression (Hollox, Armour, 
Barber 2003; Lupski et al. 1991a; Perry et al. 2007). According to the mechanism of CNV 
formation, the deletion/duplication event can cause gene interruption by disruption of the 
coding sequence causing a loss of function (Nathans et al. 1986). Rearrangements between 
different genes or the same gene or their regulatory regions can initiate gene fusion 
resulting in a gain-of-function mutation (Lifton et al. 1992); this mechanism is more likely to 
occur in cancers associated to chromosomal traslocation (Mitelman, Johansson, Mertens 
2007). CNV involving regulatory regions within a specific gene can have impact on the gene 
itself or cause pleiotropic effects; modulation of genes in CNV proximities can occur by a 
position effect or perturbations of the transcription machinery followed by genomic 
landscape modifications (alterations of chromatin structure, positioning of chromatin, 
physical dissociation of the transcription unit) (Velagaleti et al. 2005). Moreover, CNV 
formation can cause deletion of one allele that may uncover another recessive allele or 
functional polymorphism (Kurotaki et al. 2005). 
1.1.5 Phenotypic effects of CNV 
CNVs have been shown to be widely accountable for human evolution and genetic 
diversity between individuals. The relevance of CNV on the human genome has been 
underlined by several association studies which highlighted how CNV can have an effect on 
susceptibility to cancer, complex trait disorders, and be the main cause of the onset of 
Mendelian diseases or confer a benign phenotype (Almal and Padh 2011; Stankiewicz and 
Lupski 2010; Zhang et al. 2009).  
1.1.5.1 Mendelian disease 
 Frequently genetic rearrangements arisen after NAHR events result in genomic 
disorders such as Mendelian traits, contiguous gene syndromes and whole-arm 
chromosome aberrations (Stankiewicz and Lupski 2002; Zhang et al. 2009). Historically, the 
Charcot-Marie-Tooth disease type1A and hereditary neuropathy with liability to pressure 
palsies were the first disorders detected to be caused by CNV events, more specifically the 
copy number change of the dosage-sensitive gene PMP22 as a result of the duplication of a 
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large region in chromosome 17p12 (Lupski et al. 1991b). Smith-Magenis syndrome / 
Potocki-Lupski syndrome is another genomic disorder with Mendelian autosomal dominant 
inheritance resulting from haploinsufficiency of the RAI1 gene on chromosome 17p11.2 
(Slager et al. 2003). Likewise, recessive dominant disorders or X-linked disorders are 
associated to CNVs. For instance, intrachromosomal rearrangements of the long arm of 
chromosome X causing recombination of the factor VIII gene are associated to haemophilia 
A pathology (Gaucher and Mazurier 1995).  
1.1.5.2 Infectious and Autoimmune diseases  
CNVs are enriched for genes with immunological functions, however the exact way in 
which they contribute to the genetic variability responsible for the recognition repertoire of 
the immune system is not explicitly understood (Olsson and Holmdahl 2012).  
Fc γ receptors (FcγR) are low-affinity receptors for the Fc domain of immunoglobulin 
G, whose activation stimulates phagocytosis and release of cytokines and other 
inﬂammatory mediators, depending on the cell type. CNVs within this locus have been 
studied in association with several autoimmune diseases giving contradicting results. A 
recent meta-analysis of FCGR3B, encoding for a receptor variant expressed on neutrophils, 
mast cells, and eosinophils, confirmed the role of its low copy number with systemic lupus 
erythematosus (SLE) (McKinney and Merriman 2012).  
Located in major histocompatibility complex (MHC) region, complement component 
C4 (C4A  and C4B) encodes for pivotal component in the activation cascades of complement 
pathways, essential in the binding of the immune complex to the target (Carroll 1998; 
Mackay, Rosen, Walport 2001). Low and high C4A copy number are associated respectively 
to increased risk and protection to SLE, increased C4B copies with higher risk of rheumatoid 
arthritis (Lv et al. 2011; Rigby et al. 2012; Yang et al. 2007). 
β-defensin locus, a copy number variable region strictly correlated with autoimmunity, 
will be discussed in 3.1. 
1.1.5.3 Population genetics and evolution 
CNV, as a structural change that significantly contributes to phenotypic variance, is 
likely to give a relevant signature to evolution and differentiation in modern humans 
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(Hurles, Dermitzakis, Tyler-Smith 2008). In particular, CNVs overlapping genes are more 
likely to be adaptive and affect ﬁtness than in intergenic CNVs (Cooper, Nickerson, Eichler 
2007). However, most CNVs located in functional regions in the human genome appear to 
be under negative selection (Nguyen et al. 2008), and only a few CNVs empirically showed 
positive selection in the population (Hardwick et al. 2011; Kidd et al. 2007; Perry et al. 2007; 
Xue et al. 2008). 
The first CNV event to be studied showing relevant interest in evolutionary change is 
the salivary amylase gene (AMY1). Higher copy number of AMY1, correlated with different 
salivary amylase protein levels, is on average present in individuals from populations with 
high-starch diet than those with low-starch diet (Perry et al. 2007). 
 Another relevant gene showing CNV event undergoing adaptive evolution is the UDP-
glucuronosyltransferase 2B17 (UGT2B17) gene. UGT2B17 CNV associated with variation in 
urine testosterone level, fat mass, male insulin sensitivity and probably prostate cancer risk, 
differs in mean number between populations from Africa, Europe, and East Asia due to 
positive selection (Xue et al. 2008). The UGT2B17 deletion, that was found to be highly 
common in Asian individuals, is probably responsible for conserving the testosterone level, 
generally lower in this population (Iskow, Gokcumen, Lee 2012).  
A population genetics study has been done in regards of a complex CNV region, the β-
defensin region, which encodes for important players in the host defense. From the analysis 
of CNV frequencies in 68 populations, within a worldwide distribution, it appeared that 
there are significant differences between populations and continents, considered to be the 
result of recent selective or demographic events (Hardwick et al. 2011).  
1.1.6 CNV and neurodegenerative diseases  
Genetic mutations located in unrelated genes have been linked to the familial versions 
of several of neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Amyotrophic lateral sclerosis (ALS). CNV as a cause of rearrangement of the 
genome structure could play an important role in the pathogenesis of these disorders. 
AD is the most common neurodegenerative disorder of the elderly and is 
characterized by dementia and progressive cognitive decline. As a familial (1% of the cases) 
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or sporadic disorder, AD is attributed to rare mutations in several genes: the amyloid-β 
protein precursor (APP), presenilin 1 (PS1) and presenilin 2 (PS2), and the apolipoprotein E 
(APOE) ε4 allele, which are directly related to overproduction or reduced clearance of the 
amyloid-β peptides (Rogaeva, Kawarai, George-Hyslop 2006). Duplication events involving 
the APP gene have been shown to be associated with autosomal dominant early onset AD 
(ADEOAD) and also cerebral amyloid angiopathy (Rovelet-Lecrux et al. 2006). Five different 
types of duplication causing an accumulation of the APP peptide were identified causing 
ADEOAD. Interestingly, early onset AD is a common feature of Down syndrome due to the 
trisomy of chromosome 21, where the APP gene is situated (21q21.3). Several studies 
extensively investigated the impact of CNVs in AD and have shown numerous associations 
such as a duplication events on chromosome 15q11.2, copy number change of olfactory 
receptor genes cluster (14q11.2), CNV of complement receptor one (CR1) and, specifically in 
regard of sporadic ADEOAD cases, seven new rare CNVs (four of which involves genes (KLK6, 
MEOX2, SLC30A3, FPR) related to amyloid-β peptide metabolism or signalling) (Brouwers et 
al. 2011; Ghani et al. 2012; Heinzen et al. 2010; Rovelet-Lecrux et al. 2011; Shaw et al. 2011; 
Swaminathan et al. 2011). 
PD is a progressive neuromuscular degenerative disease that affects 1% of the 
population over 50 years of age. The genetic etiology of PD is quite complex and involves 
several genes, at least five of which showed mutations responsible for autosomal dominant 
or autosomal recessive onset of the disease (Pankratz and Foroud 2007). Triplication and 
duplication of the SNCA gene, encoding for the α-synuclein, have been reported in 
individuals affected by familiar form of PD, suggesting an increase of α-synuclein due to 
CNV-induced dosage effect (Farrer et al. 2004; Fuchs et al., 2007; Ibanez et al. 2004; Miller 
et al. 2004; Singleton et al. 2003). A genome scan of CNV in a familiar PD cohort identified 
CNV in two novel genes (DOCK5 and USP32) associated with an increased risk of PD 
(Pankratz et al. 2011). Exome screening in Brazilian patients with PD revealed parkin 
(PARKIN) and PTEN induced putative kinase 1 (PINK1) genes copy number variations, but no 
dosage alteration was found in SNCA and DJ-1 genes (Moura et al. 2012). Furthermore, 
alterations in copy number of the microtubule-associated protein tau gene (MAPT) and of 
other genes located in its proximity (17q21.31) encode for a broad range of mental 
dysfunctions associated to variable phenotypes, ranging from frontotemporal dementia 
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with parkinsonism to mental retardation with or without dysmorphism and to schizophrenia 
(RoveletLecrux and Campion 2012). 
ALS is a fatal neurodegenerative disease affecting the motor neurons resulting in 
progressive weakness and death, usually within about three to five years post onset, as a 
result of neuromuscular respiratory failure. Familial forms of ALS, which represent 10% of 
the total cases, have been associated with mutations in several genes such as superoxide 
dismutase-1 (SOD1), accounting for about 20 to 30% of onset (Al-Chalabi et al. 2012). 
Screening on large ALS sample cohort by MLPA analysis showed that CNV, i.e. duplications, 
of the survival motor neuron gene (SMN1), which homozygous deletion causes spinal 
muscular atrophy, represents a risk factor for sporadic ALS (Blauw et al. 2012). 
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1.2 Huntington’s disease  
 “Chorea is essentially a disease of the nervous system”: this is how George 
Huntington initiated his essay “On Chorea”, in 1872. In this article, Huntington described 
accurately an already known disease, the chorea or dancing disorder; all the main symptoms 
and an illuminating description on the heritability are reported. This remarkable 
characterization of the disease led to the designation of the disease as Huntington’s disease.  
HD is a fatal progressive degenerative brain disorder, which is clinically described by 
motor dysfunction, severe emotional / psychiatric disturbances, cognitive decline and 
dementia (MacDonald et al. 1993).  The manifestation of the disease symptoms is around 
the age of 40 years, but juvenile (onset <20 years) and older onset (>70 years) forms also 
exist. Although useful for diagnosis, movement impairment is a poor marker of disease 
severity and it may not be the main debilitating aspect of the disease (Walker 2007). HD 
carriers, in fact, show a wide range of phenotypic markers, including cognitive decline, 
personality change, anxiety, depression, irritability, sleeping disturbance, metabolic 
symptoms, all signs of high heterogeneity of the disease (Novak and Tabrizi 2011). After the 
diagnosis of a first visible symptom, HD mutation carriers have an average life expectancy of 
around 20 years. 
HD manifests in all population groups with great variability between ethnic groups 
and geographical distribution: the incidence of HD in Asia varies from 0.046 to 0.16 per 
100,000 per year, whereas incidence in Europe, North America, and Australia varies from 
0.11 to 0.8 per 100,000 per year, within any trends toward a decrease or increase in 
incidence over time. The prevalence in the North America, Europe, and Australia is about 
5.70 per 100 000 and the rate is much lower than 0.5-0.4 per 100 000 in Asia and Africa 
(Harper 1992; Pringsheim et al. 2012). The geographic difference in prevalence in HD can be 
explained by predisposing haplogroups model, albeit another model based on a founder 
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chromosome could be responsible for the variable expansion of the disease (Falush 2009; 
Squitieri et al. 1994; Warby et al. 2009). 
1.2.1 Neuropathology of HD 
HD is a neurodegenerative disease that affects all the brain but with prominent cell 
loss and atrophy within the striatal part of the basal ganglia, in the caudate and putamen 
(Vonsattel and DiFiglia 1998); this degeneration is followed by extensive astrogliosis, with an 
increasing severity in time, leading to a characteristic great enlargement of the lateral 
ventricles (Figure 8).  
Recently the analysis of presymptomatic and early stage HD mutation carriers has 
permitted the evaluation of early effects of the disease on the brain, detectable through the 
application of brain imaging techniques including structural magnetic resonance imaging 
(MRI) or positron emission tomography (PET), able to highlight macro-structural changes 
such as atrophy, micro-structural alterations such as demyelination, metabolic dysfunctions 
and functional changes (Georgiou-Karistianis et al. 2013). 
 
 
Figure 8. HD and normal brains. 
On the left it is visible the great impact of HD within a profound shrinkage of cortex and caudate and 
the resulting ventricular expansion. Normal brain on the right. [From Reiner, Dragatsis, Dietrich 
2011]. 
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Large longitudinal studies (PREDICT-HD and TRACK-HD (Paulsen et al. 2006; Tabrizi et 
al. 2009) have shown that the reduction of the striatal volume is evident from up to 15 years 
prior to symptoms onset and that rates of decline in striatal volume is significantly faster 
compared with age-matched controls (Aylward et al. 2012; Paulsen et al. 2010; Tabrizi et al. 
2011). Nevertheless other features including the whole brain atrophy, grey and white 
matter loss and cerebral spinal fluid (CSF) expansion have been detected as early signs of HD 
neurodegeneration, the striatal atrophy is the most valuable biomarker of HD progression 
(Georgiou-Karistianis et al. 2013). 
1.2.2 The genetics of HD 
HD is a monogenic disorder caused by autosomal dominant inheritance of an abnormal 
cytosine-adenine-guanine (CAG) trinucleotide expansion within the 5’ end of the huntingtin 
(HTT) gene, located on the short arm of chromosome 4 at 4p16.3. The CAG triplet is the 
genetic code for the amino acid glutamine, which forms a toxic polyglutamine tail attached 
to the huntingtin protein in HD (MacDonald et al. 1993; The Huntington's Disease 
Collaborative Research Group 1993).  
The disease shows incomplete penetrance when the mutation stretch is between 36 
and 40 repeat units in HTT gene, a threshold beyond which the disease is considered fully 
penetrant (Figure 9) (McNeil et al., 1997; Quarrell et al. 2007; Rubinsztein et al. 1996). The 
length of this repeat expansion is significantly correlated with the age of onset (AO), with 
which it is inversely correlated  (Figure 10) (Andrew et al. 1993; Brinkman et al. 1997; Duyao 
et al. 1993; Lucotte et al. 1995; Snell et al. 1993). However, in individuals with repeat units 
ranging between 36 and 50, the mutation length is a poor predictor for AO. In fact, most of 
the correlation is found with high repeat lengths > 60, which are associated with juvenile 
onset (Figure 9). 
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Figure 9. Mutation length in the HTT gene and disease onset risks. 
 
HD, as other triplet disorders, shows the phenomenon of “genetic anticipation”. 
Individuals homozygous for the HTT allele with less than 36 CAG repeat units are 
asymptomatic but, in case of the expansion size is between 29 and 36 units, there is a high 
risk for the progeny to manifest the disease. This is due to a pathogenic expansion of the 
CAG repeat caused by the inherent instability of DNA replication of repeat regions, 
especially in spermatogenesis. This effect is the cause of between 6-8 % of new cases of the 
sporadic form of HD. This effect is much more evident in the offspring of affected 
individuals: in this case there is anticipation of the disease in the offspring, who manifest the 
HD at earlier AO than the affected parent. In most of cases, subjects with juvenile onset of 
HD inherited the mutant allele from the paternal side (Kremer et al. 1995; Ranen et al. 1995; 
Trottier, Biancalana, Mandel 1994). 
Instability of the CAG repeats occurs also in somatic cells in HD: evidence of mosaicism 
have been showed in selective area of the brain in humans, in particular correlated to long 
repeats stretch, and in mouse model of the disease (Kennedy et al. 2003; Telenius et al. 
1994). 
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1.2.2.1 The age of onset in HD 
AO in HD refers to the moment when a carrier of the mutated gene exhibits explicit 
HD signs. The accurate determination of AO is critical to identify factors that modify AO or 
biomarkers of disease progression, and to develop and evaluate therapies that aim to delay 
it. In manifesting cases, the AO is estimated retrospectively by clinicians based on 
information reported by the affected individual. In presymptomatic stages, mainly in familial 
cases, the expected age of future onset is calculated considering the CAG repeats length and 
the actual age of the individuals and verified prospectively. In both case prediction of the AO 
are susceptible to inaccuracies of the rater and variability due to the formula used for the 
estimates, based on correlation between AO and CAG repeat length (Langbehn et al. 2004; 
Langbehn, Hayden, Paulsen 2010; Orth and Schwenke 2011). 
AO is estimated to range between 1 to 80 years. This wide temporal window can be 
partially explained by the inverse correlation with the variable length of the CAG expansion, 
which is best described by a curvilinear regression model, using a log-transform of AO 
(Figure 10). From this correlation arises that the CAG mutation length accounts for nearly 70 
% of the variance of AO, albeit in individuals carrying 40-50 CAG repeats the rate decreases 
significantly to 44% suggesting the presence of other modulators (Wexler et al. 2004). These 
could be stochastic, environmental / experiential or genetic factors. A study performed on 
83 independent Venezuelan HD pedigrees estimated the impact of additional genetic, and 
environmental, factors on the AO in HD. After excluding any possible influence of shorter 
HTT allele or gender, it was estimated that the residual AO variance in HD was 63 % 
attributable to shared (family) and unshared environments, and the remaining 38 % to 
genetic factors (Wexler et al. 2004). Non-influential is the presence of a second mutant HTT 
allele as homozygotes for HD show comparable AO to heterozygotes, although the disease 
progression is much more severe (Myers et al. 1989; Squitieri et al. 2003; Wexler et al. 
1987). 
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Figure 10. The inverse relationship between age of onset and repeat length. 
Box plot of AO and CAG repeat length of the longer allele. The curvilinear relationship between the 
two variables can be observed. It also is important to note the wide variability of AO within each 
repeat length, especially within the range from 40 to 50 CAG repeat units. [From Gusella and 
MacDonald 2009]. 
 
A genetic modifier of the AO in HD is a gene harbouring a mutation which both 
influence the onset of phenotypes associated with the CAG mutation and affect gene 
function. The main strategy to identify genetic modifiers in HD is usually the candidate 
approach: common genetic variants, likely involved in HD pathogenesis, are analysed in 
manifest HD carrier cohorts to test whether they are associated with earlier or later AO 
among similar CAG length carriers. So far, several screens on HD sample cohorts have been 
performed, giving a mixture of results. The table 2 lists some of the main loci or gene 
variants investigated to be genetic modifiers of AO in HD. Several recent studies performed, 
aimed to validate previous findings in large cohorts, do not replicate the association of the 
listed variants with the AO in HD, initially analysed on small sample sets.  
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Table 2. Association studies of genetic modifiers of the AO in HD. 
Gene ID 
Analysed 
Variant 
Study Population 
analysed 
HD 
samples* 
protective / 
detrimental 
allele 
p value 
GRIK2 (TAA)n 
Rubinsztein et 
al. 1997   
England 293 
all  others / 
(TAA)16, 17 
0.008 (ΔR2 =0.41) 
MacDonald et 
al.1999   
USA 258 0.009 (ΔR2 =0.006) 
Chattopadhyay 
et al. 2003   
India 77 0.009 (ΔR2= 0.02) 
Cannella et al. 
2003   
Italy 524 0.001* (ΔR2= 0.14) 
Metzger et al. 
2006a   
Europe 980 ns 
Naze et al. 
2002   
France 138 ns 
Andresen et al. 
2007  
Venezuelan 
kindreds 
368 ns 
Lee et al. 
2012a  
HD-MAPS, 
REGISTRY-
EHDN, 
COHORT 
2,911 ns 
GRIN2A rs2650427 
Arning et al. 
2007  
Germany 250 
T/C-additive 
model 
0.047*(ΔR2=0.011) 
Andresen et al. 
2007  
Venezuelan 
kindreds 
421 0.04 (ΔR2=0.003) 
Saft et al. 2011  
REGISTRY-
EHDN 
1,211 0.028 (ΔR2= 0.001) 
GRIN2B rs1806201 
Arning et al. 
2007  
Germany 250 T / C 0.005* (ΔR2=0.026) 
Andresen et al. 
2007  
Venezuelan 
kindreds 
443  ns 
Saft et al. 2011  
REGISTRY-
EHDN 
1,211 CT / all others 0.046*(ΔR2=0.003) 
PGC-1α 
rs6821591 
Weydt et al. 
2009  
Italy 447 
G/A dominant 
model 
0.0178 
rs7665116 
G/A additive, 
dominant 
model 
0.0016, 0.0003 
Taherzadeh-
Fard et al. 
2009  
Germany 400 
C/T dominant 
model 
0.012 (ΔR2=0.004) 
Che et al. 2011  Europe 854 
additive, 
dominant 
model 
0.03 (ΔR2=0.0129), 
0.0112 
(ΔR2=0.0128)    
 
(0.0172; 0.0045)
* 
 
Ramos et al. 
2012  
Southern 
European, 
Western 
European 
1,628 
C/T additive, 
dominant 
model 
0.009(β=0.090), 
0.008(β=0.113). 
 
 [0.047(β=0.069), 
0.033(β=0.089)]** 
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UCH-L1 Ser18Tyr 
Naze et al. 
2002  
France 138 
Y/S dominat 
model 
0.024 (ΔR2=0.042) 
Metzger et al. 
2006b  
Europe 946 Y/ S < 0.001* 
Andresen et al. 
2007  
Venezuelan 
kindreds 
405  ns 
BDNF 
Val66Met 
(rs6265) 
Alberch et al. 
2005  
Spain 122 
VM 
heterozygous 
/ VV 
homozygous 
< 0.001 
(ΔR
2
=0.59) 
Metzger et al. 
2006a  
Europe 980 ns 
Mai et al. 2006  Germany 250 ns 
Di Maria et al. 
2006  
Italy 244 ns 
Kishikawa et 
al. 2006  
HD-MAPS 557 ns 
Taherzadeh-
Fard et al. 
2010  
Germany 419 ns 
HAP-1 
T441 M                 
(rs4523977) 
Metzger et al. 
2008  
European 903 
MM / all 
others 
0.015* 
Taherzadeh-
Fard et al. 
2010  
Germany 419 0.041 (ΔR2=0.002) 
Karadima et al. 
2012  
Greece 298 ns 
ADORA2A 
rs5751876 
Dhaenens et 
al. 2009  
France 791 all others / TT 0.019 
rs5751876 Taherzadeh-
Fard et al. 
2010  
Germany 419 
TT ± 0.032*(ΔR2=0.003) 
rs2298383 TT ± 
0.006(ΔR2= 0.004).         
0.001*(ΔR2=0.007) 
* The statistic value refers to a specific subset.  
**Analysis adjusted for ancestry. 
± The genotype increased the R2 of the regression CAG repeats-AO, with no variance in AO. 
ΔR2 indicates the improvement of the regression model when the various genotypes are considered in 
addition to the HD CAG repeats. 
β value refers to the size of effect of the integration of the genetic variant to the model of correlation 
between CAG repeats-AO. 
 
An example of a false-positive association due to a small sample size effect is the 
study of a variant on GRIK2 (glutamate receptor, ionotropic kainate 2), gene encoding the 
GluR6 subunit of the main excitatory neurotransmitter receptor family in the brain, a 
valuable candidate possibly involved in excitoxicity in HD. A triplet expansion of 16 TAA 
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repeats in this gene was reported to be associated with earlier onset of HD in several 
studies, however in each study less than 300 individuals were analysed or the correlation 
was just present in a small subset (Cannella et al. 2003; Chattopadhyay et al. 2003; 
MacDonald et al. 1999; Rubinsztein et al. 1997). Further analyses clearly disproved this 
association analyzing the questioned variant on larger data sets, highlighting the need of 
large-scale investigations to adequately evaluate the potential effects of candidates  genetic 
modifier of the AO of HD (Lee et al. 2012a; Metzger et al. 2006). 
Another interesting example of a biased association is the case of PGC1-α 
peroxisome proliferator-activated receptor gamma, coactivator 1 alpha). Association studies 
of SNPs and haplotypes on this gene with a delay of AO in HD and much evidence of its 
active role during the neurodegenerative process supported the role of PGC1-α as a genetic 
modifier in HD (Chaturvedi et al. 2009; Taherzadeh-Fard et al. 2009; Weydt et al. 2006; 
Weydt et al. 2009). A further genetic screening on several HD cohorts highlighted that the 
strong effect seen in the previous studies was probably a result of population-dependent 
phenotype stratification. In fact, Southern European HD individuals, representing the 
majority of the previously analyzed samples, are enriched for the minor allele frequency 
(MAF) of one of the main SNP previously associated with delay of AO, and they are much 
more significantly associated to a later HD AO compared to Western European HD 
individuals. In addition to question the role of PGC1-α as a genetic modifier of the AO in HD, 
the results of this study reveals genetic ancestry as a critical factor in HD association studies 
(Ramos et al. 2012). 
Considering these and other recent works, the analysis of genetic modifiers of AO in 
HD should strive towards standardized approaches. In order to avoid batch effect or 
stratification due to population dependent phenotypes it is fundamental to perform 
association studies on a large HD individual data set provided by multi-centre, multi-national 
observational studies like the “REGISTRY” project of the European HD network (EHDN), and 
the American “COHORT” study, which catalogues natural history data on a wide range of the 
HD population (Dorsey 2012; Orth 2011). In addition to that, it is important to screen for a 
statistically well-behaved data set that conforms to the primary assumptions of linear 
regression analysis (constant variance and normally distributed error) between AO and 
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triplet mutation length. In fact, a single outlier can potentially have a huge effect on the 
inferences between the two variables, AO and CAG repeat length, misleading the evaluation 
of a potential modifier of the AO (Lee et al. 2012b). Moreover, a genetic association study 
should provide evidence of how the studied variant affects gene function and HD onset. 
Currently, genetic variants, which can be reliably considered modifiers of the AO in 
HD, are few and independent replication studies are still needed. However, noteworthy is 
the association study in regard of HAP-1 (huntingtin associated protein 1): a polymorphic 
variant in HAP-1 was found to be responsible for a change in the protein structure leading to 
a delay of motor symptoms onset in individuals with < 60 CAG. This finding was validated by 
in vitro study where the polymorphic protein was associated with a reduction of HTT-
toxicity (Metzger et al. 2008). Two further studies weakly reproduced and failed to 
reproduce respectively this previously observed association; they were however performed 
on smaller cohorts (Taherzadeh-Fard et al. 2010; Karadima et al. 2012).  
Confirming the Wexler et al. study, it has been found that the shorter / wild type 
allele is not influential on the onset and progression of motor symptoms in HD, a point of 
debate in several studies (Lee et al. 2012b), and any possible implication of HTT region SNP 
haplotypes with altered CAG repeat length distribution or residual AO of HD has been 
excluded (Lee et al. 2012c).  
An alternative approach for the discovery of possible genetic modifiers of AO in HD 
makes use of screen in simple and manageable model organisms as yeast, Caenorhabditis 
elegans and Drosophila melanogaster in which human mutant HTT is introduced. Such 
models are useful for the identification of modifiers of the effects of this fragment (Giorgini 
et al. 2005; Kaltenbach et al. 2007; Lejeune et al. 2012). Limitations of this approach lie in 
the diversity of HD expression in these organisms and in the necessary replication of 
possible findings in other models and human genetic screening. In order to reach a deeper 
knowledge and holistic view of all genomic variants (not only SNPs) associated to HD, a 
significant advantage will be provided by genome wide and exome wide sequencing and 
array studies with high quality annotation, performed on thoroughly understood cohorts. 
34 
 
This will provide a better platform from which to further interrogate potential modifiers of 
AO in HD. 
1.2.3 Huntingtin protein  
The gene encoding for the huntingtin protein (HTT) lies on a region of ∼170 kb at 
4p16.3, consisting of 67 exons. It is quite conserved among vertebrates, where the most 
divergent species shares 69% identity at the nucleotide level (Sathasivam et al. 1997). 
Huntingtin is a completely soluble protein of 3,144 amino acids, whose structure is still 
under investigations due to the large size and difficulties in creating crystals. The gene 
encodes for two alternatively polyadenylated transcripts, variable in size (~3kb) and 
localization: the shorter form is ubiquitously expressed, whereas the longer HTT is 
predominantly present in the neurons of the CNS, where the expression of the gene is 
enriched (Li et al. 1993; Lin et al. 1993; Strong et al. 1993). Specifically, HTT is highly 
localised in cortical pyramidal neurons in layers III and V that project to the striatal neurons 
(Fusco et al. 1999).  
HTT has been shown to be expressed from the embryonic stage, during which 
mutated forms or reduced expression are tolerated but not the complete deletion, which 
causes early embryonic lethality in mice (Duyao et al. 1995; Myers et al. 1989; Nasir et al. 
1995; Wexler et al. 1987; Zeitlin et al. 1995). At cellular level, the HTT protein is associated 
with a range of organelles including plasma membrane, endocytic and autophagic vesicles, 
endoplasmic reticulum, endosome, Golgi, and mitochondria (DiFiglia et al. 1995). Within 
neurons, it is present in neurites and associated with vescicular compartments at the 
synapses. This extensive subcellular localization does not facilitate the characterization of 
the HTT protein function (Zuccato, Valenza, Cattaneo 2010).  
Organized into three clusters, 16 HEAT (Huntingtin, Elongator factor3, the regulatory A 
subunit of protein phosphatase 2A, and TOR1) domains are present in the HTT protein 
(Figure 11) (Tartari et al. 2008). HEAT repeats consist of ~50 amino acids which are 
conserved in several proteins and are organized in tacked pairs of antiparallel alpha-helices; 
they are involved in protein–protein interactions (Andrade and Bork 1995). 
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Figure 11. Schematic diagram of the Htt protein sequence. 
The pink box is a regulator of HTT binding to other proteins. PolyQ indicates the polyglutamine tract. 
The red empties boxes indicate the three main groups of HEAT repeats. The yellow boxes are tissue-
specific cleavage sites of HTT: B, regions cleaved mainly in the cerebral cortex; C, regions cleaved in 
the striatum; A, regions cleaved in both. NES is the nuclear export signal and NLS is the nuclear 
localization signal. aa amino acid, HTT huntingtin, ER endoplasmatic reticulum. [Adapted from 
Zuccato, Valenza, Cattaneo 2010]. 
 
The HTT protein exhibits consensus cleavage sites for the proteolytic cut of several 
proteases including caspases, calpain and matrix metalloproteinases, which likely generate a 
wide range of NH2-terminal fragments (Figure 11) (Gafni and Ellerby 2002; Miller et al. 2010; 
Wellington et al. 1998). Despite that the wild type HTT is found in the cytoplasm, these NH2-
terminal fragments and the mutant HTT tend to shift and accumulate in the nucleus, a toxic 
event in HD Davies et al. 1997; Hermel et al. 2004; Landles et al. 2010). The inhibition of 
some of these enzymes is associated with a reduction of the toxicity, underling the 
importance of proteolysis of the mutant HTT full-length in HD Gafni et al. 2004; Wellington 
et al. 2000). Located at the COOH-terminal HTT site, the nuclear export signal mediates the 
nucleus-cytoplasm shuttle of HTT. This domain is cleaved away in mutant HTT, suggesting it 
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contributes to its accumulation in the nucleus, (Xia et al. 2003). A nuclear localization site at 
the NH2-terminal HTT fragments binds the nuclear pore protein, involved in nuclear export, 
which is disrupted in HD due to the polyQ expansion interference (Cornett et al. 2005). 
Moreover, HTT is subjected to posttranslational modifications, including 
ubiquitination, phosphorylation, acetylation, sumoylation, and palmitoylation. These could 
regulate its stability, localization, and function and be influential during HD pathogenesis, 
reducing or exacerbating the mutant HTT toxicity (Aiken et al. 2009; DiFiglia et al. 1997; 
Kalchman et al. 1996; Steffan et al. 2004). 
 1.2.3.1 Htt functions 
HTT plays a key role during embryogenesis, as its complete inactivation in HTT knock-
out mice causes embryonic death (Duyao et al. 1995; Nasir et al. 1995; Zeitlin et al. 1995). 
The absence of HTT leads to an increase in cellular death, as the anti-apoptotic function of 
the wild-type protein is lost (Zheng and Diamond 2012). In fact, it was found that the 
overexpression of wild-type HTT in brain-derived cells has a pro-survival function, whereas a 
depletion leads to higher response to apoptotic signals in neurons (Leavitt et al. 2006; 
Rigamonti et al. 2000; Zhang et al. 2003). 
HTT is implicated in several transcription pathways. It is considered to be a primary 
regulator in the production and trafficking of the brain-derived neurotrophic factor (BDNF) 
in the cerebral cortex (Gauthier et al. 2004; Zuccato et al. 2001; Zuccato and Cattaneo 
2009). Specifically, HTT regulates the activity of one of the BDNF suppressors, the repressor 
element-1 silencing transcription factor (REST) /neuro-restrictive silencer factor (NRSF) with 
which HTT interacts in a complex with other proteins, as HAP-1 (Zuccato et al. 2003; Zuccato 
et al. 2007).   
Moreover, HTT as a membrane-scaffolding protein interacts with a wide range of 
endocytic / trafficking proteins and plays an important role in axonal vesicles transport and 
synaptic plasticity (Caviston et al. 2011; Trushina et al. 2004; Velier et al. 1998). 
A better understanding of HTT functions comes from the analysis of mechanisms 
behind HD (1.2.4), where the mutant protein is a key player. 
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1.2.4 Mechanisms of neurodegeneration in HD 
There are several mechanisms that contribute to the neurodegeneration observed in 
HD which are not exclusively correlated to HTT altered functionality. This suggests that HD is 
probably a non cell autonomous disease where the mutated HTT is the triggering factor in 
the disease. 
1.2.4.1 Misfolding and Aggregation of the Mutant Huntingtin 
At a cellular level, one of the first hallmarks of HD is the accumulation of N-terminal 
fragments. These fragments are mainly formed after the cleavage by several caspase, 
calpain and other proteases enzymes on both normal and mutant HTT, although the mutant 
form is more prone to the proteolytic cut and N-terminal fragments can produced by 
aberrant splicing CAG length-dependent of the HTT transcript (Kim et al. 2001; Lunkes et al. 
2002; Sathasivam et al.,, 2013). From the cleavage of the mutant HTT, NH2-terminal 
fragments accumulate in the nucleus of non neuronal and neuronal cells, where they can 
aggregate in nuclear inclusions (DiFiglia et al. 1997; Goldberg et al. 1996). Interestingly, it 
has been shown that the inhibition of the proteolytic enzymes or mutation in the cleavage 
consensus site on the HTT gene slow down the progression of HD in mice (Gafni et al. 2004; 
Graham et al. 2006; Wellington et al. 2000).  
HTT fragments tend to aggregate into ultra-structures and deposit in neurons of all 
cortical layers and in the striatum of HD patients. Critical factors in the formation of the 
aggregates are the length and amount of the fragments, the length of the polyglutamine tail 
attached to them, and the presence of intracellular protein interactors of HTT Chen, 
Ferrone, Wetzel 2002; Hackam et al. 1998; Li and Li 1998; Martindale et al. 1998). These 
aggregates occur in different structures: oligomers, fibrils or amorphic aggregates, which 
can all form inclusion bodies (Figure 12). 
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Figure 12. Possible aggregation pathway and formation of inclusion bodies. 
 [From Ross and Poirier 2005]. 
 
Although intranuclear deposits of mutant HTT alter gene expression in HD animal and 
cell models, the specific role that the nuclear inclusions play in HD pathology is 
controversial. These particles are known to be toxic with the potential to cause axonal 
degeneration or to recruit a wide range of factors, causing disruption of axon physiological 
activity, but can also be neuroprotective for the ability to sequester toxic soluble fragments 
or other elements (Zuccato, Valenza, Cattaneo 2010). Another hypothesis defines the small 
soluble monomeric forms alone toxic but not oligomeric or aggregated mutant HTT (Lu and 
Palacino 2013). It is possible to say clearly that the toxicity of these aggregates is due to 
their formation process more than to a single species per se; the misfolding process at the 
beginning is the evident cause of toxicity generated from the mutant HTT. A better 
understanding of the role of aggregation will be achieved within the study of early stage 
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formation events and, possibly, performing in vivo experiments (Ross and Poirier 2005; 
Zheng and Diamond 2012).  
1.2.4.2 Clearance of Mutant HTT 
The two main mechanisms involved in the clearance of intracellular polyQ protein 
deposits are the ubiquitin-proteasome system (UPS) and the autophagy.  
HD being a proteinopathy, several studies have investigated the role of the UPS in the 
disease, showing that HTT protein aggregates are positively stained for ubiquitin in human 
HD post-mortem brains, HD cells and animal models (Schipper-Krom, Juenemann, Reits 
2012). According to an early study, HTT aggregates can directly inhibit the UPS, which is 
impaired in HD (Bence, Sampat, Kopito 2001; Holmberg et al. 2004). Conversely, it was 
shown that the UPS inability to completely process long polyQ proteins might lead to the 
formation of aggregation-prone polyQ peptides, suggesting an active role of the UPS in the 
pathogenesis of HD, or the inactivation of the proteasome itself, due to clogging by the 
undigested polyQ (Holmberg et al. 2004; Raspe et al. 2009; Venkatraman et al. 2004). In 
another model the nuclear inclusions in striatal neurons restore the UPS and they probably 
interact with and thereby sequester toxic forms of mutant HTT with beneficial effects 
(Arrasate et al. 2004; Mitra, Tsvetkov, Finkbeiner 2009). According to these studies, it is not 
possible to define the role of the UPS but results clearly show that enhancement of 
proteasome degradation could stimulate and improve clearance of mutant HTT and prevent 
aggregation and toxicity of the polyQ fragments (Schipper-Krom, Juenemann, Reits 2012). 
Initially observed in post-mortem brains (Tellez-Nagel, Johnson, Terry 1974), 
alterations in autophagy are typical in HD. The accumulation of aggregates in HD is shown to 
be responsible for the sequestration of mTOR, a negative regulator of the autophagic 
pathway (Ravikumar et al. 2004). The use of rapamycin, an inhibitor of mTOR, or the 
expression of small-molecule enhancer of rapamycin (SMER), enhancer of autophagy in 
yeast, attenuates the polyglutamine toxicity in various model of HD (Ravikumar et al. 2004; 
Sarkar et al. 2007). Inversely, soluble mutant HTT levels, aggregate formation, and toxicity 
augment when the autophagy is inhibited (Ravikumar, Duden, Rubinsztein 2002). 
Interestingly, HTT shares several similarities with mTOR: they are scaffolding proteins, both 
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of them containing HEAT repeats domains, important to specifically recognize membranous 
structures, and they both reversely associate to ER and Golgi membrane. Therefore, HTT is 
considered to have a potential role in the regulation of autophagy (Son et al. 2012). 
1.2.4.3 Transcriptional Dysregulation 
Initially, altered expression profiles of mRNA and protein levels of several neuronal 
peptides, evidenced by studies on post mortem HD brain and mouse HD model, supported 
the line that the transcriptional dysregulation is a causative factor of the neurodegenerative 
process in HD Andrews et al. 1999; Augood et al. 1996; Augood, Faull, Emson 2004; Cha et 
al. 1998; Cha et al. 1999). Further analysis of HD models (yeast, rat and mice) and HD human 
specimens by single gene and transcriptional profiling approaches contributed to identify a 
wide set of alterations in the expression of coding and non-coding RNAs (Borovecki et al. 
2005; Ferrante et al. 2003; Giorgini et al. 2008; Hodges et al. 2006; Kita et al. 2002; Luthi-
Carter et al. 2000; Luthi-Carter et al. 2002; Seredenina and Luthi-Carter 2012). These 
changes, mainly downregulation of gene expression, are mostly the result of the interaction 
between mutant HTT with several transcription factors such as CREB binding protein (CBP), 
TATA-binding protein (TBP), specificity protein 1 (Sp1), nuclear co-repressor (NCoR), and 
REST/NRSF and also p53, a tumour suppressor. Furthermore, the inhibition of enzymes 
involved in chromatin remodelling, and the interaction of HTT with components of the core 
transcriptional machinery and the RNA polymerase itself suggest the impairment of the 
transcriptional machinery in HD (Cha 2007). 
Although most of the functional downstream effects derived from transcriptional 
dysregulation in HD represent an epiphenomena or have no relevant impact, some of them 
actively contribute to the disease pathology, causing for instance neuronal vulnerability 
(due to reduced expression of BDNF, NMDA and several other receptors and neuronal 
peptides) or metabolic dysfunctions (due to decrease of PGC1-α, a transcriptional 
coactivator). 
1.2.4.4 Trafficking alterations 
The ability of HTT to recruit (and sequester within the aggregates) several factors 
implies that intracellular transport might be impaired in HD. Several studies on mice and 
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Drosophila HD model shown that axonal transport disruption is associated with mutant HTT 
and occurs from the early stages of the disease, causing vesicle accumulation, typical deficit 
of axonal transport in HD (Gunawardena et al. 2003; Lee, Yoshihara, Littleton 2004; Li et al. 
2001; Trushina et al. 2004). 
HAP-1, which interacts with motor proteins as kinesin light chain and dynactin, is an 
essential interacting factor of HTT in trafficking (Engelender et al. 1997; Li et al. 1995; 
McGuire et al. 2006). In HD, mutant HTT-Hap-1 complex is mainly responsible for the 
disruption of the excitatory / inhibitory homeostasis, by altering the transport of NMDA and 
GABA receptors, and depletion of BDNF trafficking Fan and Raymond 2007; Gauthier et al. 
2004; Twelvetrees et al. 2010).  
Furthermore, alterations of the endosomal recycling are found in several models of 
HD due to dysfunction in the Rab protein family, with implications on the glucose uptake in 
primary neurons in the disease (Li et al. 2009a; Li et al. 2009b; Li et al. 2012). Interestingly, 
in a Drosophila HD model early synaptic impairments can be rescued by the overexpression 
of a member of this family, Rab11, potentially a good therapeutic target Steinert et al. 
2012). 
1.2.4.5 Metabolic dysfunctions  
Metabolic abnormalities, specifically dysfunction in glucose metabolism, cholesterol 
biosynthesis and urea cyclic metabolism, are typical features present in HD human and 
mouse models (Chiang et al. 2007; Hurlbert et al. 1999; Josefsen et al. 2007; Shin et al. 
2013; Valenza et al. 2005). The application of 1H-magnetic resonance spectroscopy (1H-MRS) 
and PET showed bioenergetic disfunctions in HD patients such as higher concentration of 
lactate in the cerebral cortex and basal ganglia (sign of an elevated glycolytic rate), or 
dysfunction of the glucose metabolism, present in presymptomatic and early stages of the 
disease (Ciarmiello et al. 2012; Feigin et al. 2001; Jenkins et al. 1993; Kuhl et al. 2004). 
Interestingly, the reduction of glucose uptake in the caudate was found to be an accurate 
biomarker of disease progression in presymptomatic individuals (Ciarmiello et al. 2012). 
At cellular level disturbances of the energetic balance are mainly triggered by 
mutant HTT on the mitochondria (Panov et al. 2002). HTT interferes with calcium 
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homeostasis, production of ATP and also impairs mitochondrial trafficking, by direct effect 
on the mitochondria or modulating the expression of mitochondrial factors as PGC1-α, 
brain-type creatine kinase (CKB) or AMP-activated protein kinase (AMPK) (Ju, Lin, Chern 
2012). 
1.2.4.6 Neuroinflammation 
Since high levels of activated microglia near degenerating neurons were detected in 
post mortem examination of HD brains, several studies investigated the role of 
neuroinflammation in HD, not only an epiphenomenom but probably a triggering element of 
the neurodegeneration (Meßmer and Reynolds 1998a; Meßmer and Reynolds 1998b; 
Singhrao et al. 1999). Further studies based on PET assessment estimated that activated 
microglia are manifest as early as 15 years before the predicted age of onset (Tai et al. 
2007). Proteomic profiling of HD mutation carriers revealed the significant expression of 
components of the complement cascade and other cytokines in plasma and striatum of 
presymptomatic and early stage of the disease, indicative of the critical role of the innate 
immune system in HD (Björkqvist et al. 2008; Dalrymple et al. 2007).  
The kynurenine pathway, initially known for one of its metabolites (quinolinic acid), 
which is able to induce HD like-symptoms in mice, via excitoxicity and free radical 
generation, played an important role neuroinflammation and also metabolic perturbation 
since early stage of HD (Tan et al. 2012; Amaral et al. 2013). Interestingly, the inhibition of a 
key enzyme (kynurenine 3-monooxygenase (KMO)) in the kyneurine pathway ameliorates 
neurodegeneration in a fruit fly and mouse models of HD (Zwilling et al. 2011; 
Thevandavakkam et al. 2010), findings that started the analysis of KMO inibhithors in clinical 
trials. 
1.2.5 Models of HD 
Initially HD animal models were produced by injecting neurotoxins (glutamate 
analogs, quinolinic acid, 3-nitropropionic acid and malonic acid) into the striatum, capable of 
reproducing various aspects of the disease (Zuccato, Valenza, Cattaneo 2010). After the 
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cloning of the human HTT, HD models were designed to mimic and study the effect of the 
polyglutamine expansion in vivo and in vitro (Table 3).  
In vitro studies mainly contributed to explain the effect of aggregation of mutant HTT 
using different inducible or stable transformed cell lines such as the non-neuronal human 
HeLa cells, the human embryonic (HEK293T) and monkey kidney fibroblast cell lines (COS-7) 
as well as the Neuro2a (N2a) neuroblastoma (mouse) and neuron-like PC12 (rat) cells. 
Considering that mutant HTT is expressesed in several peripheral tissues, also immortalized 
cell lines from HD individuals specimens are used a reliable cell model for HD (Cisbani and 
Cicchetti 2012). A new promising approach is based on reverting skin fibroblast into 
inducible human pluripotent stem in order to direct these into neuronal cell development: 
with this method is possible to have direct specimens from HD individuals and to study the 
disease in untransformed human neuronal cells (Kaye and Finkbeiner 2013). 
Table 3. Comparison of HD models available.  
 
Transformed 
HD cell lines 
Human 
HD cell 
lines 
Yeast Nematode Fruit fly Zebrafish Rodent 
Availability  -/      
Cost        
Labour   - - -/   
Throughput        
Homology    -/ -/   
Pleiotropic 
studies 
- - -     
 
In vivo approaches include the use of simple organisms and more sophisticated 
mammals. Saccharomyces cerevisiae (yeast), Caenorhabditis elegans (nematode), 
Drosophila melanogaster (fruit fly), and Danio rerio (zebrafish) and are all simple organisms 
suitable for economical and valuable discovery of new disease factors, validation of genetic 
screening and testing new therapeutic compounds. Transgenic and knock-in rodent lines, 
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especially Mus musclulus (mouse), are mammalian models that offer the study of neuronal 
systems closer to humans and allow the performance of complex behavioural test not 
possible in other models, but require more time and expense. Importantly, rodent models 
represent a key step in drug development pipelines.  A subset of these models is discussed 
in detail below.  
1.2.5.1 Yeast HD model  
The budding yeast S. cerevisiae, thanks to its ease of manipulation and amenability 
to genetic modifications, large scale screening approaches, and a fully annotated genome, is 
widely used as a model organism in the study of neurodegenerative disorders (Pereira et al. 
2012). The yeast does not contain an HTT ortholog however the expression of a human htt 
fragment with a polyQ tract, in the disease range size (HTT103Q), causes typical features of 
HD such as protein aggregation, mitochondrial dysfunction, defects in trafficking and 
transcription, resulting in apoptotic death and toxicity. All of these features make yeast a 
good disease model for HD, despite a main drawback: as unicellular organism the study of 
complex mechanisms as inflammation or synaptic transmission is not possible (Mason and 
Giorgini 2011). Interestingly, yeast HD model studies highlighted a link between HD and 
yeast prions, wherein the latter are necessary to trigger the polyQ toxicity (Duennwald et al. 
2006; Meriin et al. 2002). A number of promising therapeutic compounds such as inhibitors 
of KMO (see 2.4.6) and the potent aggregation inhibitor C2-5 were identified in yeast 
screening and consequently validated in other HD models (Campesan et al. 2011; Chopra et 
al. 2007; Giorgini et al. 2005; Zhang et al. 2005; Zwilling et al. 2011). 
1.2.5.2 Fruit fly HD model  
The fruit fly is one of the most widely used genetic model organisms. Comparative 
genome wide sequence analysis of the whole fly genome, which contains only 4 pairs of 
homologous chromosomes and ~ 12,000 annotated gene, showed high structural similarity 
between fruit fly genes and human genes (Adoutte et al. 2000). As well a number of 
signalling and regulatory pathways and fundamental cellular processes (including gene 
expression, subcellular trafficking, synaptic transmission, synaptogenesis, and cell death) are 
well conserved or similar between human and fly (Ambegaokar, Roy, Jackson 2010). 
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The fruit fly is equipped with a specialized nervous system able to perform complex 
activities such as vision, olfactory processing, responsive motor behaviour (such as walking 
or climbing), learning and memory, similar to the mammalian brain (Marin et al. 2002; Rein 
et al. 2002; Wong, Wang, Axel 2002). Furthermore, the fly eye, characterized by a repetitive 
modular pattern (ommatidia) of photoreceptors (rhabdomeres), is a direct window of the 
neuronal integrity: i.g. neurodegenerative alteration can be easily recognizable by visible 
disruption of the ommatidial module under light microscope (Figure 13) (Jackson et al. 
1998).  
 
 
Figure 13. Ommatidia pattern and pseudopupil assay. 
A)The repeating ommatidial pattern shown in scanning electron microscopy images of the fruit fly 
compound eye. B) Cartoon of the structural module of an ommatidium, where the photoreceptors 
visible in cross-section are coloured in red. C) Pseudopupil assay in wild type (left) and HD flies (right). 
[From Green and Giorgini 2012]. 
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The fly life cycle is characterised by short reproductive and developmental cycles (10–
14 days from embryo to reproductively mature adults) and a short life span (~12 weeks in 
wild type background), as well as an absence of meiotic recombination in males, all features 
that, with the easy handling and cheap maintenance, make the fly an amenable model 
organism with which to study many genetic disorders.  
A wide range of genetic manipulation techniques have been developed within the 
fruit fly model to test the effect of overexpression, downregulation, deletion of endogenous 
and exogenous genes. Several null-allele mutant lines have been developed using chemically 
induced mutagenesis e.g., using ethyl methane sulfonate (EMS) or by insertion of a P 
element, an endogenous transposon that allows semi-random insertion mutagenesis with 
preferential insertion into gene promoter regions (Ambegaokar, Roy, Jackson 2010; 
Spradling and Rubin 1982). The P elements have been modified for several applications like 
chromosome engineering, gene tagging, and inducible gene expression/repression in 
combination with binary system of conditional expression. In fact, the expression of a gene 
of interest can be regulated using the GAL4/UAS system of expression, in which the yeast-
derived GAL4 transcription factor binds to the upstream activating sequence (UAS) 
enhancer element, regulating the expression of the gene downstream of the UAS (Figure 14) 
(Brand and Perrimon 1993). The GAL4/UAS system offers the possibility to regulate the 
conditional expression of all mutant lines developed in fly: “enhancer–promoter” (EP) lines 
are easily available from large worldwide stock such as the Bloomington Drosophila Stock 
Center, http://flystocks.bio.indiana.edu/). EP construct consists in a P element carrying 
several GAL4 binding site within the target element enhancer to highly activate the gene of 
interest (Rørth 1996). Moreover, the tissue specific GAL4/UAS system allows the 
development of tissue specific knockdown of almost every gene within the fruit fly genome, 
by incorporating an antisense construct by RNA interference (RNAi) (collection of these lines 
is provided by the Vienna Drosophila RNAi Center, http://stockcenter.vdrc.at/control/main) 
(Ryder and Russell 2003). RNAi occurs through a UAS-construct carrying a target gene where 
is present an inverted repeat sequence (of at least 19 nucleotide). The transcript encoded by 
this sequence will be responsibile for the activation of the RNAi machinery with a resulting 
knock down of the gene of interest (Dietzl et al. 2007). 
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Figure 14. The binary GAL4/UAS system of gene expression in Drosophila. 
The system GAL4/UAS allows the conditional expression of a gene of interest in a specific tissue, 
using GAL4 under control of tissue-specific enhancers, and the expression of deleterious gene only in 
experimental lines (allowing the maintenance of precursor lines). [Adapted from Brand and Perrimon 
1993] 
 
The simple genetics, the specialized nervous system and the available genetic tools 
make the fruit fly a good model system for in vivo neurodegenerative studies of HD. 
Different studies have already demonstrated that human pathogenic forms of disease genes 
produce relevant pathological phenotypes in flies (Kazemi-Esfarjani and Benzer 2000; Marsh 
et al. 2000; Nagai et al. 2003). Regarding HD, independent studies developed a number of 
fruit fly models of HD. These models express a wide repertoire of HD-associated changes 
evident from earliest developmental stages of the fly and, therefore, represent a good tool 
for the discovery of therapeutical targets. Although the Drosophila genome includes an 
orthologue of the human HTT, most of the fly HD models are based on the incorporation of 
an exon 1 toxic fragment from the human HTT. The majority of these models allow the study 
of conditional expression of the HTT construct, using the GAL4/UAS system utilising 
different GAL4 drivers such as elav>GAL4, which is routinely used and expresses UAS 
constructs pan-neuronally from an early stage of the fly life cycle (Green and Giorgini 2012). 
Tissue specific expression of GAL4                  Transcriptional activation of Gene X 
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Fly HD models show progressive and age-dependent neurodegenerative pathology directly 
correlated with the polyQ length (late in larval/pupal life), characterised by behavioural and 
locomotor dysfunctions and premature death. The neurodegeneration in HD flies is easily 
monitored by the analysis of the photoreceptors of the eye compound (pseudopupil assay), 
direct indication of the progressive neuronal loss (Figure 13) (Marsh, Pallos, Thompson 
2003).  
The application of Drosophila HD models has yielded significant insights into several 
aspects of HD pathogenesis, such as trafficking and axonal dysfunction (Gunawardena et al. 
2003; Steinert et al. 2012). Fly HD studies identified several suppressors of polyQ toxicity, 
being as well an appropriate model organism for rapid screening of pharmacological 
compounds (Campesan et al. 2011; Green et al. 2012; Ravikumar et al. 2004; Steinert et al. 
2012). Studies in regard of pharmacological interventions on the histone deacetylase 
(HDAC), have proven to be effective in fly and cell HD models, suggesting a potential therapy 
strategy against HD, which is now under preclinical investigation (Pallos et al. 2008; Steffan 
et al. 2001; Chen et al. 2012; Jia et al. 2012). 
1.2.5.3 Rodent HD models  
Predominantly based on the use of mouse lines, the rodent lines are most widely 
used system for modelling HD. Mouse and human share similar development and exhibit 
high genomic synteny, features that classify mouse models as eligible tools for studying HD, 
in addition to the availability of well-developed technologies for genome manipulation, 
screening and behavioural studies (Sosa, De Gasperi, Elder 2012). 
All the rodent HD models produced are genetically engineered using different 
constructs within the full-length human HTT or a fragment containing the whole or partial 
human HTT exon 1. These constructs bear the HD mutagenic locus within between 80 and to 
150 CAG repeat units, which ensures the transcription of the extended and pathogenic 
polyglutamine tail. The expression of the constructs can be regulated by either a human or 
an endogenous promoter according to the different models. Symptoms, life span and 
neuropathological features are quite variable for the several models (Zuccato, Valenza, 
Cattaneo 2010). Besides transgenic mice models of HD, also knock-out and knock-in mouse 
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models of HD has been generated. The knock-out models due to embryonic lethality 
allowed to identify the crucial role of HTT in embryogenesis, but are not widely used. The 
knock in mouse models bear the CAG mutation into their endogenous huntingtin gene (Hdh) 
or they carry a chimeric HTT/Hdh sequence, encoding for the polyglutamine stretch. 
Because of the appropriate genomic and protein context, the disease phenotype is milder 
and more similar to the human HD, making the knock-in mouse models faithful genetic 
models of the human condition (Menalled 2005). 
Among the transgenic models, the R6/2 line, designed with the human HTT promoter 
followed by exon 1 within 144 CAG repeats, represents an efficient model of HD, widely 
used in the dissection of the pathology and for therapy screenings (Gil and Rego 2009; 
Mangiarini et al. 1996). The R6/2 line replicates well the human HD phenotype with early 
and progressive manifestation of motor and cognitive symptoms and reduced lifespan. As 
most of the mice models, neuronal inclusions and atrophy are evident in R6/2 brain, where 
neurotransmitter dysfunctions, reactive astrogliosis and aberrant synaptic plasticity are also 
detected.   
1.2.6 Therapy in HD 
An effective therapy for the cure of HD has not yet been developed. Only few 
compounds ameliorating primary symptoms as psychiatric disturbances and chorea are 
available (Reilmann 2013). However, several proposed therapeutic treatments are under 
experimental investigation. The strategies followed for the development of an HD therapy 
are mainly three. Commonly, potential treatments are designed to restore or control the 
altered functionality of interacting factors or pathways that are involved in the disease, with 
the aim of decreasing or delaying the progression of HD. A more recent approach focuses on 
mutant HTT with the intent of blocking the expression with RNA interference or interfering 
with the toxic polyQ affecting aggregation. Furthermore, still at an experimental level, a 
potential treatment of HD is based on stem cells transplantation in lesioned areas of the HD 
brain (Zuccato, Valenza, Cattaneo 2010).  
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So far, several potential therapeutic targets have been identified and many candidate 
drugs have been tested in different model organisms showing improvement of motor and/ 
or cognitive dysfunctions, but only one drug passed all the clinical phases of screening. 
Tetrabenazine (TBZ), an inhibitor of the dopamine pathway, is a the only therapeutical 
compound accepted by the Food and Drug Administration (United States) for the treatment 
of choreic symptoms in HD. TBZ, reducing monoamines and serotonin from pre-synaptic 
central nervous system neurons, alleviates the motor deficits and reduces striatal cell loss in 
HD mice. Human clinical trials confirmed that the use of TBZ reduces uncontrolled 
movements, albeit with several side effects such as dyspahgia, depression or parkinsonism 
(Frank et al. 2008; McLellan, Chalmers, Johnson 1974; Tang et al. 2007). 
Obstacles in designing a therapy for HD are mainly based on the discrepancies 
between model organisms and humans. The failure of several drugs during clinical trials 
suggested that several mechanisms in human HD are different from its models and/or still 
unknown. Therefore, it is necessary to test single compounds in several HD models, bearing 
different levels of disease severity. Moreover, the high heterogeneity manifested in HD 
human individuals, correlated with the multi-factorial functionality of the HTT protein, 
suggests that an efficient therapeutical approach will be based on the combination of 
several compounds. This strategy could be valid if only the triggering pathogenic events, 
distinct from the several epiphenomena in the disease, will be targeted. For this reason it is 
necessary to identify presymptomatic biomarkers of the disease progression and, among 
the corresponding pathways, genetic factors with the power to modify the symptoms onset 
in HD. Considering that the identification of biomarkers is based on laborious screening 
(which are usually related to a small number of individuals due to technical and 
experimental duties), the discovery of genetic modifiers of the disease onset in large disease 
cohort studies and their following validation in different HD models represent a valid 
approach to identify new therapeutical targets. 
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1.3 Candidate genetic modifiers of AO in 
HD 
CNVs as genetic variants are widespread in the human genome and with their 
potential to affect gene expression, it stands that they could be involved in HD pathology. A 
variance of the genomic copy number of a gene, implicated in any of the disease pathways, 
could result in either protective or toxic effects and be a genetic modifier of the AO in HD. 
CNV in the human β-defensin region and CNV involving the member 3 of the facilitated 
solute carrier family 2 (SLC2A3) locus, with a potential role respectively in 
neuroinflammation and the neuronal glucose uptake, were investigated in this study. 
1.3.1 Human β defensin 2 (DEFB4) 
Human β-defensin 2 (h-BD2) is a member of the defensin family, a category of 
antimicrobial peptides. Most defensins are small cationic peptides, with a molecular weight 
ranging from 2 to 6 kDa, able to interact with the bacterial membrane during the immune 
response in vertebrate and invertebrate organisms. In primates the defensins are 
characterized by a conserved motif of 6 cysteine residues (C-X6-C-X4-C-X9-C-X6-CC) that 
confers a peculiar tertiary structure; different disulphide bond configurations of this motif 
distinguish α, β and θ defensins (Lehrer 2004). Among all defensins, identified in several 
species, β-defensins are likely to be the common ancestor of all vertebrate defensins (Xiao Y 
et al. 2004).   
All over the human genome there are three main clusters encoding for β-defensins 
located on chromosome 8, 6 and 20. hBD2 is encoded by the DEFB4 gene, within a genomic 
region of ~2 kb, located in the defensin cluster on the chromosomal region 8p21-p23, which 
also includes several other β-defensin genes DEFB1, DEFB103, DEFB104, DEFB105, DEFB106, 
DEFB107), and all the α-defensins genes. DEFB4 genomic structure, typical of most of the β-
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defensin genes, consists of two exons and one intron, encoding a precursor peptide and a 
post translational signal for the modification of this precursor into a mature peptide. 
Isolated for the first time from lesional psoriatic skin, hBD2 (64 aa) is expressed at a 
basal level in epithelia (for example in the respiratory tract, gastrointestinal tract, urogenital 
system, pancreas and skin), and also in leukocytes and the bone marrow (Harder et al. 
1997). However, its up-regulation can be induced in response to a wide range of pro-
inflammatory stimuli including Gram-negative bacteria, lipopolysaccharides (LPSs), and 
interleukin-1α (IL-α), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), interferon-
gamma (IFN-γ). These factors promote the expression of h-BD2 through the nuclear 
transcription factor KB (NF-KB), sometimes supported by activated protein 1, by mitogen-
activated protein kinase (MAP-kinase) and by protein kinase C (PKC) (Pazgier et al. 2006). 
Following their activation, β-defensins “cross-talk” with the adaptive immune system via an 
interaction with toll-like receptors (TLRs), which recognize pathogen-associated molecular 
patterns and modulate the expression of several genes (Biragyn et al. 2002; Froy 2005; 
Weinberg et al. 2012; Yang et al. 1999).  
h-BD2 is a potent immunomodulator with an important role in regulating both innate 
and adaptive immune responses. The activation of h-BD2 is most powerful in the presence 
Gram-negative bacteria and some fungi but less potent against Gram-positive bacteria, 
particularly at low concentrations of salt and plasma proteins ties. From an 
immunoregulatory perspective, h-BD2 shows chemoattractant activity, engaging a number 
of cell surface receptors such as the CCR6 receptor on immature dendritic cells (DC) and 
peripheral blood memory T cells and, in a chemokine manner, recruits these cells to the 
sites) of interest. This feature defines the important role of h-BD2 in signalling pathways 
with respect to the innate and adaptive immune response (Ganz 2003; Hardwick et al. 
2012). 
1.3.1.1 DEFB4 CNV  
DEFB4 and other β-defensin genes on 8p23.1, with the exception of DEFB1, are on a 
large repeat unit that shows multiallelic CNV, as several studies using different CNV 
discovery tools have confirmed (Conrad et al. 2010; Hollox, Armour, Barber 2003). Normal 
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population have between 2 to 8 copies per diploid genome, but rare individuals with up to 
12 copies have been identified by cytogenetic analysis (Hollox, Armour, Barber 2003; 
Linzmeier and Ganz 2005). In respect to CNV size (~250 kb), gene content and numeric 
variability of β-defensin region, 8p23.1 represents one of the CNV hotspot in the human 
genome (Figure 15) (Groth et al. 2010). 
 
Figure 15. β-defensin region. 
The chromosomal region is shown at the top of the diagram. DGV Struct Var bar refers to the 
Database of Genomics Variants from which Conrad et al. data are reported in the diagram (Conrad et 
al. 2010). The blue bar indicates a gain in size relative to the reference; the red bar indicates a loss in 
size relative to the reference. In the lower half of the diagram are indicated all the reference genes 
located in this region. Highlighted in yellow the 2 isoforms of DEFB4, DEFB4A and DEFB4B). [From 
(GRCh37/hg19) Assembly,Genome browser, http://genome.ucsc.edu]. 
 
Quantitative analysis of h-BD2 mRNA and protein levels in lymphoblastoid 
immortalized lymphocyte cell lines (LCLs), serum and cultured keratinocytes showed the 
direct correlation between DEFB4 copy number and h-BD2 expression levels. (Groth et al. 
2010; Jansen et al. 2009; Hollox, Armour, Barber 2003). Interestingly, higher genomic copy 
number of β-defensin region was associated to a greater risk of psoriasis, an inflammatory 
skin disease. Likely caused by a gene copy number-dosage effect, the higher h-BD2 protein 
level found in psoriatic skin tissue could be an early enhancer of inflammation (Hollox et al. 
2007; Zeeuwen et al. 2008). Interestingly, higher β-defensin copy number was associated 
with increased HIV load and impaired immune reconstitution following initiation of highly 
active antiretroviral therapy in Sub-Saharan Africans individuals (Hardwick et al. 2012). 
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These studies suggest that β-defensin copy number variation may be a risk factor in other 
infectious and inflammatory diseases (Hardwick et al. 2012).  
1.3.1.2 DEFB4 CNV: a potential genetic modifier of AO in HD 
Studies performed in rats showed that the β-defensins r-BD1 and r-BD2, the latter 
which shares ~ 50% amino acid identity with h-BD2, are constitutively expressed in the brain 
(Froy et al. 2005). In human, the expression of h-BD2 in the brain was analysed in few 
studies (Hao et al. 2001; Tiszlavicz et al. 2011). One study tested the expression of h-BD2 
and h-BD1 (founded previously in human brain biopsy tissue) in cultured astrocytes, 
microglia, meningeal fibroblasts and neurons, all derived from normal human (foetal) brain, 
in normal and inflammatory conditions. h-BD2 expression was inducible and only detected 
in astrocyte cultures, mainly after inoculation with LPS (within a dose sensitive effect) and 
IL-1β or TNF-α (Hao et al. 2001). Furthermore, it was found that brain capillary endothelial 
(BB19) cells, which are a human cell culture model for the blood-brain barrier (BBB), express 
hBD-2 upon infection of Chlamydia pneumoniae (common cause of infection and 
inflammation of the brain and meninges) (Tiszlavicz et al. 2011). 
In common with most age-associated neurodegenerative disorders, 
neuroinflammation is a typical hallmark of HD (see paragraph 2.4.6) (Harry and Kraft 2008; 
Hirsch and Hunot 2009; Möller 2010; Rogers 2008). The number of activated microglia and 
reactive astrocytes were shown to be correlated with disease severity in mice and patients 
with HD, whereas the suppression of microglial activation prolonged the lifespan of HD mice 
(Hsiao et al. 2013; Pavese et al. 2006; Politis et al. 2011; Sapp et al. 2001; Tai et al. 2007; 
Zwilling et al. 2011). Moreover, the innate immune activation detectable in plasma of 
presymptomatic HD individuals suggests that an innate or adaptive response of the immune 
system is present in HD pathology (Björkqvist et al. 2008). Inflammatory changes in 
peripheral and CNS tissues could be independent and regulated by mutant HTT, ubiquitously 
expressed, causing analogous derangements centrally and peripherally; or an initial 
peripheral inflammatory response to the mutant HTT could spread to the CNS,  through the 
passage of immunomodulatory elements across the BBB.  
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In the CNS, h-BD2, expressed in activated astrocytes and in BBB cell models, could play 
an important role in the neuroinflammation observed in HD (Figure 16).  
 
Figure 16. Proposed inflammatory role of h-BD2 in HD. 
A) NF-KB expression in astrocytes activates h-BD2 in a copy number dependent way and h-BD2 
through TLR4 mediates an exacerbation of neuroinflammation. B) Inflammatory stimuli passing 
through the BBB could activate h-BD2 expression in a copy number dependent way leading to an 
activation of neuroinflammation. 
*Known to be highly expressed in HD. ** Expression dependent by DEFB4 copy number. 
 
The aberrant activation of NF-κB occurring only in HD reactive astrocytes could induce 
the expression of h-BD2, which in turn could exacerbate the inflammatory response 
interacting with toll receptor like 4, a key player in the neuroinflammation in AD and PD 
(Figure 16) (Biragyn et al. 2002; Hsiao et al. 2013; Fellner et al. 2013; Michaud et al. 2013). 
Moreover, h-BD2 expression could be induced by immuno-modulators through the BBB, 
leading to an increased neuroinflammation in HD (Figure 16). 
h-BD2 could play an important role in HD neuroinflammation and β-defensins CNV 
could drastically change its relevance in the context of disease, where high copy number, 
and so high circulating protein level, could exacerbate inflammatory response mediated by 
h-BD2 and aggravate HD progression (Figure 16). Thus, β-defensin CNV could be a genetic 
modifier of AO in HD. 
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1.3.2 The neuronal glucose transporter GLUT3 (SLC2A3) 
Glucose is the essential fuel to most mammalian cells; its passage across cell 
membranes is facilitated by a family of integral membrane transporter proteins, the GLUTs. 
Among these transporters there are the members of the facilitated solute carrier SLC2 
family including the neuronal glucose transporter 3 GLUT3 (Kayano et al. 1988; Nagamatsu 
et al. 1992). Based on sequence, functional and predicted structural similarities the 14 
GLUTs have been divided into three classes and GLUT3 together with GLUT1, -2, and -4 
comprise the class 1 (Joost et al. 2002). These transporters differ in localization, hormone 
sensitivity and glucose facilitated transport. Interestingly, GLUT3, which is the main 
neuronal GLUT, has both a higher affinity for glucose than GLUT1, -2, or -4 and at least a 
five-fold greater transport capacity than GLUT1 and -4 (Simpson et al. 2008).  
GLUT3 protein (45kDa) is encoded by the gene SLC2A3, within a genomic region of 
17kb on chromosome 12p13.31, in the proximity of a highly homologous gene, SLC2A14, 
which encodes GLUT14 (mainly expressed in testis). With SLC2A14, SLC2A3 is located in a 
highly repeated sequence genomic region where NAHR might occur, leading to CNV of 
between 1 to 3 copies of the two genes (Conrad et al. 2010). Although the X-ray crystal 
structure of GLUTs is not available, GLUT3 protein, like all the sugar transporter family 
members, is predicted to have twelve transmembrane domains that combined to form a 
central aqueous pore or channel through which the substrate crosses the lipid bilayer 
(Figure 17) (Simpson et al. 2008). 
Expressed in placenta across early stage of gestation, GLUT3 has an important role 
for the energy exchange between embryo and mother and is essential during 
developmental stages (Brown et al. 2011). Mouse embryos homozygous for the Slc2a3 null-
allele (bearing a deletion of exons 7-10) showed increased apoptosis, developmental 
restriction and premature death at early stage of gestation (Ganguly et al. 2007). 
Heterozygotes for the null allele (Slc2a3+/-) are viable but are associated with an abnormal 
distribution of GLUT1 in the blastocyst, suggesting the role of GLUT3 in polarization. In adult 
life, Slc2a3 haploinsufficiency in mice does not affect brain glucose intake, body weight and 
growth pattern but is associated to a sexually dimorphic adiposity with insulin resistance in 
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males and features of autism spectrum disorders (Ganguly and Devaskar 2008; Stuart et al. 
2011; Zhao et al. 2009). 
 
 
Figure 17. Putative structure of GLUTs of class I and II. 
[Adapted from Manolescu et al. 2007]. 
 
Throughout cerebral maturation, GLUT3 mRNA and protein expression increases in a 
regional and activity-dependent manner; its expression level coincides with areas of the 
brain with high glucose demand, maturation and synaptic connectivity (Duelli and 
Kuschinsky 2001; Khan et al. 1999; Zeller et al. 1995). Among all the GLUTs present in the 
brain, GLUT3 is characterised by a high glucose capacity and within its localization is the 
main player of the glucose metabolism in the neurons. Physiological stimuli such as insulin, 
insulin growth factor 1 (IGF-1), and glucose deprivation can promote the translocation of 
GLUT3 to the plasma membrane but they do not influence the glucose uptake in neurons 
(Cheng et al. 2003; Uemura and Greenlee 2006). Furthermore GLUT3 expression can be 
sensitively altered during aging or in pathological conditions that affect the brain 
functionality and metabolism such as hypoxia after ischemic brain injury, AD and brain 
tumour (Boado, Black, Pardridge 1994; Simpson et al. 1994; Vannucci et al. 1998).  
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GLUT3 is also expressed in human white blood cells, namely in lymphocytes, 
monocytes/macrophages, neutrophils, and platelets. Its expression can be up-regulated 
following inflammatory stimuli in monocytes and lymphocytes, suggesting a role of GLUT3 in 
the immune response (Fu et al. 2004).  
1.3.2.1 Cerebral glucose metabolism in HD 
Aberrant metabolism of the CNS is a typical hallmark for several brain diseases. The 
glucose utilization rate is a valid age dependent parameter for tracking functional and 
metabolic change in the brain. Commonly detected by 18F-fluorodeoxyglucose (18FDG) PET 
technique, glucose utilization brain scans have been performed in the study of several brain 
diseases including depression, multiple sclerosis, and AD, contributing to a better 
understanding of these pathologies and being used as an efficient tool for the diagnosis and 
tracking of complex disorders such as AD (Baxter Jr et al. 1989; Mosconi 2005; Roelcke et al. 
1997; Yoshii et al. 1988). 
18FDG-PET scanning of HD carriers revealed the loss of the glucose uptake in the 
striatum (caudate and putamen) and cortex (frontal and temporal lobes), remarkably before 
the onset of clinical symptoms of the disease reference). In asymptomatic HD gene carriers 
the striatal metabolism is significantly decreased in absence of atrophy and the progression 
rate of HD shows a better correlation with the detected hypometabolism independent from 
the CAG length (Antonini et al. 1996; Ciarmiello et al. 2006; Grafton et al. 1990; Hayden et 
al. 1987; Kuhl et al. 1982; Mazziotta et al. 1987). Interestingly, a 5 year follow-up study on 
asymptomatic HD subjects showed that the caudate glucose metabolism was significantly 
decreased in subjects that became symptomatic in the course of the study, and this change 
was not correlated with the CAG mutation length (Ciarmiello et al. 2012). In the same study, 
the relative caudate glucose metabolism added to the CAG mutation length increases the 
regression coefficient in the prediction of the AO, suggesting the glucose metabolism as a 
good predictor of disease onset (Ciarmiello et al. 2012; Shin et al. 2013). 
The role of the glucose metabolism in HD has also been demonstrated in several HD 
model studies. R6/2 mice showed an early and progressive metabolic impairment 
significantly associated with lower glucose uptake, independent of cell loss; primary cortical 
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neurons, derived from HD140Q knock-in mice, showed a reduced uptake of glucose that was 
restored by reinforcing Rab11 function, altered in HD. Increasing glucose entry in glia was 
found to reduce glia-induced pathology in fly models of HD Besson et al. 2010; Cepeda-
Prado et al. 2012; Li et al. 2012). 
These studies suggest that dysfunction of glucose metabolism is actively contributing 
to the disease progression and its restoration is a potential therapeutic target in HD.  
1.3.2.2 SLC2A3 CNV in HD: a potential genetic modifier of AO in HD 
In the complex scenario of the possible causes leading to a reduced glucose 
metabolism in the HD brain, several studies focused on the role of insulin, whose release 
appears to be affected by mutant HTT expressed in pancreatic β-cells. Besides insulin 
dysfunction, a possible cause of the reduced glucose uptake in the brain might be caused by 
alteration of GLUT3, the glucose uptake mechanism that is insulin and IGF-1 independent. 
From a post-mortem brain study, a significant reduction of GLUT3 and GLUT1 protein 
expression levels was found in the caudate of HD brain at grade 1 and grade 3 but not in the 
cortex compared to controls samples. This suggests that the lessened expression of GLUT1 
and GLUT3 transporters is specific for HD caudate and not merely a feature of post-mortem 
degradation or HD-specific brain atrophy (Gamberino and Brennan 1994). Interestingly, a 
decreased concentration of GLUT1 and GLUT3, not correlated to synaptic loss, was found as 
well in AD brain, where this depletion correlates with abnormal hyperphosphorylation of 
tau (Liu et al. 2008; Simpson et al. 1994). Furthermore, using the fruit fly model to study AD 
and HD it has been found that the increased expression of the fly ortholog of SLC2A3 can 
suppress tau toxicity in the AD model and ameliorate locomotor activity and life span in a 
glial HD model (Besson et al. 2010; Shulman et al. 2011). 
These studies suggest that HD progression could be affected by GLUT3 expression 
level and functionality as glucose uptake is mainly dependent in the neurons by this 
transporter. CNV involving SLC2A3 could directly affect its protein expression level by gene-
dosage effect and have an impact of HD. In fact, according to a previous study, SLC2A3, 
encoded from a sequence on chromosome 12p13.31, is located in a copy number variable 
region where two units of a tandem duplication recombine together through blocks of high 
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sequence similarity (up to 94%). Through a specific recombination point, indentified in the 
study, NAHR involves the two units arising to a combination of gain or loss of a segment of 
129 kb DNA shared between the two units (Figure 18) (Veal, et al. 2013). As it has been 
shown in different studies, NAHR in 12p.13.31 is quite rare as the frequency of duplication 
event is between 5 to 7% and the frequency of deletion event is around 0.5 up to 2%  in the 
populations analysed (Conrad et al. 2010; Veal, et al. 2013). Recently it was found an 
association with SLC2A3 deletion and a substantial protection against Rheumatoid Arthritis 
andwas found in the context of attention-deficit/hyperactivity disorder-related 
psychopathology (Lesch et al. 2010). Increased SLC2A3 copy number encoding higher 
protein level could improve the glucose uptake rate in neurons and protect the neuronal 
functionality in HD. Thus, SLC2A3 CNV could be a potential genetic modifier of AO in HD. 
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Figure 18A-B. Units of the tandem duplication involved in the NAHR that leads to CNV of SLC2A3. 
A) The chromosomal region shown is part of chromosome 12p13.31 where SLC2A3 is located ((GRCh36/hg18) Assembly (http://genome.ucsc.edu )). DGV 
Struct Var bar refers to the Database of Genomics Variants from which Conrad et al., data are reported (Conrad et al. 2010). In the lower half of the diagram 
all the reference genes located in this region are indicated. In the upper part of the diagram the red and the blue bars represent the units of the tandem 
duplication involved in the NAHR for SLC2A3 CNV formation. B1,2) Hypotetical products of NAHR from a common recombination point in European ancestry 
individuals (adapted from Reekie 2011).The black lines indicated the annealing site for the primers of a SLC2A3 PRT assay (Veal et al. 2013). The grey boxes 
indicate fragments of the gene produced after the NAHR .B-1) Possible duplication product. B-2) Possible deletion product. 
A) 
B-1) 
B-2) 
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The aim of this study is to test DEFB4 CNV and SLC2A3 CNV as potential genetic modifiers 
of AO in HD. For this purpose we are going to analyse the distribution of diploid genomic copy 
number of these candidates in a cohort of HD individuals provided by the EHDN project, which 
includes only symptomatic subjects with variable AO and CAG mutation length, and is unbiased for 
ethnicity and gender. The study of CNV distribution for both candidates will be performed using 
the PRT approach, which allows rapid and efficient CNV genotyping of large data sets. Any positive 
association of our candidate genes with a variance of the AO in HD will require following 
validations in suitable in vivo HD models in order to test their functional role. 
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CHAPTER THREE: 
MATERIALS AND 
METHODS 
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Buffer compositions are given in section 3.7. 
 
3.1 DNA samples  
3.1.1 Control samples 
All the DNA samples used as a standard controls were DNA samples purified from 
lymphoblastoid cell lines from the European Collection of Cell Cultures (ECACC), the HapMap 
panel, the Human Genome Diversity Cell Line (HGDP-CEPH) panel and the Leicester Panel. The 
controls sample list is reported in Table 25. 
3.1.2 Disease cohort samples 
Disease samples used in this study are unrelated European ancestry with HD, part of the 
EHDN “REGISTRY” project. REGISRTY enrols manifest and premanifest HTT mutation carriers, 
individuals at risk and controls into a multicenter observational study with annual follow-up visits. 
An informed written consent, according to the International Conference on Harmonisation-Good 
Clinical Practice guidelines was given by all the participants (http://www.ich.org/). Where there 
was inability of the participant to consent, the guidelines of the collecting country were followed. 
In case of minors, the assent of the parents was also requested. Furthermore, ethics approval was 
needed from the local ethics committee for each study site contributing to REGISTRY. Data 
collection uses electronic case report forms available in Czech, Danish, Dutch, English, Finnish, 
French, German, Italian, Norwegian, Polish, Portuguese, Spanish, Swedish and Russian. Each 
patient was assessed for motor, psychiatric and cognitive signs scored according to the Unified 
Huntington’s Disease Rating Scale by the local clinicians. Blood samples was collected and shipped 
to BioRep (BioRep, Milano) in order to extract DNA, measure HTT CAG repeats length and for the 
creation of lymphoblastoid cell lines. Our study included 1000 HD manifest samples from 
REGISTRY, provided at different times in two separate cohorts of 500 samples each. The DNA 
samples were supplied in 96-multi well plate at different concentrations, which were adjusted 
with MilliQ water (Merck Millipore, Billerica, MA, USA) to the concentration of 10ng/µl. A nine 
digit pseudonym for each DNA sample was provided, allowing the identification of the samples in 
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the EHDN database. At the beginning of the study no clinical information was given in order to 
assess blind study on these cohorts. 
 
3.2 Standard Methods  
3.2.1 Polymerase Chain Reaction (PCR)  
3.2.1.1 PCR in 10X KAPA Biosystem buffer A   
The DNA sequence of interest was amplified by the PCR method. PCR mix using KAPA 
Biosystem 10X buffer A (15 mM Mg2+) was commonly prepared in this study. Usually, 10μl PCR 
reactions were prepared as a master mix with the final concentrations of 1X buffer A, 0.2 mM each 
dNTP, 0.05U Taq DNA polymerase and 10ng input DNA. PCRs were performed in a Veriti thermal 
cycler as follows: 98˚C for 1 minute; 25-30 cycles of 95˚C for 15 seconds, annealing phase and 72˚C 
for 1 minute followed by a final extension of 72˚C for 5 minutes. Exact cycle temperatures and 
times depended on the primers and the expected product. For DNA sequence of interest where 
the CG base content was significantly high (CG>60% of total sequence), betaine was added to the 
mix at a final concentration of 0.1M. 
3.2.1.2 PCR in 10X Low dNTPs (LD) PCR buffer 
PCR mix using 10X Low dNTPs (LD) PCR buffer (3.7) was commonly prepared in this study. 
Usually, 10μl PCR reactions were prepared as a master mix with the final concentrations of 1X LD 
PCR buffer, 0.5U Taq DNA polymerase and 10ng input DNA. The primers were used at a final 
concentration optimized for each protocol. PCRs were performed in DNA Engine Tetrad thermal 
cycler (MJ research, Quebec, Canada) as follows: 98˚C for 1minute; 30 cycles of 95˚C for 30 
seconds, annealing phase and 70˚C for 30 seconds, followed by a single “chase” phase of annealing 
for 1 minute and 70˚C for 20 minutes to reduce levels of single-stranded DNA and complete 
terminal 3’ dA addition. Precise cycle temperatures and times depended on the primers and the 
expected product length.  
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3.2.2 DNA electrophoresis  
3.2.2.1 Agarose gel electrophoresis 
 To measure the yield and size of PCR products amplified, DNA was separated by non-
denaturing agarose gel electrophoresis. Agarose (Lonza, Basel, Switzerland) was dissolved by 
boiling in an appropriate amount of 0.5X TBE (3.7) containing 0.5μg/ml ethidium bromides to give 
a gel in the range of 0.7-2% w/v. DNA samples and DNA ladders to be run were prepared with an 
appropriate amount of loading buffer and then loaded into the wells. Samples were run at 120V 
for 1 to 2 hours; bands were visualized by illumination under UV light and a photograph of the gel 
was kept for records using a Gene Flash Syngene Bioimaging device (Synoptics Inc, Frederick, MD, 
USA).  
3.2.2.2 Capillary electrophoresis  
Capillary electrophoresis was carried out in this study using ABI Genetic Analyzer 3130 XL 
instrumentation. GeneScan analysis was performed using fluorescently labeled DNA. 0.01 to 1μl of 
PCR products were mixed with 10μl HiDi formamide and 1% of the internal size standard 
GeneScan-ROX400 was included for precise determination of the length of the amplicons. After 
denaturation for 3 minutes at 98°C, the products were separated on POP-7 polymer with 30 
seconds of injection time and collected by Genetic Analayzer data collection software v3.0. 
Scanning results of fluorescent-dye-labeled PCR products (peak area) by GeneScan v3.7 software 
were collected and transferred to an Excel spreadsheet file through GeneMapper v4.0 software 
for further analysis.  
 
3.3 PRT-based assays 
3.3.1 DEFB4 assay 
The DEFB4 assay is a method developed in a previous study to measure the copy number 
of β-defensin per diploid genome (Aldhous et al. 2010). The assay consists of a duplex PRTs assay 
and one indel measurement assay, respectively called PRT107A, HSPD21 and 5DELR4. The assays 
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were carried out as follows (3.3.1.1) separately and analyzed all together in a single capillary 
electrophoresis run (3.2.2.2). The data from the duplex PRTs assay were validated as described in 
3.3.1.1 and the copy number call was inferred from the PRTs and indel estimates by a maximum 
likelihood analysis, described in 3.3.1.3.  
3.3.1.1 Duplex PRT assays 
In order to measure the copy numbers of β-defensin per diploid genome, two different 
systems of PRT assays were performed following the protocol used in Aldhous et al. 2010 study. 
PRT107A amplifies a reference region on chromosome 11 ((chr11:97,384,722-97,384,877) 
(Febr.2009 (NCBI37/hg19) Assembly)) and a test locus on chromosome 8 
((chr8:7,387,448+7,387,605; chr8:7,648,479-7,648,636) (Febr.2009 (NCBI37/hg19)). This PCR is 
performed in duplicate for each sample using FAM- or HEX-labeled forward primer and an 
unlabelled reverse primer at the final concentration of 0.5M (Table 26). HSPD21 amplifies a 
reference region on chromosome 21 ((chr21:30,260,100-30,260,279) (Febr.2009 (NCBI37/hg19)) 
and the test locus found on each of the β-defensin clusters on chromosome 8 
((chr8:7277405+7277576), (chr8:7749011-7749182) (Mar. 2006 (NCBI36/hg19) Assembly)). This 
PCR is performed in duplicate for each sample using an unlabeled forward primer and a FAM- or 
HEX-labeled reverse primer at the final concentration of 0.5M (Table 26). HSPD21 and PRT107A 
products were amplified simultaneously using the same PCR mix with 10X LD PCR buffer (3.2.1.2) 
with pre-denaturation of 95˚C for 5 minutes, followed by 22 cycles of 95˚C for 30 seconds, 58˚C for 
30 seconds and 70˚C for 1 minute, ending with a single “chase” phase of 58˚C for 30 seconds and 
70˚C for 40 minutes. In total, two parallel amplifications were carried out for each sample, one 
with a FAM label, the other with HEX/NED; 1μl from each reaction was analyzed by capillary 
electrophoresis (3.2.2.2). 
Data analysis 
For PRT107A areas corresponding to the 158bp from near DEFB107 and the 155bp from 
chromosome 11 and peak areas corresponding to the 172bp from near DEFB4 and the 180bp from 
chromosome 21 in HSPD21 were recorded using Genetic Analyzer data collection software v3.0 
and Genemapper v4.0 software. The ratio 158bp/155bp and 172bp/180bp for PRT107A and 
HSPD21 respectively were compared between FAM- and HEX- or NED- labeled products and the 
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results were accepted if the difference between the ratios was less than 15% of their mean; this 
criterion led to the rejection of about  less than 20% of tests. If accepted, the mean of the FAM 
and HEX or FAM and NED ratios was used in further analysis. Mean ratios were used in 
conjunction with reference samples of known copy number to calibrate each experiment, and the 
resulting (least-squares) linear regression used to infer the copy numbers for unknown samples. 
Selected DNA samples (Table 25) giving reproducible results from several PRT assays tested in 
previous studies were used as calibration standards (Figure 19) (Aldhous et al. 2010; Fode et al. 
2011). 
Calibration of reference DNA for  PRT107
0 1 2 3 4 5 6 7 8
0
1
2
3
4
5
6
y = 1.1158x + 0.0373
R² = 0.9342
Known copy number
O
b
se
rv
ed
 r
at
io
 
Calibration of reference DNA for HSPD21
0 1 2 3 4 5 6 7 8
0.0
0.5
1.0
1.5
2.0
2.5
3.0
y = 2.3006x + 0.0701
R² = 0.9904
Known copy number
O
b
se
rv
ed
 r
at
io
 
Figure 19 A, B. Reference DNA standard calibration for PRT107A (A) and HSPD21 (B). 
An example of the calibration standard on selected reference DNA samples, which give reproducible results 
from the PRT systems. The linear regression (red line) shown above was used to infer the copy numbers for 
unknown samples. 
A) 
B) 
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3.3.1.2 Indel ratio measurements  
In order to have further clarification about of the copy numbers of β-defensin in diploid 
genomes indicated by PRT assays, an indel ratio measurement assay was performed according to 
5DELR4 assay from a previous study (Abu Bakar, Hollox, Armour 2009). 5DELR4 assay used the 
same couple of primers (Table 26) to amplify two separate regions at chromosome 8 
((chr8:7,659,491+7,659,624 and chr8:7,376,438-7,376,566 (Febr.2009 (NCBI37/hg19)) wherein 
rs71230882 is located. Depending on the triallelic indel polymorphism the products were variable 
in size (Table 26) and could differ for each DEFB4 repeats.  The PCR was performed using FAM- or 
HEX-labeled forward primer and unlabeled reverse primer at the final concentration of 5M and 
the PCR mix with 10X LD PCR buffer (3.2.1.2). PCR amplification was performed as follows: 22 
cycles of 95˚C for 30 seconds, annealing temperature at 50˚C for 30 seconds and 70˚C for 30 
seconds, followed by a single “chase” phase of 58˚C for 1 minute and 70˚C for 20 minutes to 
complete 3’ dA addition. Two parallel amplifications were carried out for each sample, one with a 
FAM label and the other with HEX; then 1μl from each reaction was added to 10μl HiDi formamide 
with ROX-400 marker and products and analyzed by capillary electrophoresis (3.2.2.2). All peak 
areas corresponding to the 5DELR4 respectively were recorded for both FAM- and HEX- labelled 
products using Genetic Analyzer data collection software v3.0 and Genemapper v4.0 software.  
3.3.1.3 Maximum Likelihood Analysis 
The Maximum Likelihood (ML) approach was used to infer the copy number call from the 
analyses combined together, namely PRT104, HSPD21 and 5DELR4 (Aldhous et al. 2010). The ML 
analysis calculates the probability that the observed estimate from each assays with error 
following a Gaussian normal distribution reflected each integer value from 1 to 9.  For each sample 
the relative likelihood of the PRTs observed values referring to an integer value of 1 to 9 were 
calculated. The relative likelihoods of 5DELR4 observed ratio were calculated for integers of 1 to 9. 
Whereas the 5DELR4 assay gave three peaks, two ratios were estimated and the sum of the two 
ratios was calculated. The ML estimate of copy number for each sample was calculated multiplying 
the highest probability for each assay for each observed value. The standard deviation of the 
Gaussian distribution was estimated by multiplying the observed value by the coefficient of 
variation used as a threshold in the PRT or the maximum coefficient of variation from 
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experimental repeat measurements for 5DELR4 analysis. The level of confidence in each diplotype 
was calculated by -2(LNb-LNa) where a is the estimated probability for a specific copy number and 
b is the pooled probability for all other copy number diplotypes. Considering that this statistic 
follows a χ2 distribution, the p-value was determined using χ2 test for each copy number 
diplotype call. 
3.3.2 SLC2A3 copy number assay 
In order to estimate the copy number change for SLC2A3 locus, we performed a PRT assay, 
developed in a previous study (Veal et al. 2013), adapted to analysis on capillary electrophoresis 
analyzer, instead of agarose gel analysis. The primers were designed to amplify two paralogue 
genomic loci involved in their communal NAHR, the first lying on the last exon of SLC2A3 
((chr12:8073299+8073583 (Febr.2009 (NCBI37/hg19)) and the second on the 3’UTR of  SLC2A14 
((chr12:8,073,299-8,073,583 (Febr.2009 (NCBI37/hg19)) (Table 26). Two parallel PCRs were set up 
using 10ng of DNA, 0.15 μM FAM and HEX-labelled forward primer, 0.15μM unlabelled reverse 
primer (Table 26) and a PCR mix following the PCR in 10X KAPA Biosystem buffer A protocol 
(3.2.1.1). Products were denatured at 98°C for 1 minute and then amplified using 25 cycles of 98°C 
for 15 seconds, 50°C for 15 seconds and 72°C for 1 minute and 70°C for 5 minutes to enhance 
complete extension in the final round and hence reduce levels of single-stranded DNA products. 
PCR products were analyzed by capillary electrophoresis (3.2.2.2). 
 Data analysis 
The signal intensity of each product was calculated from the area of the peak detected by 
Genemapper v4.0 after capillary electrophoresis run. The ratio of product from each unit of the 
tandem duplication was calculated by dividing the peak area of SLC2A3 amplicon by the peak area 
of SLC2A14 amplicon. Mean ratios were used in conjunction with reference samples of known 
copy number (Table 25) to calibrate each experiment and the resulting linear regression was used 
to infer the copy numbers for unknown samples. The normalized ratio 285bp/200bp was 
compared between FAM- and HEX-labeled products and the results were accepted if the 
difference between the ratios was less than 15% of their mean; this criterion led to the rejection of 
less than 10% of tests. The mean of the FAM and HEX ratios was used to infer the copy number of 
the three different genotypic variants. 
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3.4 Statistical analysis of genetic modifiers 
of AO in HD 
We analyzed the potential role of our candidates as genetic modifiers of the AO in HD 
testing their CNV frequencies in our cohort using SPSS 20.0 (IBM Inc., Armonk, NY, USA). The 
analysis was carried out creating a generalized linear model in analysis of variance and covariance. 
Firstly, we applied a model of analysis of variance with the expanded CAG repeat length as a scalar 
predictive variable, CNV as an ordinal predictor variable and the log2 transformed AO of HD as the 
scalar dependent variable, resulting in the best goodness-of-fit, estimated by the Wald Chi-Square 
(χ2). We then applied the same model to investigate any possible association of CNV frequencies 
and the major estimated symptoms at the onset of HD, using the CNVs and the expanded CAG 
repeat length as independent variables and the different symptoms as categorical dependent 
variables. 
 
3.5 Lymphoblastoid cell lines from HD 
patients study 
3.5.1 Cell lines used 
The lymphoblastoid cell lines (LCLs) used were provided by EHND. The LCLs were originated 
from individuals of our HD cohorts (3.1.2). Five LCLs were selected among each group of 
individuals, previously genotyped, carrying 1, 2 and 3 copy number of SLC2A3. The cell lines were 
cultured in filter cap flask, 50 and 250 ml (Greiner Bio-One Ltd, Stonehouse, UK), at 0.5-
1x106cell/ml concentration and cultured with RPMI 1640, GlutaMAX (TM) media, supplemented 
with 10% fetal bovine serum (Biowest SAS, Nuaillé, France) and 100 units/ml penicillin and 
100μg/ml streptomycin. The cells were harvested at 37°C, in 5% of CO2. 
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3.5.2 GLUT3 quantification by immunoblot  
3.5.2.1 Protein extraction  
Cells were counted using a haemocytometer and 10 to 20x106 cells were taken for protein 
extraction. The cells were centrifuged at 300g for 5 minutes and washed in Phosphate buffered 
saline (PBS). Cells were lysed for 10 minutes on ice, using a Lyses buffer (LB) (3.7). The volume of 
LB was adjusted according the cell concentration using 100μl of LB for each 10x106 cells. The 
lysates were centrifuged at 13,000 rpm for 10 minutes at 4°C and the supernatant was collected 
and stored at -80°C. In order to measure the protein concentration, 1μl of the protein 
supernatants was diluted in 1ml of 1:5 Bradford’s Reagent (Sigma-Aldrich, St. Louis, Missouri, USA) 
dilution and consequently quantified by measurement of the optical density at FLUOstar Omega 
plate reader (BMG LABTECH GmbH, Ortenberg, Germany). 
3.5.2.2 Sodium dodecyl sulphat-polyacrylaminde gel electrophoresis (SDS-
PAGE) 
  An appropriate amount of 1X western blot (WB) loading buffer (3.7) was added to the 10µg 
of protein product from each sample in order to adjust the final concentration for the 
electrophoresis run and everything was incubated at 95˚C for 10 minutes. Two pre-stained broad 
range ladder (250-10 kD) were loaded into the gel with the samples. The stacking gel and the 
resolving gel, namely the two partition of the acrylamide gel, were prepared using the component 
respectively listed in Table 4 and Table 5. The gel was run using 1X running buffer (3.7) at 15mA for 
approximately 2 hours. 
Table 4. Components list for stacking gel. 
Component (Stock) v/v  in ~4ml  
Stacking buffer* 1000 µl 
30% Acrylamide** 680 µl 
H2O 2275 µl 
Ammonioum persulfate(H2O) 10% 40 µl 
TEMED 4 µl 
 *see 3.7  
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** Acrylamide/Bis-acrylamide=37:1 
Table 5. Components list for 10% resolving gel. 
Component (Stock) v/v  in ~10ml 
Resolving buffer*  2.5 ml 
30% Acrylamide** 3.3 ml 
H2O 4.0 ml 
Ammonioum persulfate (H2O) 10%  75 µl 
TEMED 7.5 μl 
 *see 3.7  
** Acrylamide/Bis-acrylamide=37:1 
 
3.5.2.3 Transfer onto Nitrocellulose Membrane 
After the separation on the acrilamide gel, the proteins were electrically transferred onto 
polyvinylidene difluoride membrane. Each blotting sandwich was prepared surrounding the gel 
and the membrane either side by 3 layers of absorbent filter papers (Whatman plc, Maidstone, 
UK) to ameliorate the absorbance of the transfer buffer (3.7) used in this step. The protein blotting 
was done at 100 V for approximately 2 hours at 4°C. 
3.5.2.4 Immunostaining with Antibodies and Protein Detection 
Blocking buffer (3.7) with 5% w/v milk powder was used to block aspecific sites and 
proteins onto the nitrocellulose membrane for 1 hour. The membrane was then probed with 
1:400 dilution of a rabbit polyclonal antibody against GLUT3 (ab15311, Abcam plc, Cambridge, UK) 
in TBS-T with 1%w/v milk (11.2) at 4°C overnight with continuous slight agitation. Subsequently 
the membrane was washed using TBS-T 3 times for 15 minutes each and with TBS-T with 1% w/v 
milk 2 times for 10 minutes. Afterwards the membrane was probed with 1:10,000 dilution of anti-
rabbit IgG secondary antibody conjugated to horseradish-peroxidase (PI-1000, Vector 
Laboratories, inc., Burlingame, California, USA), in TBS-T with 1%w/v milk for 1 hour at 4°C with 
continuous agitation. The procedure was repeated for α-Tubulin, the reference protein, using for 
the immunostaning of the primary antibody a 1:200 dilution of a mouse antibody against α-
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Tubulin (sc-8035, Santa Cruz Biotechnologies inc., Santa Cruz, California, USA) and for the 
secondary antibody a 1:10,000 dilution of anti-mouse IgG secondary antibody conjugated to 
horseradish-peroxidase (PI-2000, Vector Laboratories, inc., Burlingame, California, USA), both in 
TBS-T with 1%w/v milk. The proteins were detected through colorimetric analysis. The blot was 
treated for 1 minute with a solution containing ECL substrate (SuperSignal West Dura Extended 
Duration Substrate) (Thermo Fisher Scientific, Waltham, USA) and then exposed for an appropriate 
time to photographic film (Fujifilm, Minato, Japan), subsequently developed. Relative proteins 
levels were estimated by densitometry and mixed effects linear regression analysis was performed 
to study the variance in relative protein expression levels of GLUT3 in our samples. 
 
3.6 Studies with HD model fruit-flies 
3.6.1 Fly stocks  
All the experiments were done using D. melanogaster adult flies grown on standard 
sucrose-yeast medium (72 g/L maize meal, 80 g/L glucose, 50 g/L brewer’s yeast,  8.5 g/L agar , 2 
g/L of Nipagine [methyl p-hydroxybenzoate], dissolved in 10 ml 100% ethanol). All stocks were 
reared either at 18°C or 25°C under a cycle of 12 hours of light and dark (LD 12:12).  
The D. melanogaster strains used are described below: 
 w1118;; : strain carries a null mutant in the white gene that produces white colored eyes. 
This strain is used as a standard genetic background for the production of transgenic flies 
and in general is used as a control in experiments; 
 FM7a; Cyo/Sco; and FM7a;; MKRS/TM6B: strains carry chromosome balancers respectively 
for the sexual chromosome, the second and the third chromosomes, associated with 
visible markers that are useful and allow following genes in crosses scheme; 
 y,w;; actinGAL4/TM6: a yellow white strain carrying actin, an ubiquitous promoter which 
drives the expression of the yeast S. cerevisiae protein GAL4; 
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 elavGAL4;; : strain carries a P-element on the X chromosome that, fused with GAL4, drives 
expression of UAS-genes pan-neuronally; 
 w;; UAS-Q93httexon1: strain carries a UAS-element on the third chromosome which 
permits the expression of the first exon fragment of human Huntingtin with 93 poly 
glutamine, upon GAL4 activation (Steffan et al. 2001); 
 w;; Glut117J /TM6B: strain carries a lethal mutation caused by alkylating agent in Glut1 gene 
(Wei et al. 2003); 
 w;; Glut1d05758: strain carries a transposable P-element inserted in the position 
3L:959,584..959,584 of Drosophila genome (Fly base genome browser,  
http://flybase.org/cgi-bin/gbrowse/dmel/); 
 w; Glut1KK108683; : strain carries a construct designed to generate dsRNA for RNA 
interference (RNAi) specific for Glut1 and inserted in a attP landing site (Vienna Drosophila 
RNAi Centre,Vienna, Austria); 
 w; KK; : strain carries a construct designed to generate dsRNA for RNAi with no specific 
target and inserted in a attP landing site (Vienna Drosophila RNAi Centre (VDRC),Vienna, 
Austria); 
 w; 3M; : strain carries an empty vector in the attP landing site used by VDRC, in general 
used as a control for experiment with RNAi construct. 
Male flies carrying the tissue specific GAL4 drivers were crossed to virgin females carrying the UAS 
construct(s) in order to obtain female in the F1 progeny expressing the transgene of interest.  
3.6.2 Crossing scheme 
In this study elavGAL4 was the only driver used in order to induce the expression of the 
transgenic constructs of our interest in the Drosophila CNS. We investigated the effect of Glut1 
overexpression in HD background analysing elavGAL4;; Glut1d05758/UAS-Q93httexon1 for several 
metrics. This strain was obtained following the crossing scheme in Figure 20. Hereafter, we will 
refer to elavGAL4;; Glut1d05758/UAS-Q93httexon1 as EP-Glut1_Htt93Q. We investigated the effect 
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of single nucleotide mutation in Glut1 in HD background analysing elavGAL4;; Glut117J /UAS-
Q93httexon1 for several metrics. We investigated the effect of single nucleotide mutation in Glut1 
in HD background analysing elavGAL4;; Glut117J /UAS-Q93httexon1 for several metrics. This strain 
was obtained following the crossing scheme in Figure 20 and we will refer to it as mut-
Glut1_Htt93Q. 
 
Figure 20. Crossing scheme adopted to generate EP-Glut1_Htt93Q flies and mut-Glut1_Htt93Q 
flies. 
 
In this study EP-Glut1 flies and mut-Glut1 flies were compared to elavGAL4;; UAS-Q93httexon1, 
(abbreviated with Htt93Q). Control strains for EP-Glut1_Htt93Q, mut-Glut1_Htt93Q and Htt93Q 
(Table 27) were always analysed for each metric of investigation. 
We explored the effect of Glut1 downregulation by RNAi in HD background analysing 
elavGAL4; Glut1KK108683 ; UAS-Q93httexon1 flies for several metrics. This strain was obtained 
following the crossing scheme in Figure 21. From now on we will refer to elavGAL4; Glut1KK108683 ; 
UAS-Q93httexon1 as Glut1-RNAi_Htt93Q. In this study Glut1-RNAi flies were compared to 
elavGAL4; 3M; UAS-Q93httexon1 strain, where 3M refers to the insertion site designed for KK 
constructs for RNAi of Glut1 (VDRC, Vienna, Austria) filled with an empty vector. From now on we 
will refer to elavGAL4; 3M; UAS-Q93httexon1 as Htt93Q3M. Control strains for Glut1RNAi_Htt93Q, 
and Htt93Q3M (Table 27) were always analysed for each metrics of investigation. 
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Figure 21. Crossing scheme adopted to generate RNAi-Glut1_Htt93Q flies. 
 
3.6.3 RNA extraction 
D. melanogaster fly samples (more than 15 samples for each strain) were collected at a 
specific time points during their lifespan, frozen in liquid nitrogen and stored in -80˚C fridge. Each 
batch of flies was homogenised in 400μl TRIZOL reagent using a plastic pastel. Ulterior 600μl of 
TRIZOL were added to the homogenate for 5 minutes at room temperature. Consequently, 200μl 
of chloroform were added to the mixture, which was shaken vigorously for 15 seconds. The 
mixture was left to stand for 10 minutes and then centrifuged at 13,000 rpm for 15 minutes at 4°C. 
The supernatant was collected and transferred into a RNA-free tube, 500μl of isopropanol were 
added to the solution, left to stand at room temperature for 10 minutes. To facilitate the 
collection of the RNA, the solution was centrifuge at 13,000 rpm for 15 minutes at 4°C. The 
supernatant was discharged and the pellet, containing the RNA precipitated, was washed in 80% 
EtOh and then re-suspended in 20μl of Diethylpyrocarbonate (DEPC)-treated dH2O. The RNA 
extracted was tested for quality at 2100 BioAnalyzer and concentration at NanoDropTM (Thermo 
Fisher Scientific, Waltham, USA).  
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3.6.4 cDNA synthesis 
Before cDNA synthesis, RNA was treated with TURBO DNA-free™ kit to remove 
contaminating DNA, and afterward to remove the DNase and divalent cations from the samples. 
The treatment consisted in the preparation of this mix in a RNase-free microcentrifuge tube: 1-2μg 
of RNA sample; 1μl of 10X DNaseI reaction Buffer; 1μl DNase I, Amp Grade (1 U/μl); 10μl DEPC-
treated H2O. The reaction was carried out for 30 minutes at 37°C. The DNase was inactivated 
adding 2 μl of DNase Inactivation Reagent to the reaction mixture for 5 minutes at room 
temperature. The tubes were then centrifuged at 10,000 × g for 1.5 minutes and transfer the RNA 
to a fresh tube. cDNA synthesis was carried out using ImProm-II™ Reverse Transcriptase kit. 5μl of 
DNase treated RNA were mixed with 0.5μl of oligo-dT primer (100ng) and 0.5μl of Random Primers 
(100ng) at 72°C for 5 minutes and then chilled on ice for 5 minutes. The following components 
were added to the solution: 4μl of 5X ImProm-II™ Buffer; 2.5μl of 25mM MgCl2; 1μl of dNTP mix 
(10mM of each); 0.5μl of Rnasin Ribonulcease Inhibitor; 5μl of DEPC-treated H2O; 1μl of ImProm-
II™ Reverse Trascriptase. The solution was always mixed after adding each component. The 
reaction was incubated on a thermocycler (MJ research Inc., Quebec, Canada) at 25°C for 5 
minutes, 42°C for 1 hour, followed by final step of inactivation of reverse transcriptase at 70°C for 
15 minutes. The product was verified on electrophoresis gel.  
3.6.5 Real-time quantitative PCR (qPCR) 
Single strand cDNA was amplified with the qPCR method in order to quantify mRNA 
relative expression level of Glut1. Normally, the qPCR was placed in white propylene 96 well plate 
and performed in LightCycler® 480 machine (Roche, Penzberg, Germany). 10μl volume reactions 
were prepared with a final concentrations of 1X Fermentas Maxima SYBR Green qPCR Master Mix 
(Thermo Fisher Scientific, Waltham, USA), 0.15 mM of each primer and 1 μl cDNA, which dilution 
from the reverse transcription product (3.6.4) was adjusted according to the efficiency of the 
primers used. The efficiency, reproducibility of the primers used for the assay and the dynamic 
range of SYBR Green assay was determined by constructing a standard curve based on serial 
dilutions of cDNA. The standard curve was constructed by LightCycler® 480 Software 1.5 plotting 
the dilution factor against the threshold cycle (CT) value obtained during amplification of each 
sample. qPCR assays conditions were chosen when the standard curve showed efficiency value (E) 
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of approximately 100%. After the optimization, qPCR was performed for each sample in three 
technical replicates and a minimum of three biological replicates. The relative expression of each 
sample was analysed as 2ΔCT where ΔCT = CT (calibrator) – CT (test) and statistical comparison of the 
data was done performing an ANOVA analysis and post hoc tests (GraphPad Software, Inc., La 
Jolla, California, USA). 
3.6.5.1 Glut1 relative quantification by qPCR 
QPCR was used to quantify the mRNA expression levels of Glut1 in several fly stocks used in 
our study. Changes in expression were calculated by relative quantification, where expression 
level of Glut1 was normalized for expression level of ribosomal protein L32 (RpL32), ubiquitously 
expressed in the fruit fly. The primers for Glut1 were designed using IDT® SciTools RealTime PCR 
software (http://eu.idtdna.com/scitools/Applications/RealTimePCR/; Integrated DNA 
Technologies, Inc., Coralville, Iowa, USA), the primers for RpL32 (Table 26). Glut1 and RpL32 
qPCRs, prepared as separated mix as reported in 3.6.5, were performed simultaneously with 
LightCycler® 480 machine following the protocol in Table 6.  
Table 6. qPCR protocol for Glut1 and RpL32. 
 
Analysis mode Target 
(°C) 
Acquisition 
mode 
Hold 
Ramp rate  
(°C/s) 
Acquisition     
(per °C) 
Pre-incubation (1 x) − 95 none 10‘ 4.4 − 
Amplification (38 x) quantification 95 none 15‘’ 4.4 − 
  62 none 30‘’ 2.2 − 
  72 single 30‘’ 4.4 − 
Melting curve (1 x) melting curve 95 none 5‘’ 4.4 − 
  65 none 30‘’ 2.2 − 
  97 continuous − − 5°C 
Cooling (1 x) − 40 none 30‘’ 2.2 − 
x refers to cycle. ‘ refers to minute; ‘’ refers to second. 
Data analysis was done as reported in 3.6.5. 
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3.6.6 Lifespan assay 
The Drosophila lifespan was assessed approximately on 100 female flies for each fly strain 
analysed. The flies were collected within 24 hours of emergence and 10 females were allocated in 
a vial at 25°C. According to the genotype of interest, the flies were transferred daily or every 3-4 
days in a new tube and the dead flies were counted. Survival curves were generated, data were 
analysed by using Kaplan–Meier method and statistical significance was tested by using log rank 
statistics software (GraphPad Software, Inc., La Jolla, CA, USA). 
3.6.7 Pseudo-pupil Assay 
The pseudo-pupil assay was assessed on flies expressing the genotype of interest at day 1 
and day 7 post-eclosion. The tested fly was anesthetized, decapitated and the head affixed to a 
microscope slide with a drop of nail varnish. The pseudo pupil analysis was performed using either 
a Nikon Optiphot-2 (Nikon, Shinjuku, Japan) or an Olympus BH2 (Olympus, Tokyo, Japan) light 
microscopes with oil immersion optics and a 500X magnification. The number of rhabdomeres was 
counted for 20-30 ommatidia for each eye of 10-15 flies. Statistical comparison of the data was 
done performing an ANOVA analysis and post hoc tests (Statistica v 5.0, StatSoft, Inc., Tulsa, OU, 
USA). 
3.6.8 Eclosion Assay 
The eclosion assay was performed by setting up 10 independent crosses between 5 males 
carrying the elav-GAL4 driver and 5 virgin females homozygous for the UAS-trasgene. Flies were 
left to mate for 5 days after which the parental flies were removed from the vial. The crosses were 
cleared each day and the numbers of males and females were counted until all of the viable F1 
progeny had eclosed. The adult emergence percentage was calculated as a ratio between female 
and all progeny, where the females express the transgene of interest.  The data collected were 
analysed performing an ANOVA (Statistica v 5.0, StatSoft, Inc., Tulsa, OU, USA). 
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3.7 Miscellaneous   
3.7.1 Suppliers 
The following companies were suppliers of laboratory consumables for this thesis: 
 Bioline, London, UK (agarose gel electrophoresis reagents) 
 Biorad, Hercules, CA, USA (WB kit and ladders) 
 Bloomington Drosophila Stock Center, Indiana University, Bloomington, IN, USA (fly strains) 
 Eppendorf, Hambuerg, Germany (General) 
 KAPA Biosystem, Woburn, MA, USA (buffer A and Taq polymerase) 
 Life Technologies, Carlsbad, CA, USA (PCR reagent and machine; Capillary electrophoresis 
equipment and reagents; RNA extraction and DNase treatment; cell media) 
 Promega, Madison, WI, USA (dNTPs; ImProm-II™ Reverse Transcriptase kit) 
 Sigma-Aldrich, St Louis, MO, USA (General) 
3.7.2 Buffers 
All pH values at 25°C.  
 10X LD PCR buffer=50mM Tris-HCl (pH 8.8), 12.5mM ammonium sulphate, 1.4mM 
magnesium chloride, 125μg/ml BSA, 7.5mM 2-mercaptoethanol, 200μM of each dNTP 
 5X TBE (pH 8.3): Tris Base 0.45M, Boric acid 0.4M, EDTA 0.1M 
 LB: 20 mM/L Tris-acetate, 1 mM/L EGTA, 1% Triton X-100, 10 mM/L β-glycerol phosphate, 
5 mM/L sodium orthovandate, 10 mM/L β-glycerophosphate, 1 mM/L dithiothreitol, 50 ul 
Complete Mini Protease Inhibitor Cocktail (Roche) 
 4X WB loading buffer 4x: 62.5 mM Tris-HCl ph 6.8; 2% SDS; 0.1% Bromophenol-Blue; 10% 
Glycerol ; 10% β-mercaptoethanol 
85 
 
 4X Stacking buffer: 0.5M Tris HCl pH 6.8; 0.4%v/v SDS 
 4X Separation buffer: 1.5M Tris HCl pH 8.8; 0.2% v/v SDS 
 5X Migration buffer: 250mM Tris; 1.9M Glycine; 0.5% v/v SDS 
 1X Transfer buffer: 20mM Tris; 150mM Glycine; 12% v/v methanol; 0.1% v/v SDS 
 10X Tris-Buffered Saline (TBS): 200mM; 1.5M NaCl; pH 7.6 
 1X TBS-Tween (TBS-T): 1X TBS; 0.1% v/v Tween 20 
 Blocking buffer: 1X TBS-T, 5% w/v milk powder 
 TBS-T with 1%w/v milk: 1X TBS-T; 0.1% w/v milk powder 
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CHAPTER FOUR: 
RESULTS 
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4.1 Characterisation of the HD cohorts 
From now on we refer to the first HD sample cohort that we analysed in our study as HD 
cohort 1 and the other, which was provided in at second time, as HD cohort 2. The information 
provided for each cohort (given after completion of our analysis) included sex, the HTT gene CAG 
repeat length, AO of HD and main symptom(s) present at the disease onset according to the rater. 
The CAG mutation length was analysed by the local laboratory, where the sample was originally 
collected, and reanalysed by BioRep (BioRep, Milano); though this information was not provided 
for all samples. For our study the CAG mutation length of the HTT larger allele estimated by 
BioRep (BioRep, Milano) was considered and when this information was not available, the data 
from the local laboratory was used.  
The clinical data for 495 samples of the HD cohort 1 were provided by EHDN after the 
completion of our analysis, except for 5 samples that were therefore excluded from our study. In 
the HD cohort 1 the CAG mutation length considered was in most of the cases provided by BioRep, 
except for 90 samples for which the data from the collecting laboratory were used. One sample 
carrying a 35 CAG repeat HTT allele, which by definition is not a disease allele, was included in the 
analysis due to ambiguity with the data provided by the collecting laboratory, where a 40 CAG 
repeat length mutation was identified. In the HD cohort 1 the expanded trinucleotide repeats 
ranged from 36 to 67 with a mean (±SD) of 44±4 CAGs, and AO ranged from 10 to 79 years, with a 
mean onset of 43±11 (SD) years. Two-hundred and fifty eight patients were diagnosed by motor 
disturbances (mean±SD motor AO= 44±11 years), 114 with psychiatric disturbances (mean±SD 
psychiatric AO= 39±10 years), 44 with cognitive decline (mean±SD cognitive AO= 41±12 years), 5 
with symptoms such as weight loss or insomnia, 1 with oculomotor deficits and the remaining 73 
with mixed symptoms (mean±SD mixed symptoms AO= 44±10 years) (Table 7). The HD cohort 1 
included 263 men and 232 women.  
Clinical data for 493 samples of the HD cohort 2 were provided by EHDN at the time of our 
analysis. The CAG mutation length considered was provided by BioRep (BioRep, Milano) for 425 
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samples and by the collecting laboratory for 68 samples. One sample was excluded from the 
analysis because was genotyped with only 29 CAG repeats units, which is not considered to cause 
HD by definition. In the HD cohort 2 the expanded trinucleotide repeats ranged from 37 to 77 with 
a mean (±SD) of 45±4 CAGs, and AO ranged from 6 to 83 years, with a mean onset of 44±13 (SD) 
years. Three hundred and sixty-two samples were diagnosed by motor disturbances (mean±SD 
motor AO= 45±13 years), 55 with psychiatric disturbances (mean±SD psychiatric AO= 41±12 years), 
35 with cognitive decline (mean±SD cognitive AO= 42±15 years), 3 with symptoms such as weight 
loss or insomnia, 1 with oculomotor deficits and the remaining 36 with mixed symptoms 
(mean±SD mixed symptoms AO= 44±4 years) (Table 7). The HD cohort 2 included 227 men and 265 
women.  
Table 7. Main symptom estimated at HD onset for the samples of our cohorts. 
Main symptom at onset Cohort 1 Cohort 2 Cohort 1+2 
Motor  258 364 620 
Cognitive 44 35 79 
Psychiatric 114 55 169 
Oculomotor 1 1 2 
Weight loss, insomnia 5 3 8 
Mixed 73 36 109 
Total 495 493 987 
 
The clinical data in regards of the HD cohort 1 and 2 did not include any information of the 
ethnic origin of the samples, however a list of the provenience of the samples according to the 
recruiting clinical centre was provided. The location of the recruiting centres all over Europe 
suggests that the two cohorts are representative of different ethnic groups, but more detailed 
information are needed in order to exclude any possible bias towards ethnic groups or 
demographic origin (Figure 22). 
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Figure 22. Location of the collecting centres of the REGISTRY HD samples in our study. 
The percentage of each country is calculated on the number of the patients included in our study, recruited 
in a clinical centre in that country. 
 
In order to asset the validity of our cohorts as well representative of the HD population we 
plotted the HTT CAG repeat length for the AO in HD cohort 1 and HD cohort 2 and it is clear the 
inverse correlation within the two variables, typical feature of HD (Figure 23). 
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Figure 23 A, B. Scatter plots of AO and HTT CAG repeat length in HD cohort1 (A) and HD cohort 2 
(B). 
 
B) 
A) 
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In order to investigate the size of the effect of HTT CAG repeat length on the variability of 
AO in HD cohort 1 and HD cohort 2 and in the two cohort together, we constructed a generalized 
linear model (GLM) using SPSS 20.0 (IBM Inc., Armonk, NY, USA) calculated using Type III statistics 
with Wald confidence intervals, with an identity link, assuming a normal distribution of the 
dependent variable. The AO was included in the model as Log2 transformed AO, which is assumed 
to follow a normal distribution (Figure 24) and better fits the correlation within the HTT CAG 
repeat length. 
 
 
 
Figure 24 A, B. Histograms of age of onset (A) and Log2 transformed age of onset (B) frequencies 
distribution in our HD cohorts. 
 
B) 
A) 
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Log2 transformed AO of HD was the scalar dependent variable and HTT CAG repeats length the 
scalar predictor variable. As expected, the CAG repeat length is significantly contributing to the 
prediction of the AO in HD cohort 1, HD cohort 2 and HD cohorts together (Table 8).  
Table 8. Effect of the HTT CAG repeat length on the age of onset in HD cohort 1 and 2. 
 Mean (95%CI) (years 
per CAG repeat) 
p-value 
Effect for extra CAG repeat in HD cohort 1 −2.14 (−2.33 to −1.96) <5×10−6 
Effect for extra CAG repeat in HD cohort 2 −2.5 (−2.68 to −2.39) <5×10−6 
Effect for extra CAG repeat in HD cohort 1+2 -2.34 (−2.46 to −2.22) <5×10−6 
 
The inclusion into the GLM of the sex, as categorical predictor factor, is not associated to any 
significant effect in HD cohort 1 (p value = 0.332), HD cohort 2 (p value = 0.754) and HD cohort 1 
and 2 together (p value = 0.392). Furthermore, we performed a one-way ANOVA to test if there is 
any correlation between major symptom(s) at onset and the HTT CAG repeat length and no 
significant association was found in HD cohort 1 (p value = 0.828), HD cohort 2 (p value = 0.569) 
and HD cohort 1 and 2 (p value = 0.851). 
The two HD cohorts independently and taken together are well representative of the variability of 
AO in HD, which is main attributable to the HTT CAG repeat length, within an inverse correlation 
between the two variables. Furthermore, the two HD cohorts independently and taken together 
show no bias towards the mayor symptom(s) at onset or sex. 
 
4.2 β-defensin CNV distribution in HD 
cohort 1 
We analysed β-defensin CNV in 500 samples from HD cohort 1. The β-defensin copy 
number for each sample was inferred from six values, resulting from the β-defensin assay, which 
were corrected for inter-experiment variability using known controls (Aldhous et al. 2010) (Table 
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25). The quality of copy number calling was evaluated qualitatively by analysing histograms of the 
mean of the normalized ratio for each PRT (PRT107A, HSPD21) expecting to have clusters around 
every integer value which indentified each copy number of the β-defensin locus (Figure 25, Figure 
26). The histograms in Figure 25 and Figure 26 show clear clustering around integer values from 
each PRT. In order to adjust the copy number calling for contiguous values, the β-defensin method 
combines the two PRTs with the 5DELR assay, which allows distinguishing between contiguous 
copy number calls producing different value for even and odd copy number samples. The 
reproducibility of the β-defensin assay was tested comparing the raw data from the control 
samples, which were used in each reaction. The control samples showed similar raw PRT ratios 
from separate reactions confirming the reproducibility of the β-defensin assay; the variance of 
their raw values could be explained by procedural variability (sample dilution batch, PCR mix) 
(Figure 27). 
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Figure 25. Histogram of PRT107A ratios frequencies plotted for final β-defensin copy number in HD cohort 1. 
“CN” refers to final β-defensin copy number, as determined by the maximum likelihood associated to each PRT raw ratio. “n” to the number of individuals.
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Figure 26. Histogram of HSPD21 ratios frequencies plotted for final β-defensin copy number in HD cohort 1. 
“CN” refers to final β-defensin copy number, as determined by the maximum likelihood associated to each PRT raw ratio. “n” to the number of individuals. 
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Figure 27 A, B. Scatter plot of raw ratios from 72 controls samples used in each PRT107A (A) and 
HSPD21 (B) reaction. 
It represents repeat testing of six DNA samples, available from the European Collection of Cell Cultures, 
CO088 4 copies, CO207 5 copies, CO849 6 copies, CO913 3 copies, CO940 4 copies, CO969 5 copies. The 
different symbols for each plate represent the PRT replicates done with different labelled primers.  
A) 
B) 
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For all the samples of HD cohort 1 we calculated p value that reflects the confidence in the 
inferred copy number compared to all the other copy number calls using the maximum likelihood 
approach. We determined β-defensin copy number with p value < 0.05 for 495 and among these 
99% have copy number call with p value < 0.01. Five samples were not included in the analysis 
because having a copy number with p value > 0.05.  
In order to investigate the effect of β-defensin CNV on the AO in HD, we excluded 5 
samples because no clinical data were available at the time of the analysis. Firstly, we analysed the 
β-defensin copy number distribution in the HD cohort 1 dividing the cohort into three groups 
according to the age of onset: juvenile, AO ≤ 20 years; typical, AO between 20 and 50 years; late, 
AO ≥ 51 years (Wexler et al. 2004) (Table 9).  
Table 9. β-defensin CNV genotypes in each AO class, in the HD cohort, and the European 
population. 
β-defensin Juvenile AO Typical AO Late AO HD European 
copy number 
HD group 
 
HD group 
 
HD group 
 
cohort  
 
population 
 
1 0 1 0 1 0 
2 0 8 3 11 8 
3 3 62 24 89 70 
4 2 129 51 182 205 
5 5 99 34 138 131 
6 1 44 11 56 44 
7 0 8 3 11 9 
8 0 1 1 2 4 
9 0 0 0 0 1 
n 11 352 127 490 472 
 
We carried out a one-way ANOVA to test whether there was any variation in β-defensin CNV 
distribution among each group, and all the groups and the European population without HD, 
analysed in a previous study (Fode et al. 2011). The distribution of no AO class had a β-defensin 
CNV distribution that was significantly different from any other class or the European non-HD 
population and, the β-defensin CNV distribution in the whole HD cohort 1 was not significantly 
different from the European population without HD (one-way ANOVA, p value = 0.91) (Figure 28) 
(Fode et al. 2011). 
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Figure 28. Cumulative frequencies of β-defensin CNV genotypes in HD individuals subsets and 
European population. 
HD subjects were grouped according to the AO in juvenile AO, typical AO, late AO and of the non-HD 
European population. The p-value is two-sided, calculated by one-way ANOVA. 
 
 We constructed a GLM to explore the effect of CAG repeat length and β-defensin copy number, as 
ordinal predictor variable, on AO in HD. The addition of CAG repeat length into the model 
improved the prediction of AO (p value < 5×10−6, Table 4), but subsequent incorporation of β-
defensin copy number into the model found no significant improvement in the prediction of AO (p 
value = 0.41, Table 10). No significant effect was found adding the gender to the model (p value = 
0.34). We also used a GLM to investigate the effect of β-defensin copy number and CAG repeat 
length on the major estimated symptom(s) at onset of HD (categorical dependent variable) and no 
significant effect with any of the symptoms at the onset and CAG repeat length (p value = 0.76) 
nor β-defensin copy number (p value = 0.85) was found. Thus, it appeared that β-defensin CNV 
does not significantly affect the AO of HD in HD cohort 1. 
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Table 10. Effect of the β-defensin CNV on the age of onset in HD. 
 Mean (95%CI) (years) p-value 
Effect per extra CAG repeat −2.17 (−2.36 to −1.98) <5×10−6 
Effect per extra copy of DEFB4 −0.28 (−0.96 to 0.4) 0.415 
 
 
4.3 SLC2A3 CNV in HD 
4.3.1 SLC2A3 CNV distribution in HD cohort 1 and 2 
SLC2A3 assay was performed and analysed separately in HD cohort 1, HD cohort 2 and 
afterwards analysed in both cohorts together. SLC2A3 copy number was defined by a mean ratio 
corrected for inter-experimental variability using known controls (Table 25), whose SLC2A3 copy 
number was determined in a previous study using the same PRT assay and recombination assays 
(Veal et al. 2013). The reproducibility of the SLC2A3 assay was tested comparing the raw data from 
the control samples (Table 25), which were used in each reaction. The control samples show 
similar raw PRT ratios from separate reactions confirming the reproducibility of the SLC2A3 assay 
(Figure 29). 
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Figure 29. Scatter plot of raw ratios from 36 controls samples used in each SLC2A3 assay. 
It represents repeat testing of 3 DNA samples, NA19920 3 copies (from HapMap Panel), NA11840 2 copies 
(from CEPH panel), L31 1 copy (from Leicester panel). The different symbols represent different SLC2A3 
assay reactions. 
 
The copy number calling was evaluated qualitatively by plotting the normalized ratio for each 
replicate of the SLC2A3 assay expecting to have clusters around every integer value which 
indentified each copy number of the SLC2A3 locus. Two clear clusters were identified after plotting 
values from technical replicates from HD cohort 1 genotyping, allowing defining technical cut-off 
for copy number calling. The first threshold used to distinguish between 1 copy and 2 copies was 
set at 0.65: any sample with a mean normalized ratio equal or less than 0.65 was inferred to be 1 
copy number sample (Figure 30-A). The second threshold was set up to distinguish between 2 and 
3 copies: any sample with a normalized ratio equal or higher than 1.35 was called 3 copies (Figure 
30-A). Samples with ratio between 0.65 and 1.35 were called as 2 copy number samples  (Figure 
30-A). Plotting the data from two technical replicates of SLC2A3 assay performed on HD cohort 2 
gave the same distribution of normalized values. Therefore, the cut-offs used to infer SLC2A3 copy 
number in HD cohort 1 were identical in HD cohort 2 (Figure 30-B). Eventually, the same cut-offs 
were confirmed combining the HD cohort 1 and HD cohort 2 normalized value plots together. 
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Figure 30 A-B. SLC2A3 data plots in HD cohort 1 (A), HD cohort 2(B). 
For each cohort normalized ratios from assay replicates were plotted together. Clear clusters allowed to 
identify technical cut off for inferring integer SLC2A3 copy number. The dot lines represent the technical cut-
offs used to distinguished between 1 and 2 SLC2A3 copy number and 2 and 3 SLC2A3 copies. The sample in 
B) showing a ratio of ~ 2 was considered an outlier.  
A) 
B) 
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From HD cohort 1, we successfully genotyped 495 samples and we found 4 deletion 
carriers, 12 duplication carriers and 479 individuals with normal diploid set. Five samples were 
excluded from the study because repeated analysis gave results that were rejected according our 
experimental condition. Firstly we compared SLC2A3 CNV distribution in HD cohort 1 and the 
British population (Reekie 2011) and no significant difference was found between the two groups 
(t-test two-tailed, p value = 0.38) (Table 12). As previously described, we constructed a GLM to 
investigate the effect of CAG repeat length and SLC2A3 copy number (as ordinal predictor 
variable) on AO in HD. As expected, including the CAG length into the model bettered the 
prediction of AO (p value < 5×10−6, Table 11) and the subsequent incorporation of SLC2A3 copy 
number into the model was associated to a significant improvement in the prediction of AO (p 
value = 0.038, Table 11). No significant effect was found adding the sex to the model (p value = 
0.30). Furthermore, we used a GLM to investigate the effect of SLC2A3 copy number and CAG 
repeat length on the major estimated symptom(s) at the onset of HD and no significant effect with 
any of the symptoms at the onset diagnosis and CAG repeat length (p value = 0.69) nor SLC2A3 
copy number (p value = 0.49) was found.  
Table 11. Effect of the SLC2A3 CNV on the age of onset in HD cohort 1 
 Mean (95%CI) (years) p value 
Effect per extra CAG repeat -2,20 (-2,39 to -2,04) <5×10−6 
Effect per extra copy of SLC2A3 4.53 (0.23 to 9.23) 0.038 
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Figure 31. Scatter plot of AO and HTT CAG repeat length in our HD cohort 1 within SLC2A3 copy 
number genotype. 
Grey dots indicate individuals with 2 copies, green triangles with 3 copies and red squares with 1 copy of 
SLC2A3. 
 
In order to investigate the effect of SLC2A3 CNV on the AO in HD we analysed SLC2A3 CNV 
distribution in additional 500 samples of the HD cohort 2. We determined SLC2A3 copy number in 
499 samples of HD cohort 2 using and we identified 1 deletion, 24 duplications, with the remaining 
474 samples having a SLC2A3 diploid set. One sample was excluded from our analysis because it 
showed a copy number of 4, which was not verified due to the absence of any standard control of 
copy number higher than 3 in our assay or of other methods to test the origin and structure of this 
CNV event. Firstly we tested SLC2A3 CNV distribution in HD cohort 2 compared to HD cohort 1 and 
the British population. There was no significant difference between HD cohort 2 and HD cohort 1 
(t-test two-tailed, p value = 0.99) nor the British population (t-test two-tailed, p value = 0.38), 
moreover the two cohorts taken together were not significantly different from the British 
population (t-test two-tailed, p value= 0.42) (Table 12). 
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Table 12. SLC2A3 CNV genotypes in the HD cohorts and the British population. 
SLC2A3 HD HD HD British 
copy number Cohort 1 
 
Cohort 2 
 
Cohorts 1+2 
 
population 
 
1 4 
 
(0.8%) 1 (0.2%) 5 (0.5%) 58 
 
(0.9%) 
2 479 (96.8%) 474 (95%) 953 (95.8%) 6016 (95.4%) 
3 12 (2.4%) 24 (4.8%) 37 (3.7%) 234 (3.7%) 
 
To measure the effect of the SLC2A3 CNV distribution on AO in HD cohort 2, 7 samples 
(with SLC2A3 copy number of 2) were excluded from the study due to the lack of clinical data at 
the moment of the analysis. As previously described (2.4), we constructed a GLM to investigate 
the effect of HTT CAG repeat length and SLC2A3 copy number (as ordinal predictor variable) on AO 
of HD in HD cohort 2. Including the HTT CAG repeat length into the model bettered the prediction 
of AO (p value < 5×10−6, Table 13). The subsequent incorporation of SLC2A3 copy number into the 
model did not give a significant improvement in the prediction of AO of HD (p value = 0.325, Table 
13). No significant effect was found including the sex into the model (p value = 0.768). 
Furthermore, we used a GLM to investigate the effect of SLC2A3 copy number and CAG repeat 
length on the major estimated symptom(s) at the onset of HD and no significant effect with any of 
the symptoms at the onset diagnosis and CAG repeat length (p value = 0.66) nor SLC2A3 copy 
number (p value = 0.22) was found.  
Table 13. Effect of the SLC2A3 CNV on the age of onset in HD cohort 2. 
 Mean (95%CI) (years) p value 
Effect per extra CAG repeat −2.47 (−2.63 to −2.33) <5×10−6 
Effect per extra copy of SLC2A3 1.6 (−1.53 to 4.99) 0.325 
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Figure 32. Scatter plot of AO and HTT CAG repeat length in our HD cohort 2 within SLC2A3 copy 
number genotype. 
Grey dots indicate individuals with 2 copies, green triangles with 3 copies and red squares with 1 copy of 
SLC2A3. 
 
The negative correlation between SLC2A3 CNV distribution in HD cohort 2 and the positive 
correlation in HD cohort 1 suggested that the two cohorts, formed in order to be well-
representative samples of the HD population (considering the HTT CAG repeat length and also AO 
of HD), did not behave as a good estimator for studying SLC2A3 CNV as a genetic modifier of AO in 
HD. Furthermore, it was important to consider the size of the genetic variation analysed: copy 
number change of SLC2A3, namely deletion or duplication, was present in the HD cohort 1 and 2 
taken together (996 individuals) and in the British population (6308 individuals) as a rare event 
involving only on average ~4.5% of the samples in each of these groups. The size of this genetic 
variation, which effect on AO of HD was analysed as covariant with the HTT CAG mutation length, 
could negatively affect the power of the analysis in the single HD cohort 1 or HD cohort 2, 
probably leading to false positive or false negative associations. Therefore, considering that the 
two cohorts were not distinct population but samples of the same population, it was appropriate 
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to combine them together in order to have a larger sample which could improve the power of our 
analysis to describe the effect of SLC2A3 CNV on AO of HD. Performing a GLM to studying the 
effect of SLC2A3 CNV in the HD cohort 1 and 2 taken together (Figure 33), we found that SLC2A3 
CNV was associated to a significant improvement in the prediction of AO, higher than in regards of 
the HD cohort 1 alone (p value = 0.028, Table 14). 
Table 14. Effect of the SLC2A3 CNV on the age of onset in HD cohort 1 and 2. 
 Mean (95%CI) (years) p value 
Effect per extra CAG repeat −2.37 (−2.48 to −2.24) <5×10−6 
Effect per extra copy of SLC2A3 2.89 (0.28 to 5.61) 0.028 
 
 
Figure 33. Scatter plot of AO and HTT CAG repeat length in our HD cohort 1 and 2 within SLC2A3 
copy number genotype. 
Grey dots indicate individuals with 2 copies, green triangles with 3 copies and red squares with one copy of 
SLC2A3. 
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No significant effect was found adding to the GLM the gender (p value = 0.39). Constructing a GLM 
for the main symptom(s) at onset in HD cohort 1 and 2 together, no significant effect for any of 
the symptoms detected at onset of HD was found incorporating CAG repeat length (p value = 0.65) 
nor SLC2A3 CNV (p value = 0.074) to the model. Thus, it appears that SLC2A3 CNV can affect the 
AO in HD where individuals bearing 3 SLC2A3 copy number showed a delay of the AO up to ~ 6 
years compared to individuals with 1 or 2 SLC2A3 copy number, with no bias towards sex or major 
symptom at onset. 
 
4.3.2 Analysis of SLC2A3 CNV in patient cell lines 
In order to understand the significant effect of SLC2A3 CNV on the AO in our HD cohorts, 
we investigated the role of CNV on SLC2A3 gene expression quantifying GLUT3 (encoded by 
SLC2A3) expression level. For this purpose we collected 15 LCLs originated from different samples 
of our two cohorts, 5 for each SLC2A3 copy number. Among the individuals carrying 1 copy of 
SLC2A3 the mean AO was 44.4 years (SD± 9.6) and the mean CAG mutation length was 43.8 (SD± 
1.8); among the individuals carrying 2 copy of SLC2A3 the average AO was 47 years (SD± 8.2) and 
the mean CAG mutation length was 42.6 (SD± 1.9); among the individuals carrying 3 copy of 
SLC2A3 the average AO was 45 years (SD± 10.5) and the mean CAG mutation length was 43.8 (SD± 
0.8) (Table 15).  
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Table 15. Clinical data and SLC2A3 CNV genotype related to LCLs. 
LCLs code Age of onset (Mean ±SD) CAG mutation length (Mean ±SD) SLC2A3 copy number 
1 40 45 1 
2 34 43 1 
4 60 41 1 
8 44 45 1 
11 44 45 1 
 (44.4 ± 9.6) (43.8 ± 1.8)  
6 34 46 2 
8 51 42 2 
10 48 42 2 
13 48 42 2 
14 56 41 2 
 (47 ± 8.2) (42.6 ± 1.9)  
3 44 45 3 
5 50 44 3 
9 53 43 3 
12 27 44 3 
15 50 43 3 
 (45 ± 10.5) (43.8± 0.8)  
 (Mean ± SD) refers to mean and standard deviation values (as indicated) for each SLC2A3 copy number 
group. 
 
4.3.2.1 Immuno-quantification of GLUT3 protein level in LCLs 
We quantified GLUT3 expression levels in our LCLs by immunoblotting analysis. According 
to a gene dosage effect we expected to detect GLUT3 protein level in direct correlation with 
SLC2A3 copy number. One protein lysates was prepared for each cell line, after 72 hours 
incubation in normal media. Immunoblot experimental replicates were performed to reduce the 
effect of technical variability on the final analysis. We analysed the protein lysates of each sample 
in 5 different blots, except for LCL 3 and LCL 12, which were analysed in 4 different gels. The 
GLUT3 band was always detected at 45 kilo Dalton (kDa) and the α-Tubulin band, which was used 
to normalize the GLUT3 expression signal, at 55 kDa (Figure 34,Table 16).  
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Table 16. Descriptive data of GLUT3 relative protein level in the 3 CNV groups. 
SLC2A3 copy number Observations Mean relative intensity Std.dev. Median Min Max 
1 24 0.66 0.24 0.67 0.24 1.12 
2 25 0.58 0.25 0.56 0.18 1.15 
3 24 0.82 0.30 0.89 0.31 1.52 
Std.dev indicates the standard deviation. Min refers to the minimum value. Max refers to the maximum 
value. 
 
 
Figure 34. GLUT3 expression levels in LCLs by immunoblot.  
 
Mixed effects linear regression was used to explore the association between the 
normalized intensity ratios, indicating the relative GLUT3 protein expression level, with SLC2A3 
copy number associated to each cell line. The analysis was designed to take into account the gel 
where the samples were loaded as a source of the experimental variability intra-replicates. SLC2A3 
copy number was found to be significantly associated with the protein level (p value = 0.02, Figure 
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35, Table 17). Furthermore we compared the relative GLUT3 expression levels among different 
SLC2A3 CNV groups. The relative protein expression level for the group with SLC2A3 CN=3 is 
significantly different to SLC2A3 CN=1 (p value = 0.02, Table 18) (Figure 36) and SLC2A3 CN=2 (p 
value <0.001, Figure 37) (Figure 37). No significant difference was found comparing the relative 
protein expression level in the group with SLC2A3 CN=1 and SLC2A3 CN=2 (p value = 0.30,Table 
18-Table 19) (Figure 37). 
 
Figure 35. GLUT3 relative expression levels according to SLC2A3 copy number. 
The vertical bar indicates the minimum and the maximum value and the horizontal bar the mean value of 
each group. 1 SLC2A3 copy number, 3 SLC2A3 copy number: 24 observations each; 2 SLC2A3 copy number: 
25 observations. Statistical comparison by mixed effects linear regression. 
 
Table 17. Effect of SLC2A3 copy number on protein expression level.  
 Mean (95%CI) (GLUT3/ α-Tubulin intensity ratio) p value 
Effect per extra copy of SLC2A3 0.09 (0.02 to 0.17) 0.02 
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Figure 36. GLUT3 protein level in LCLs with 1 SLC2A3 copy number compared to the other copy 
number classes. 
The vertical bar indicates the minimum and the maximum value and the horizontal bar the mean value of 
each group. 1 SLC2A3 copy number, 3 SLC2A3 copy number: 24 observations each; 2 SLC2A3 copy number: 
25 observations.  Statistical comparison versus GLUT3 relative expression in 1 SLC2A3 copy number (orange 
box) by mixed effects linear regression. 
 
Table 18. Effect of SLC2A3 copy number 1 compared to the other CNV classes on protein 
expression level.  
Effect compared to SLC2A3 CN=1 Mean (95%CI) (GLUT3/ α-Tubulin intensity ratio) p value 
SLC2A3 CN=2  -0.07 (-0.22 to 0.07) 0.30 
SLC2A3 CN=3 0.18 (0.04 to 0.33) 0.01 
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Figure 37. GLUT3 protein level in LCLs with 2 SLC2A3 copy number compared to the other copy 
number classes. 
The vertical bar indicates the minimum and the maximum value and the horizontal bar the mean value of 
each group. 24 observations each for 1 SLC2A3 copy number and 3 SLC2A3 copy number, 25 observations 
for 2 SLC2A3 copy number.  Statistical comparison versus GLUT3 relative expression in 2 SLC2A3 copy 
number (blue box) by mixed effects linear regression. 
 
 Table 19. Effect of SLC2A3 copy number 2 compared to the other CNV classes on protein 
expression level. 
Effect compared to SLC2A3 CN=2 Mean (95%CI) (GLUT3/ α-Tubulin intensity ratio) p value 
SLC2A3 CN=1  0.07 (-0.07 to 0.22) 0.30 
SLC2A3 CN=3 0.26 (0.12 to 0.40) <0.001 
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4.4 Functional study of the neuronal 
glucose transporter Glut1 in a Drosophila 
model of HD 
Considering the significant correlation between SLC2A3 CNV and the AO of HD in the 
tested cohorts and the significant effect of SLC2A3 CNV on GLUT3 protein expression level in cell 
lines (LCLs) from HD individuals, we decided to study the function of the glucose transport in an in 
vivo model of HD. The study aimed to investigate if genetic alterations of a main neuronal glucose 
transporter could modulate the HD phenotype in the model and, specifically, if an increased 
expression of this transporter can have a protective effect against HD progression. For our 
purposes we decided to use a Drosophila HD model that within a central nervous system allows 
one to investigate the effect of selected gene expression specifically in the brain. Furthermore, the 
application of the Drosophila HD model includes the possibility to test the effect of a transgene 
through several metrics, such as survival, neurodegeneration in the eye and eclosion (emergence 
of the adult fly from the pupal case).  
 There are several sugar transporters annotated in the fruit fly genome (FlyBase, 
http://flybase.org/) and from those a number of glucose and sugar transporter amino acid 
sequences were selected in Uniprot, a protein database (http://www.uniprot.org/), and compared 
through multiple alignment with the main human GLUTs expressed in the brain using Clustal 
Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). From the analysis of this multiple alignment 
(Figure 38), Drosophila Glut1 (Q6NNA9_DROME, Uniprot code) showed homology to human 
GLUT3 (GTR3_HUMAN, Uniprot code) (encoded by SLC2A3), sharing 46% of amino acid identity 
with its protein sequence (Figure 39).   
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Figure 38. Dendogram of human GLUT1-5, 8 protein sequences and several sugar transporters in 
Drosophila. 
The proteins are indicated with their Uniprot code. 
 
 
Figure 39. Aminoacid sequences alignment of the Drosophila Glut1 and GLUT3. 
The proteins are shown with their Uniprot code. 
 
Data provided in FlyAtlas, an online database of a comprehensive expression study in Drosophila, 
showed that Glut1 mRNA is mainly expressed in the brain of the adult fly (http://www.flyatlas.org/ 
(Chintapalli et al. 2007)) (Figure 40). Furthermore, comparing each structural domain and 
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functional residues in the Drosophila Glut1 and the human GLUT1-5 a transmembrane transporter 
activity can be inferred upon Glut1 (Escher et al. 1999). All this evidence and the availability of 
transgenic strains (for modulating Glut1 expression) make Glut1 the most promising candidate for 
designing a Drosophila model to recapitulate observed aberrations in the human SLC2A3 gene. 
 
Figure 40. Drosophila Glut1 mRNA expression profile - array data. 
Data from Chintapalli et al. 2007. 
 
Among several Drosophila HD models, we used transgenic flies encoding a human HTT 
exon 1 fragment with a 93 glutamine (Htt93Q) repeat length under control of a UAS-enhancer; the 
expression of the transgene is induced by a GAL4 driver using the GAL4/UAS bitransgenic system 
(Steffan et al. 2001). This model using the pan-neuronal elavGAL4 driver, allowing selectively the 
expression of the mutant HTT in the Drosophila brain, shows phenotype changes attributable to 
mutant HTT insertion such as early toxicity from larva stage, progressive neurodegeneration 
detectable by the analysis of the pseudopupil as well as reduced half-life.   
In order to evaluate the role of Glut1 in a Drosophila HD model (Htt93Q) we tested the 
effect of reduction, alteration and over-expression of Glut1 gene expression (RNAi, mutant lines, 
EP lines) in the HD background. Changes in disease-relevant phenotypes were evaluated using 
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different metrics such as loss of the rhabdomeres, longevity and eclosion rate. The pseudo-pupil 
test gives direct information of the neurodegenerative process through counting the loss of visible 
rhabdomeres of mutant flies. Through analysis of eclosion, which takes in account the number of 
viable mutant flies versus non mutant flies at the emergence from the pupa, and the longevity, for 
which the life span of flies of interest are compared, it is possible to deduce if modulation of the 
gene of interest has beneficial or toxic effect on the fly. 
4.4.1 Validation of fly strains used 
The expression of Glut1 mRNA levels in the fruit fly strains carrying a construct for the 
expression shRNA targeting Glut1 via RNAi (w; Glut1KK108683;+) and EP construct for the 
overexpression of Glut1 (w;; Glut1d05758) was validated by relative qPCR analysis. These strains 
were crossed with yw;; actinGAL4/TM6B in order to have a F1 progeny where actinGAL4 induces 
the RNAi or overexpression of Glut1 ubiquitously. The relative expression of Glut1 in these flies 
was compared to the driver control (w;; actinGAL4/+). For each strain five biological replicates 
were used in our investigation. The relative expression of Glut1 was normalised for Rpl32 and 
calculated as ΔCt. ΔCt for each biological replicate was normalised for the mean ΔCt of the 
controls. ANOVA and multiple comparisons test were performed to test the difference in Glut1 
relative expression between the strains. ANOVA and post-hoc test of comparison with the driver 
control showed that the relative expression of Glut1 was decreased by 34% in flies expressing 
RNAi for Glut1 (ANOVA, post-hoc test p value = 0.023) and increased by 78% in flies expressing the 
EP construct for Glut1 overexpression (ANOVA, post-hoc test p value = 0.00023) (Figure 41). Thus, 
the genetic manipulations modulating Glut1 expression have been confirmed.  
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Figure 41.  Relative quantification of Glut1 expression levels in the fly strains used. 
Relative quantification of normalised ΔCt mean (± SEM) per ctrl, RNAi and EP. n≥ 30 flies per each strain. 
Statistical comparisons by ANOVA and post hoc tests versus ctrl flies. (*p value <0.05; **** p value < 
0.0001). “ctrl” refers to yw;; actinGAL4/+; “RNAi” refers to w ; Glut1KK108683;actinGAL4; “EP” refers to w;; 
actinGAL4/Glut1d05758.  
 
4.4.2 Glut1 downregulation in HD flies 
We initially analysed RNAi-Glut1_Htt93Q and the relative control strains (Table 27) for our 
metrics of investigation: eclosion rate, rhabdomere neurodegeneration and survival rate (see 
Supplementary material). The same was done for Htt93Q3M and the relative controls strains (Table 
27)  (see Supplementary material).  
4.4.2.1 Eclosion test results 
The eclosion rate was calculated for Glut1-RNAi_Htt93Q flies from 10 ♂elavGal4;; Χ ♀w; 
Glut1KK108683 ;UAS-Q93httexon1 crosses and the same strategy was used for Htt93Q3M flies 
(♂elavGal4;; Χ ♀w; 3M; UAS-Q93httexon1). For all of these crosses only the female F1 progeny 
expressed the transgenes of interest and the eclosion rate was calculated as total female F1/ total 
F1. The eclosion rate for Glut1-RNAi_Htt93Q was stastically different from the eclosion rate of the 
controls (see Supplementary material) except elavGAL4;KK; UAS-Q93httexon1 strain, where a KK 
represents the empty “site specific” transgenic inserting site (ANOVA, post hoc test p value ≥ 
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0.05). As well, the eclosion rate for Glut1-RNAi_Htt93Q was not statistically different from the 
eclosion rate of Htt93Q3M (ANOVA, p value = 0.48) (Figure 42). Therefore, it appeared that the 
knocking down of Glut1 in a HD background does not further impair the development of fruit flies.  
 
 Figure 42. Eclosion rate for Htt93q3M flies and Glut1-RNAi_Htt93Q flies.  
Knocking down Glut1 expression in flies carrying the mutant HTT does not affect the eclosion rate. n ≥ 1000 
progeny for each cross. Statistical comparisons by ANOVA (n.s. not significant).  
 
4.4.2.2 Pseudopupil test results 
The loss of rhabdomeres, detected by peudopupil assay, was estimated at day 1 and 7 
post-eclosion in Glut1-RNAi_Htt93Q and Htt93Q3M. In both Glut1-RNAi_Htt93Q flies and Htt93Q3M 
flies a progressive loss of rhabdomeres was detected; the mean rhabdomeres per each ommatidia 
analysed was statistically different between Glut1-RNAi_Htt93Q flies and Htt93Q3M flies at day 1 
(MANOVA, post-hoc test p value = 0.00012) and at day 7 (MANOVA, post-hoc test p value = 0.028) 
(Figure 43). Thus, it appeared that downregulating Glut1 by RNAi in a HD background enhanced 
the neurodegeneration in the adult fly. 
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Figure 43. Glut1-RNAi_Htt93Q flies exhibit augmented rhabdomere loss compared with 
Htt93Q3M flies. 
Quantification of mean rhabdomeres (± SEM) per ommatidium in Htt93Q and Glut1-RNAi flies at day 1 and 
day 7 after eclosion. n= 9 to 15 flies per genotype. Statistical comparisons by MANOVA and post hoc tests 
versus Htt93Q3M flies (*p value <0.05; *** p value < 0.001).  
 
4.4.2.3 Lifespan test results 
The lifespan of RNAi-Glut1_Htt93Q flies was recorded and compared to Htt93Q3M flies. 
Statistical analysis by Kaplan–Meier survival curve analysis with log rank test was calculated on 
100 animals per genotype showing that RNAi-Glut1_Htt93Q flies have a decreased lifespan 
(median lifespan = 17 days) compared to Htt93Q3M flies (median lifespan = 18 days), with a 
reduction of the median life span of 1 day (p value = 0.034) (Figure 44). Thus, it appeared that 
reducing levels of Glut1 by RNAi modestly exacerbated HD phenotype in the adult fly.  
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Figure 44. Glut1-RNAi_Htt93Q flies exhibit reduced life span compared with Htt93Q3M flies. 
Glut1 downregulation decreased median survival of adult HD flies. The number of flies surviving 
from each cohort was determined every day. Statistical analysis by Kaplan–Meier survival curve 
analysis with log rank test (*p value < 0.05). n=100 animals per genotype. 
 
4.4.3 Glut1 overexpression and Glut1 mutant in HD flies 
We initially analysed EP-Glut1_Htt93Q, mut-Glut1_Htt93Q and their relative control strains 
(Table 27) for our metrics of investigation: eclosion rate, rhabdomere number and lifespan(see 
Supplementary material). The same was done for Htt93Q and the relative controls strains (Table 
27) (see Supplementary material). Afterwards, EP-Glut1_Htt93Q and mut-Glut1_Htt93Q were 
compared to Htt93Q for our metrics of investigation. 
4.4.3.1 Eclosion test results 
The eclosion rate for EP-Glut1_Htt93Q was calculated from 10 ♂elavGal4;; Χ ♀w; 
Glut1d05758 ;UAS-Q93httexon1 crosses, for mut-Glut1_Htt93Q was calculated from 10 ♂elavGal4;; 
Χ ♀w; Glut117J ;UAS-Q93httexon1 crosses and for Htt93Q flies from 10 ♂elavGal4;; Χ ♀w;; UAS-
Q93httexon1 crosses. For all of these crosses the ratio of the female F1 progeny, expressing the 
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transgenes of interest, versus the total F1 progeny was counted. ANOVA of the eclosion rate of EP-
Glut1_Htt93Q, mut-Glut1_Htt93Q and Htt93Q showed that there was a significant correlation 
between eclosion rate and genotype (ANOVA, p value = 0.0048). Mut-Glut1_Htt93Q flies was 
significantly associated with a reduced eclosion rate compared to Htt93Q flies (ANOVA, post hoc 
test, p value = 0.015) and EP-Glut1_Htt93Q flies (ANOVA, post hoc test, p value = 0.0023) (Figure 
45). Thus, it was clear that mutation of Glut1 can worse early disease events in a fly model of HD 
and overexpression of Glut1 can potentially rescue from this process, though the increase in 
eclosion rate between Htt93Q and EP-Glut1_Htt93Q flies was not significant. 
 
Figure 45. Alterations of Glut1 affect eclosion rate in HD background. 
Mut-Glut1_Htt93Q flies showed a decreased adult emergence from the pupal case compared to Htt93Q and 
EP-Glut1_Htt93Q flies. n ≥ 1000 progeny for each cross. Statistical comparisons by ANOVA and post-hoc test 
(*p value < 0.05; ** p value < 0.01).  
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4.4.3.2  Pseudopupil test results 
The pseudopupil test was performed on mut-Glut1_Htt93Q flies and EP-Glut1_Htt93Q flies 
compared to Htt93Q flies at day 1 and day7 post eclosion. EP-Glut1_Htt93Q flies showed a 
significant reduction of neuronal loss at day 1 and day 7 compared to Htt93Q flies (MANOVA, post-
hoc test, p value = 0.0011 at day 1, p value = 0.0013 at day 7) as well to mut-Glut1_Htt93Q flies 
(MANOVA, post-hoc test, p value = 0.00016 at day 1, p value = 0.0037 at day 7) (Figure 46). From 
these data it was possible to say that overexpressing Glut1 partially rescued neurodegeneration in 
adult HD flies and alteration of Glut1 could potentially worsen the neurodegenerative process, 
although the decrease in rhabdomere number between Htt93Q and mut-Glut1_Htt93Q flies was 
not significant. 
 
Figure 46. Overexpression of Glut1 reduces neuronal loss in HD flies. 
Quantification of mean rhabdomeres (± SEM) per ommatidium in Htt93Q, mut-Glut1_Htt93Q and EP-
Glut1_Htt93Q flies at day 1 and day 7 post eclosion. n= 9 to 15 flies per genotype. Statistical comparisons 
by MANOVA and post hoc tests (**p value < 0.01; *** p value < 0.001).  
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4.4.3.3 Lifespan test results 
The lifespan of mut-Glut1_Htt93Q flies and EP-Glut1_Htt93Q flies was recorded and 
compared to Htt93Q flies. Kaplan–Meier survival curve statistical analysis with log rank test was 
calculated on 100 animals per genotype and it showed that the survival rate of Htt93Q flies was 
not significantly different compared to mut-Glut1_Htt93Q flies (p value = 0.11) (Figure 47) and EP-
Glut1_Htt93Q flies (p value = 0.52) (Figure 48). Thus, in this experimental context, alteration or 
overexpression of Glut1 did not affect the lifespan in HD model flies. 
  
Figure 47. mut-Glut1_Htt93Q flies exhibit no different life span compared with Htt93Q flies. 
Glut1 alteration does not affect survival of adult HD flies. The number of flies surviving from each 
cohort was determined every day. n=100 animals per genotype. Statistical analysis by Kaplan–
Meier survival curve analysis with log rank test (n.s. not significant).  
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Figure 48. EP-Glut1_Htt93Q flies exhibit no different life span compared with Htt93Q flies. 
Glut1 overexpression does not affect survival of adult HD flies. The number of flies surviving from 
each cohort was determined every day. n=100 animals per genotype. Statistical analysis by 
Kaplan–Meier survival curve analysis with log rank test (n.s. not significant).  
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CHAPTER FIVE: 
DISCUSSION 
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Encompassing nearly 4 % of the human genome and leading to structural rearrangements 
that involve from ~ 50bp up to several Mb, CNV is a large contributor to genomic variation. CNVs 
have been investigated with regards to their functional impact on the full range of biology, from 
gene-expression studies to GWAS interrogating all the classes of human genetic diseases: 
Mendelian, complex, sporadic, infectious and neurodegenerative. 
HD is a monogenic disorder caused by an autosomal dominant mutation in the HTT gene. 
Notwithstanding its relentless course, the wide temporal range of AO (ranging from 1 year to 80 
years) of the motor symptoms and the several phenotypes associated with HD are not fully 
accounted for by the expanded CAG repeat in the HTT gene. As previously shown in a study on 
Venezuelan families, the additive genetic heritability of the residual age of onset is 38%, 
suggesting the presence of other genetic factors involved which modulate onset and progression 
of the disease (Wexler et al. 2004). Several studies have analysed common genetic variants in 
manifest HD carrier cohorts to test whether they are associated with earlier or later AO among 
similar CAG length carriers. Notwithstanding, few genetic modifiers of the AO so far identified 
have been confirmed by independent studies. Beyond the genetic variability of the candidate 
modifiers studied, it is fundamental to consider the heterogeneity and complexity of HD 
pathology. The association of genetic variants to phenotypic variance in HD, within or without 
taking into account the effect of the HD mutation, needs to be assesed on a large HD sample 
cohort that can widely represent multiple aspects of HD pathology in terms of CAG mutation 
length, age of onset, sex, major symptoms at onset and ethnicity. As such information on a large 
panel of HD patients are provided by international consortia such as the EHDN, it is important to 
standardize the practise of evaluation for candidate genetic modifier of the AO of HD with regards 
of the characteristics of the sample cohort adopted and appropriate statistical methods for the 
analysis. Additionally, accessible online databases should be created to collect all the data from 
genetic analysis performed on each HD patient, as well as clinical assessment data of HD 
biomarkers evaluation, psychiatric, cognitive and motor test scores were accessible. 
To our knowledge this is the first study that tests the potential role of CNVs ( e.g. DEFB4 
and SLC2A3) as genetic modifiers of the age of onset in HD. This study relies on the application of a 
validated PRT method for CNV genotyping (Aldhous et al. 2010; Veal et al. 2013) and investigates 
the impact of CNV on the AO in HD on large sample cohorts which accurately reflect the HD 
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population in terms of CAG mutation length, AO, sex,major symptoms at onset and sample 
provenence. 
 
5.1 β-defensin CNV in HD  
From our study it is clear that β-defensin genomic copy number is not associated with the 
modulation of HD pathogenesis and does not affect the age of onset of any main symptoms at 
onset. Nevertheless, we cannot formally exclude the potential implication of single nucleotide 
polymorphisms within this region, given that of course not only copy number change but also 
sequence variants can affect the expression of hBD2 (Groth et al. 2010). 
 In order to explain the output of our investigation, firstly it is important to take into 
account the characteristic of the gene-dosage effect of β-defensin CNV on the expression of h-
BD2. So far a number of studies showed the correlation between genomic copy number and h-BD2 
mRNA or protein level in several tissues. A strong correlations (R2 = 0.96; p = 0.02) between β-
defensin copy number and h-BD2 mRNA level was found in nasal epithelial cells (Janssens et al. 
2010); higher significances but moderate correlations between genomic copy number and protein 
level were found in serum of healthy (Pearson’s R = 0.46 p< 7×10-5 in Jansen et al. 2009; Pearson’s 
r correlation = 0.370; p < 0.001 in Jaradat et al. 2013) and disease individuals (Pearson’s r 
correlation = 0.458; p < 0.001 in Jaradat et al. 2013). These studies suggest that the effect of β-
defensin CNV on h-BD2 gene expression have a stonger effect in cell type where h-BD2 is normally 
expressed rather than secreted, and might vary in normal or a disease background. Beyond that, it 
is important to say that I took in account as evidence of the dosage effect mechanism only Jansen 
et al. 2009 and Hollox et al. 2003, based on reliable and more accurate methods for the CNV 
genotyping have been used (qPCR: Janssens et al. 2010 and Jaradat et al. 2013; PRT and REDVR, 
and MAPH: Jansen et al. 2009; MAPH, FISH, PFGE: Hollox et al. 2003). 
With regards to our hypothesis, we can say that the activated microglia and reactive 
astrocytes, shown to be correlated with disease severity in HD, might not influence (or be 
influenced by) the β-defensin CNV. The inducible expression of hBD2 in astrocytes driven by TNF-α 
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and IL-β (Hao et al. 2001), which are both expressed in the striatum of HD brains (Björkqvist et al. 
2008), or by the aberrant activation of NF-κB (Hsiao et al. 2013), may not be copy number 
dependent or the gene-dosage effect could be responsible for a weak correlation with protein 
level in astrocyte, negligible in the HD brain. It is also possible that transcriptional and trafficking 
alterations in astrocytes due to mutant huntingtin (Kuhn et al. 2007; Luthi-Carter and Cha 2003) 
might interfere with hBD2 expression or function, masking any possible modulation in the 
expression driven by its copy number. Furthermore, we can say that inflammatory stimuli at the 
BBB might not activate hBD2 expression contributing significantly to the inflammatory burden in 
HD and further studies are actually necessary to clarify the role of hBD2 on the BBB. This study 
does not exclude any possible implication of β-defensins in HD which could contribute to a pro-
inflammatory state within the brain or exacerbating the inflammatory response (Williams WM et 
al. 2012) in neurodegenerative disorders. Further studies are necessary to clarify the effects of β-
defensin copy number on hBD2 expression in CNS tissues in both normal physiological and 
neurodegenerative milieus. 
 
5.2 SLC2A3 CNV in HD 
From our genetic screening and analysis in patient cell lines, it is possible to say that 
SLC2A3 CNV is a genetic modifier of the age of onset in HD. We determined SLC2A3 copy number 
for 988 HD individuals, representing an extensive sample cohort, appropriate for the detection of 
genetic modifiers of the AO in HD. 
In order to test any association between SLC2A3 CNV distribution and variance of the AO in 
HD, we used the natural-logarithmic transformed AO into a generalized linear model, where the 
CAG mutation length and the SLC2A3 CNV were independent predictors. Using the log-
transformed AO improves the linearity of the regression between the dependent variable and the 
CAG mutation length which is its main predictors. Several studies used a simple linear regression 
model in which it is erroneously assumed a constant, symmetrical variance of onset ages around 
the estimated means. Instead, the using of a GLM betters to address linearity in response on the 
specified scale and accommodates skewness through variance weighting. 
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From the analysis of the SLC2A3 CNV distribution in our two HD cohorts it was evident that 
SLC2A3 CNV is a rare genomic variation event, involving < 5% of the population. The frequencies of 
SLC2A3 CNV distribution in the two cohorts were not significantly different although the analysis 
of their correlation with variance of AO in the separate cohorts gave contradictory results. More 
likely slight differences between the two cohorts (for instance in HD cohort 2 there are 5% more of 
samples with AO > 60 years old than in HD cohort 1, which could have affected the correlation 
between CAG and AO and therefore the size effect of SLC2A3 CNV on the AO prediction) and 
stochastic effect on SLC2A3 copy number distribution in the two cohorts significantly increased 
and reduced the power of the effect of SLC2A3 CNVs respectively in HD cohort 1 and HD cohort 2. 
However, considering that two cohorts are samples of the HD population, it was possible to 
estimate the effect of SLC2A3 CNV combining the two cohorts together in order to have a larger 
samples set. From the analysis of the effect of SLC2A3 CNV on the AO in 988 HD samples it arises 
that increase in copy number is significantly associated to a delay of up to ~ 6 years of AO in HD, a 
sizeable effect comparable to another genetic modifier of AO such as HAP1, where the protective 
allele is associated to a delay of the AO of 8 years. 
We investigated the functional effect of SLC2A3 CNV analysing the GLUT3 expression level 
in lymphoblastoid cell lines of previously genotyped patients from our HD cohorts. A significant 
correlation between SLC2A3 duplication and an augmented GLUT3 expression compared to 
samples with 1 and 2 SLC2A3 copies was found. The functional effect on protein expression levels 
allowed us to indentify SLC2A3 CNV as a genetic modifier of the AO of HD. While SLC2A3 
duplication, associated with an increased gene expression, was found to be protective, SLC2A3 
deletion was not associated to earlier onset of HD. Likely no detrimental effect was visible due to 
the small number of 1 SLC2A3 copy carriers in our cohorts (n=5). Regarding the analysis of GLUT3 
relative expression level in patient cell lines, no significant difference was found between SLC2A3 
deletion carriers and controls probably due to a stochastic effect involving protein expression 
related to low gene copies (Elowitz et al. 2002). 
In order to clarify the role of SLC2A3 CNV in HD, we used a Drosophila model of HD to 
investigate the effects of overexpression and underexpression of a main glucose transporter in the 
fly CNS. In HD flies the overexpression of the Drosophila Glut1, homologue of human GLUT3, 
rescued neurodegeneration whilst alteration of this transporter was associated with a worsening 
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of the disease progression. We showed underexpression of Glut1 worsened the 
neurodegeneration in early stage causing more severe rhabdomere loss at day 1 than at day 7, as 
well as increased mortality at a few days post eclosion, and an overall reduced eclosion rate. These 
findings indicate that dysfunctions of Glut1 in a Drosophila model of HD are not well tolerated at 
early stage, likely because of the role of Glut1 during larva development. In agreement with 
previous studies investigating the role of Glut1 in fly models of HD and AD (Besson et al. 2010; 
Shulman et al. 2011), the overexpression of Glut1 can rescue the neurodegeneration significantly 
in the adult fly and with a non significant but indicative effect even in the early stage of the fly life, 
confirming that higher level of glucose transporter can delay HD progression. 
This is the first study to identify a CNV event as a genetic modifier of the age of onset in 
HD. Specifically we showed that SLC2A3 CNV, affecting the gene expression level, was associated 
to a delay of AO in HD. This study highlighted a new aspect of the role of GLUT3 and the neuronal 
glucose metabolism in HD pathology. As GLUT3 (and GLUT1) reduction was suggested to be 
involved in HD pathology and the brain hypometabolism, present without a significant atrophy, is 
a potential biomarker of HD progression in presymptomatic patients, our study supports the 
hypothesis that increased expression of GLUT3 could counter an early energetic deficit in HD 
neurons delaying the disease progression (Gamberino and Brennan 1994; Ciarmiello et al. 2012). 
In HD neurons, expression of the additional SLC2A3, constitutively expressed or activated by 
inflammatory or energy-deficiency stimuli, could contrast to the deficit of the transporter, which 
expression or trafficking could be directly or indirectly affected by the mutant HTT. Further 
evidences supporting our hypothesis were provided using a Drosophila model of HD where we 
selectively studied the effect of the overexpression and underexpression of the main glucose 
transporter in the brain in an HD background, causing respectively amelioration and worsening of 
the disease progression. 
To unequivocally confirm the correlation between SLC2A3 CNV and a variance of the AO in 
HD, an independent replication study is necessary on an even larger cohort to confirm the size of 
effect, and to test the effect of deletion. To understand if SLC2A3 is involved at an early stage in 
HD progression, it will be fundamental to investigate if regulation of gene expression is affected by 
the mutant protein. Studies on murine neuroblasts and trophoblasts highlighted the role of 
Sp1/Sp3 and CREB transcription factors on GLUT3 expression, whose functions are both affected in 
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HD, suggesting a potential effect on GLUT3 expression dependent upon mutant HTT (Rajakumar et 
al. 1998; Rajakumar et al. 2004; Cha 2007). Moreover, dysfunction in vesicle trafficking in HD 
neurites might affect the recycling of GLUT3, as it colocalizes with SNARE complex proteins that 
are found to be lowered in HD brains (Heather West Greenlee et al. 2003; Morton et al. 2001; 
Smith et al. 2007). 
To confirm the findings from our in vivo study using the Drosophila HD model, a HD model 
in mouse bearing an extra copy of Slc2a3,the murine homologue of human SLC2A3, should be 
developed to test if the overexpression of this transporter will be protective against HD and how 
this will affect the cerebral metabolism and atrophy. From this mouse model and from neuronal 
cell lines cultured from it, it will be fundamental to analyse any possible effect of GLUT3 
overexpression in HD. These studies could represent a further step to explain the role of GLUT3 
and specifically of SLC2A3 CNV in HD and improve our knowledge of HD pathology. 
In parallel to these studies screening of xenobiotic compounds able to stimulate Glut1 
expression in a Drosophila model of HD could be performed in order to define a new therapeutic 
strategy against the disease. Strikingly, studies in rodent models of aging and Alzheimer’s disease 
have already identified a potential compound (lipoic acid) that could be administered to murine 
models of HD in order to stimulate GLUT3 expression and rescue the glucose uptake in the brain 
(Jiang et al. 2013; Sancheti et al. 2013), and test for disease-related phenotypic improvements. 
This study remarks the important role of the glucose metabolism in HD, which alteration is 
an early biomarker the disease progression, and highlighted a potential therapeutical target, 
SLC2A3, which increased expression could restore the glucose homeostasis in the brain and delay 
HD progression. 
134 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANNEX 
136 
 
 
Supplementary material 
Eclosion test in control strains. 
 
Figure 49. Eclosion rate in Glut1-RNAi and relative control strains. 
Statistical comparisons of mean eclosion rate ((Female F1/total F1) %) (±SEM) by ANOVA and post-hoc test  
versus Glut1-RNAi flies (n.s. not significant; **** p value < 0.0001). n ≥ 1000 progeny for each cross. 
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Figure 50. Eclosion rate in Htt93Q3M and relative control strains. 
Statistical comparisons of mean eclosion rate ((Female F1/total F1) %) (±SEM) by ANOVA and post-hoc test 
versus Htt933M flies (**** p value < 0.0001). n ≥ 1000 progeny for each cross. 
 
 
Figure 51. Eclosion rate in mut-Glut1 and relative control strains. 
Statistical comparisons of mean eclosion rate ((Female F1/total F1) %) (±SEM) by ANOVA and post-hoc test 
versus mut-Glut1 flies (**** p value < 0.0001). n ≥ 1000 progeny for each cross. 
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Figure 52. Eclosion rate in EP-Glut1 and relative control strains. 
Statistical comparisons of mean eclosion rate ((Female F1/total F1) %) (±SEM) by ANOVA and post-hoc test 
versus EP-Glut1 flies (**** p value < 0.0001). n ≥ 1000 progeny for each cross. 
 
 
Figure 53. Eclosion rate in Htt93Q and relative control strains. 
Statistical comparisons of mean eclosion rate ((Female F1/total F1) %) (±SEM) by ANOVA and post-hoc test 
versus Htt93Q flies (***p value < 0.001 ;**** p value < 0.0001). n ≥ 1000 progeny for each cross. 
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Lifespan test in control strains. 
The number of flies surviving from each cohort was determined every day for flies in HD background and every 3 to 4 days for controls strains. 
Statistical analysis was done by Kaplan–Meier survival curve analysis with log rank test on approximately 100 animals per genotype. 
 
Figure 54. Survival curve of Glut1-RNAi versus control strains. 
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Table 20. Statistical analyses of survival curve of Glut1-RNAi versus control strains. 
Genotype elavGAL4;Glut1KK
108683
;UA
S-Q93httexon1 
elavGAL4;KK;UAS-
Q93httexon1 
elavGAL4;Glut1KK
10868 
3
/+; 
elavGAL4;KK; elavGAL4;; w; 
Glut1KK
108683
/+; 
Median survival (day) 17 20 60 74 70 77 
Curve comparison with 
Glut1-RNAi: p value 
/ <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
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Figure 55. Survival curve of Htt93Q3M versus control strains. 
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Table 21. Statistical analyses of survival curve of Htt93Q3M versus control strains. 
Genotype  elavGAL4;3M;UAS-Q93httexon1 elavGAL4;3M; elavGAL4;; w ;; UAS-Q93httexon1 
Median survival (day)  18 75 70 81 
Curve comparison with Htt93Q
3M
 
: p value 
 
 
/ <0.0001 <0.0001 <0.0001 
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Figure 56. Survival curve of mut-Glut1 versus control strains. 
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Table 22. Statistical analyses of survival curve of mut-Glut1 versus control strains. 
Genotype elavGAL4;; Glut1
17J
/UAS-Q93httexon1 elavGAL4;; Glut1
17J
/+ elavGAL4;; w ;; Glut1
17J
 /UAS-Q93httexon1 
Median survival (day) 7 76 70 71.5 
Curve comparison with 
mut-Glut1: p value 
/ <0.0001 <0.0001 <0.0001 
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Figure 57. Survival curve of EP-Glut1 versus control strains. 
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Table 23. Statistical analyses of survival curve of EP-Glut1 versus control strains. 
Genotype elavGAL4;; Glut1
d05758
/UAS-
Q93httexon1 
elavGAL4;; Glut1
d05758
/+ elavGAL4;; w ;; Glut1
d05758
/UAS-Q93httexon1 
Median survival (day) 9 61 70 78 
Curve comparison with EP-Glut1 : 
p value 
/ <0.0001 <0.0001 <0.0001 
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Figure 58. Survival curve of Htt93Q versus control strains. 
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Table 24. Statistical analyses of survival curve of Htt93Q versus control strains. 
Genotype elavGAL4;; UAS-Q93httexon1 elavGAL4;; w ;; UAS-Q93httexon1 
Median survival (day) 10 70 81 
Curve comparison with Htt93Q : p value / <0.0001 <0.0001 
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Appendix 
Table 25. Controls samples used in PRT assays.                 
Sample Code Origin Assay 
C0088 ECACC DEFB4 
C0207 ECACC DEFB4 
C0849 ECACC DEFB4 
C0913 ECACC DEFB4 
C0940 ECACC DEFB4 
C0969 ECACC DEFB4 
NA19920 HapMap Panel SLC2A3 
NA11840 CEPH panel SLC2A3 
L31 Leicester panel  SLC2A3 
 
Table 26. List of primers used for PCR-based assays. 
Assay Sequence (5’-3’) Size  
PRT107A Forward: AGTCCTCATTTAACTTTGGTGC 
Reverse: GGCTATGAAGCAATGGCCTA 
155bp (reference),  
158bp (test)  
HPSD21 Forward: GAGGTCACTGTGATCAAAGAT 
Reverse: AACCTTCAGCACAGCTACTC 
172bp (test),  
180bp (reference) 
5DELR4 Forward: AAACCAATACCCTTTCCAAG 
Reverse: TTCTCTTTTGTTTCAGATTCAGATG 
119 to 125bp 
 
SLC2A3  Forward: TATTGCACCTTAACCTCTCCAGC 
Reverse: CCTCACTTCCATACAGCTCTACG 
200bp (reference),  
285bp (test) 
qPCR-
Glut1 
Forward: ATAATGGTTGTTATGACGCTCGTGT 
Reverse: GTGATGAAGATTGAGAAGATGAACA 
110bp 
150 
 
 
qPCR-
RpL32* 
Forward: ATCGGTTACGGATCGAACAA 
Reverse: ACAATCTCCTTGCGCTTCT 
164bp 
*from Zordan et al.2006 
 
Table 27. Control fly strains. 
Investigation strains Control strains 
Htt93Q/ Htt93Q* w;; UAS-Q93httexon1 
 w1118;; 
 elavGAL4;; 
Only for Htt93Q* elavGAL4;3M; 
 elavGAL4;KK; 
 elavGAL4;KK; UAS-Q93httexon1 
RNAi-Glut1 w; Glut1KK108683; 
 elavGAL4; Glut1KK108683; 
EP-Glut1 w;; Glut1d05758 
 elavGAL4;; Glut1d05758 
 w;; Glut1d05758/UAS-Q93httexon1 
 elavGAL4;; Glut1 d05758 
mut-Glut1 w;; Glut117J 
 elavGAL4;; Glut117J 
 w;; Glut117J /UAS-Q93httexon1 
 elavGAL4;; Glut117J 
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